Epidemiology and dynamic of dengue and chikungunya in several provinces in Vietnam

Kim Lien Pham Thi

To cite this version:

HAL Id: tel-01763165
https://tel.archives-ouvertes.fr/tel-01763165
Submitted on 10 Apr 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Délivré par Université de Montpellier

Préparée au sein de l’école doctorale GAIA – ED 584
Et de l’unité de recherche Intertryp

Spécialité : Biologie des Interactions

Présentée par Pham Thi Kim Lien

Epidemiology and dynamic of dengue and chikungunya in several provinces in Vietnam

Soutenue le 15 Décembre 2015 devant le jury composé de

Mme Sofia MUBARIKA, Prof, Universitas Gadjah Mada Rapporteur
M Toan NGO VAN, Prof, Hanoi Medical University Rapporteur
M Christian DEVAUX, DR, CNRS Rapporteur
Mme Laurence BRIANT, CNRS Examineur
Mme Nga PHAN THI, Prof, NIHE Examineur
M Duong TRAN NHU, Prof, NIHE Directeur
M Roger FRUTOS, DR, CIRAD Directeur
# TABLE OF CONTENTS

ACKNOWLEDGEMENTS

LIST OF ABBREVIATIONS

LIST OF FIGURES AND TABLES

GENERAL INTRODUCTION ........................................................................................................ 1

PART I. LITERATURE REVIEW .................................................................................................... 5

1. Arboviruses ........................................................................................................................... 5

2. Different of Arbovirus families.............................................................................................. 6

2.1. Family Flaviviridae .............................................................................................................. 6

2.1.1. Classification .................................................................................................................. 6

2.1.2 Genome structure ............................................................................................................ 9

2.1.3 Vector .............................................................................................................................. 11

2.1.4 Flavivirus replication cycle ............................................................................................ 16

2.1.5 Main disease .................................................................................................................. 17

2.2. Family Togaviridae (genus Alphavirus) ........................................................................... 20

2.2.1. Classification .................................................................................................................. 20

2.2.2. Genome structure ......................................................................................................... 21

2.2.3. Vector ............................................................................................................................ 22

2.2.4. Togaviridae replication cycle ......................................................................................... 22

2.2.5. Main diseases ............................................................................................................... 24

2.3. Family Bunyaviridae ......................................................................................................... 27

2.3.1. Classification .................................................................................................................. 27

2.3.2. Genome structure ......................................................................................................... 27

2.3.3. Bunyaviridae replication cycle ....................................................................................... 28

2.3.4. Vector ............................................................................................................................. 29

2.3.5. Main disease .................................................................................................................. 30

3. Flavivirus and Dengue ......................................................................................................... 32

3.1. Classification ..................................................................................................................... 32
3.2. Genetic evolution ........................................................................................................ 33
3.3. Vectors .......................................................................................................................... 34
   3.1.1 *Aedes aegypti* and *Aedes albopictus* ................................................................. 34
   3.1.2 Transmission cycle ................................................................................................. 35
3.4. Dengue epidemiology .................................................................................................. 37
   3.4.1. History and origin of Dengue ............................................................................... 37
   3.4.2. Global burden ........................................................................................................ 38
3.5. Diagnosis .......................................................................................................................... 52
   3.5.1. Classification in clinical ......................................................................................... 52
   3.5.2. Disease course ........................................................................................................ 54
   3.5.3. Laboratory diagnosis ............................................................................................. 56
   3.5.4. Treatment and prevention .................................................................................... 60
   3.5.5. DHF immunopathogenesis ................................................................................... 63
4. Alphaviruses and Chikungunya virus .............................................................................. 70
4.1. Classification .................................................................................................................. 70
4.2. Genetic evolution ........................................................................................................... 71
4.3. Replication cycle .......................................................................................................... 73
4.4. Vector ............................................................................................................................ 73
4.5. Chikungunya Epidemiology ......................................................................................... 75
   4.5.1. History and origin of chikungunya ......................................................................... 75
   4.5.2. Global burden ........................................................................................................ 76
   4.5.3. Epidemiology trend in several regions of the world ............................................. 78
   4.5.4. Diagnosis ............................................................................................................... 83
   4.5.5. Treatment and prevention ..................................................................................... 86
   4.5.6. Chikungunya immunopathogenesis .................................................................... 88
5. Combined arboviral infections ....................................................................................... 89
5.1. Combined Flavivirus infections .................................................................................... 89
5.2. Combined Dengue and Chikunguni viruses in the world ........................................... 90
PART II. DENGUE AND CHIKUNGUNYA IN VIETNAM ................. 93
CHAPTER 1. ROLE OF Aedes SPECIES IN THE TRANSMISSION OF DENGUE IN URBAN AREAS IN NORTH VIETNAM ................. 94
   1.1. Context of study ............................................................................................................. 94
   1.2. Objective ....................................................................................................................... 95
   1.3. Discussion and conclusions .......................................................................................... 96
CHAPTER 2. SURVEILLANCE OF DENGUE AND CHIKUNGUNYA VIRUS INFECTION IN DONG THAP ............................................. 98
   2.1. Context of the study ...................................................................................................... 98
   2.2. Objective ...................................................................................................................... 99
   2.3. Discussion and conclusions ........................................................................................ 99
CHAPTER 3. DENGUE VIRUS, CHIKUNGUNYA VIRUS AND RISK FACTORS IN SEVERAL PROVINCES OF VIETNAM. ........... 101
   3.1. Context of study .......................................................................................................... 101
   3.2. Objective ...................................................................................................................... 103
   3.3. Discussion and conclusions ........................................................................................ 103
GENERATION CONCLUSION AND PERSPECTIVES ............. 107
REFERENCES ......................................................................................................................... 110
ACKNOWLEDGEMENTS

To write this thesis, I am greatly indebted to program, institutes and many people for their support and encouragements.

First of all, I would like to my thanks to the Eramus Mundus program, granted me the scholarship to pursue this doctoral program; To Ecole doctoralle Sibaghe, Montpellier 2 University, French. To Centre d’études d’agents Pathogènts et Biotechnologies pour la Santé, center National de la recherche scientifique (CPBS, CNRS), Montpellier, France, and National Institute of Hygiene and Epidemiology, Ha Noi, Vietnam for giving me an opportunity to follow this academic program and for equipping me with such an updated knowledge to make this thesis possible.

I want to express my deep gratitude to Dr Christian Devaux (IRD), Professor Sofia Mubarika (U. Gadjah Mada) and Professor Ngo Van Toan (Hanoi Medical University) for having accepting and making me the honor to review this PhD work.

My deep gratitude goes to Professor Roger Frutos, from French Agricultural Research center, and Centre d’études d’agents Pathogènts et Biotechnologies pour la Santé, center National de la recherche scientifique (CPBS, CNRS), Montpellier, France for accepting to be my supervisor, for his great support, effort and help in articles and thesis writing, for making several round trips between France and Vietnam.

My special thanks goes to my cosupervisor, Associate Professor Tran Nhu Duong, deputy of National Institute of Hygiene and Epidemiology, Ha noi Viet Nam for firstly allowing me to work as part of his project, for his great support, encouragement to complete the PhD program.

My huge thanks and appreciation to my cosupervisor, Dr. Laurence Briant, Head of Virus host cell interactions Laboratory, Centre d’études d’agents Pathogènts et Biotechnologies pour la Santé, center National de la recherche scientifique (CPBS, CNRS), Montpellier, France accepting me to her laboratory, for transferring her expertise in biomolecular necessary for the accomplishment of the work in this thesis.

My special thanks to my cosupervisor, Prof. Phan Thi Nga, former Head of Training and Science Management Department, National Institute of Hygiene and Epidemiology, Ha Noi Viet Nam for her support and allowing me to work as part of her team and help me in her laboratory.
I would like to thanks to **Dr Laurent Gavotte**, teacher of Montpellier 2 University (UM 2) for allowed me to his lab in Parasitology, Evolutionary Biology, Ecology Department, UM 2, French for the accomplishment of the work, for his help and support in an article.

My thanks to **Dr Pierrick Labbé**, teacher of Evolution, Vector, Adaptation in Symbioses Department, Montpellier 2 University, French for generously accepting me to his laboratory at Montpellier 2 University for sharing his precious expertise in DNA mosquitoes extraction, for his kindness.

I would like to express my sincere gratitude and appreciation to **Dr Babatunde Olowokure**, Director of Surveillance, Disease Prevention and Control, Caribbean Public Health Agency for his patient and encouragement to improve myself, valuable comments enabling me to attend and complete the PhD program.

I would like to thanks the medical doctor and nursing staff of the **General Hospital in Dong Thap** for their care of patients, supported, and their cooperation for this research.

My grateful to the **Preventive Medicine Centers** in three regions in the North, Center, South were Ha Noi, Ha Tinh, Quang Tri, Thua Thien Hue, Dak nong and Long An, Vietnam for their cooperation during conducted of this study.

My thanks to **Arbovirus laboratory**, Virological Department National Institute of Hygiene and Epidemiology, Hanoi, Vietnam for allowed me to work as part of their team, and for their help.

I would like to thank the following Professors, friends and colleagues:

To my colleagues at Entomology Department, National Institute of Hygiene and Epidemiology, Hanoi, Viet Nam thanks to **Le Thi Yen, Tran Chi Cuong, Dang Duc Dong, Nguyen Van Soai** for their help collected vector and serum samples, shared to me the hard trips and very interested in provinces of three regions in Vietnam, for their generosity and for being so helpful in all the works in order to generate data used in this thesis.

My thanks to **Eric Bernard, Patric Eldin, Nathalie Chazal, Eymeric Neyret, Simon Fontanel, Roy Matkovic** in the Virus host cell interactions Laboratory, Centre d’études d’agents Pathogènts et Biotechnologies pour la Santé, center National de la recherche scientifique, Montpellier, France allowed me to work as part of their team, and for their help in Montpellier, France.
Special many thanks mention to Marco Perriot Sanguinet, Evolutionary Biology, Ecology Department, Montpellier 2 University, France for his help during the time in France.

To Dr. Emmanuel Cornillot, CPBS, CNRS for taking interest in this work.

To Dr. Vu Trong Duoc, Vice head of Entomology department, National Institute of Hygiene and Epidemiology, Hanoi, Vietnam for his support and help on data analysis.

To Dr. Truong Ba Tang, General Dong Thap hospital for his cooperation to collected sample in General Dong Thap hospital.

All teachers, friends and colleagues for their help during the course.

Last but not a least, my heartfelt thanks and love to my parents, my daughter, my young brother, my niece, and sister who have helped me in every possible way to my completion of this Doctor of physolophy study.
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AIDs</td>
<td>Acquired immune deficiency syndrome</td>
</tr>
<tr>
<td>Ae</td>
<td>Aedes</td>
</tr>
<tr>
<td>APCs</td>
<td>Antigen presenting cells</td>
</tr>
<tr>
<td>BALB/c</td>
<td>An Albino, laboratory-bred strain of the House Mouse</td>
</tr>
<tr>
<td>CCD</td>
<td>Charge couple device</td>
</tr>
<tr>
<td>CCHFV</td>
<td>Crimean- Congo Hemorrhagic fever virus</td>
</tr>
<tr>
<td>cDNA</td>
<td>Complementary Deoxyribonucleic acid</td>
</tr>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>CHIKV</td>
<td>Chikungunya virus</td>
</tr>
<tr>
<td>CPBS</td>
<td>Center Agents Pathogens and Biotechnology for Health study</td>
</tr>
<tr>
<td>CNRS</td>
<td>The French National Centre for Scientific Research</td>
</tr>
<tr>
<td>CNS</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>CTF</td>
<td>Colorado tick fever</td>
</tr>
<tr>
<td>CTL</td>
<td>Cytotoxic T-Lymphocyte</td>
</tr>
<tr>
<td>CTLA 4</td>
<td>Cytotoxic T-Lymphocyte associated protein 4</td>
</tr>
<tr>
<td>DC-SIGN</td>
<td>Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin</td>
</tr>
<tr>
<td>DENV</td>
<td>Dengue virus</td>
</tr>
<tr>
<td>DF</td>
<td>Dengue fever</td>
</tr>
<tr>
<td>DHF</td>
<td>Dengue hemorrhage fever</td>
</tr>
<tr>
<td>DSS</td>
<td>Dengue shock syndrome</td>
</tr>
<tr>
<td>E</td>
<td>Envelope protein</td>
</tr>
<tr>
<td>EEE</td>
<td>Eastern Equine Encephalitis</td>
</tr>
<tr>
<td>ER</td>
<td>Endoplasmic reticulum</td>
</tr>
<tr>
<td>GAC</td>
<td>IgG antibody capture</td>
</tr>
<tr>
<td>G6PD</td>
<td>Gluco 6-phosphate dehydrogenase</td>
</tr>
<tr>
<td>HI</td>
<td>Hemagglutination Inhibiton assay</td>
</tr>
<tr>
<td>HLA</td>
<td>Human leucocyte antigen</td>
</tr>
<tr>
<td>HTNV</td>
<td>Haanta virus</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>ICTV</td>
<td>International Committee on Taxonomy of Virus</td>
</tr>
<tr>
<td>IgG</td>
<td>Immunoglobulin G</td>
</tr>
<tr>
<td>IgM</td>
<td>Immunoglobulin M</td>
</tr>
<tr>
<td>IHC</td>
<td>Immunohistochemical</td>
</tr>
<tr>
<td>IVM</td>
<td>Integrate vetor management</td>
</tr>
<tr>
<td>JE</td>
<td>Japanise Encephalitis</td>
</tr>
<tr>
<td>KUN</td>
<td>Kunjin virus</td>
</tr>
<tr>
<td>LACV5</td>
<td>La crosse virus</td>
</tr>
<tr>
<td>MAC-ELISA</td>
<td>M antibody- capture Enzyme Link Immuosorbent Assay</td>
</tr>
<tr>
<td>MBL2</td>
<td>Mannose- binding lectin 2</td>
</tr>
<tr>
<td>MRC</td>
<td>Medical Research Council</td>
</tr>
<tr>
<td>MVE</td>
<td>Murray Valley Encephalitis virus</td>
</tr>
<tr>
<td>NHEK</td>
<td>Normal Human Epidermal Keratinocytes</td>
</tr>
<tr>
<td>NS</td>
<td>Nonstructural protein</td>
</tr>
<tr>
<td>NSS</td>
<td>Non-structural protein NS-S</td>
</tr>
<tr>
<td>NIHE</td>
<td>National Institute of Hygien and Epidemiology</td>
</tr>
<tr>
<td>OD</td>
<td>Optical Density</td>
</tr>
<tr>
<td>ORF</td>
<td>Openreading frame</td>
</tr>
<tr>
<td>RNA</td>
<td>Ribonucleic Acid</td>
</tr>
<tr>
<td>RT- PCR</td>
<td>Reverse Transcriptase Polymerase Chain Reaction</td>
</tr>
<tr>
<td>RVFV</td>
<td>Rift Valley fever virus</td>
</tr>
<tr>
<td>SDS-PAGE</td>
<td>Sodium dodecyl sulfate polyacrylamide gel electrophoresis</td>
</tr>
<tr>
<td>SEA</td>
<td>Southeast Asia</td>
</tr>
<tr>
<td>SLE</td>
<td>St. Louis Encephalitis</td>
</tr>
<tr>
<td>SNV</td>
<td>Sin Nombre virus</td>
</tr>
<tr>
<td>SSRNA</td>
<td>Single Stranded ribnucleic Acid</td>
</tr>
<tr>
<td>TBE</td>
<td>Tick born encephalitis</td>
</tr>
<tr>
<td>TDR</td>
<td>Tropical disease research</td>
</tr>
<tr>
<td>TNF</td>
<td>Tumor necrosis factor</td>
</tr>
<tr>
<td>TGF</td>
<td>Transforming growth factor</td>
</tr>
<tr>
<td>TV</td>
<td>Tetravalent vaccine</td>
</tr>
<tr>
<td>UTR</td>
<td>Untranslate region</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>US</td>
<td>United state</td>
</tr>
<tr>
<td>VCAM-1</td>
<td>Vascular cell adhesion molecular -1</td>
</tr>
<tr>
<td>WEE</td>
<td>Western Enquin Encephalitis</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>WNV</td>
<td>West Nile Virus</td>
</tr>
<tr>
<td>YFV</td>
<td>Yellow fever virus</td>
</tr>
</tbody>
</table>
Figure 1: Three genera of the *Flaviviridae* family in the Phylogenetic tree. ......................... 7
Figure 2: Devided from the GenBank library, phylogenetic tree of the flaviviruses derived from partial Non-structural protein NS-S sequences. ......................................................... 8
Figure 3: Schematic structure of flavivirus virion .................................................................. 9
Figure 4: The single open reading frame is depicted with the structural and non structural protein coding region (colored is blue and green repectively). ................................. 10
Figure 5: The detail of cleavage sites for cellular proteases, NS2B/ NS3 and unknown protease are indicated. .......................................................... 10
Figure 6: Transmission cycle for tick-born encephalistic virus. ........................................... 11
Figure 7: Life cycle of *Culex* mosquito ........................................................................... 13
Figure 8: Depicting the hypothetical evolutionary history of endemic or epidemic DENV emergence from zoonotic transmission cycles ......................................................... 16
Figure 10: Genome structure of Togaviruse ..................................................................... 21
Figure 14: Endemic or potentially endemic to 144 countries of Dengue transmission, 2015 ..38
Figure 15: Worldwide. Dengue, cases.............................................................................. 39
Figure 16: Average annual number of DF/DHF case reported to WHO, and average of countries reporting dengue, 1955-2007 ............................................................ 40
Figure 17: The change in distribution of dengue serotype. The figure shows the distribution in 1970 (A) and 2004(B) .............................................................................. 41
Figure 18: Western Pacific region. Dengue cases (A), deaths (B).................................. 43
Figure 19: Southeast Asian region. Dengue, cases (A) deaths (B). ................................. 45
Figure 20: Vietnam map. ................................................................................................. 46
Figure 21: Distribution of DF/DHF in Vietnam in 2009 .................................................... 47
Figure 22: Vietnam. Dengue /DHF, cases (A) and death (B) ........................................... 48

Despite the existence of a National dengue control Program since 1998, dengue remains a major health problem in Vietnam. Over the past 15 years, the number of DENV cases has been increasing................................................................. 48
Figure 23: European Union, Dengue cases

Figure 24: Americas region. DHF, cases (A) and deaths (B).

Figure 25: Dengue case classification and levels of severity

Figure 26: The Course of Dengue disease

Figure 27: Comparison of diagnostic tests according to their accessibility and confidence

Figure 28: Dengue research and training supported and encouraged by the UNICEF-UNDP-World Bank-WHO.

Figure 29: Model of antibodies-dependent enhancement

Figure 30: Chikungunya virus Genetic and Physical Structure

Figure 31: Chikungunya virus and dispersal and evolution

Figure 32: Origin, spread, and distribution of chikungunya virus and its vector.

Figure 33: Predicted dispersal pattern of Chikungunya virus from Africa to the Indian Ocean and Europe during the past 20 to 50 years

Figure 34: Chikungunya active transmission regions established from published data illustrate geographic and temporal knowledge of previous outbreaks

Figure 35: Endemic or potentially endemic to 96 countries

Figure 36: Map showing the distribution of chikungunya virus enzootic strains in Africa and the emergence and spread of the Asian lineage (red arrows and dots) and the Indian Ocean lineage (yellow arrows and dots) from Africa

Figure 37: Outbreak of Chikungunya, 2004-2007

Figure 38: European Union, chikungunya, case.

Figure 39: Introduction of chikungunya to the Caribbean by epidemiological week first reported in December 2013 to August 2014.

Figure 40: Timeline of Infection, Symptom, and Biomarkers

Figure 41: Distribution of Dengue, Yellow Fever, and their principal vector, the *Aedes aegypti* mosquito.

Figure 42: Location of the five selected study provinces in the north, center, south of Vietnam.

Figure 43: Location of the eight selected study districts in Hanoi, Vietnam
Table 1: The geographic distribution of spatially unique occurrence for the Americas, Europe/ Africa, and Asia/ Oceania ................................................................. 14

Table 2: Summarize of current dengue vaccines . ................................................................. 63


Mặc dù chương trình phòng chống sốt xuất huyết quốc gia ở Việt Nam đã được thực hiện từ năm 1999, tuy nhiên sốt xuất huyết ở Việt Nam được coi là vùng dịch lưu hành địa phương, chủ yếu ở các tỉnh miền Nam và Nam Trung Bộ. Thống kê của Bộ Y tế Việt Nam cho thấy, hiện nay sốt xuất huyết Dengue đứng thứ 7 trong số 10 nguyên nhân nhập viện hàng đầu. Cơn chikungunya vi rút được phát hiện ở Việt Nam từ 10 người lính Mỹ vào năm 1967, nhưng cho tới nay, bệnh sốt xuất huyết do vi rút chikungunya tại Việt nam vẫn còn là một vấn đề cần được quan tâm. Ở Việt nam, tập quán trữ nước trong các dụng cụ chứa nước sinh hoạt để đối phó với thời tiết khó của người dân cũng là yếu tố làm gia tăng quân số muỗi truyền bệnh và gia tăng nguy cơ xảy ra dịch lớn, đặc biệt là tại Miền Nam. Việc
sử dụng các hóa chất diệt côn trùng không được kiểm soát làm tăng tình kháng của vector truyền bệnh. Sự gia tăng các hoạt động giao lưu, buôn bán và du lịch giữa các vùng miền trong nước, ngoài nước như Cambodia và Lào góp phần làm tăng nguy cơ lan truyền SXH trong cộng đồng.

Mục tiêu nghiên cứu của luận văn này nhằm hiểu rõ hơn về bệnh sốt xuất huyết và tình hình vi rút chikungunya ở một số tỉnh tại Việt nam, đặc biệt ở một số tỉnh có chung đường biên giới với Lào và Campuchia, nghiên cứu chi số Stegomya của hai vec tò truyền bệnh sốt xuất huyết 

* Ae. aegypti* và *Ae. Albopictus*, với những tác động của vec tò sốt xuất huyết dengue và chikungunya khác nhau tại năm huyện tại miền Bắc, miền Trung và miền Nam, Việt Nam. Ngoài ra nghiên cứu cũng mô tả vai trò của bệnh sốt xuất huyết ở những bệnh nhân thu thập được ở bệnh viện Đồng Tháp, Việt Nam. Mất khác, để hiểu rõ hơn về sự tương quan giữa mạt độ của *Ae. aegypti* và *Ae. Albopictus* gây sốt xuất huyết Dengue bùng phát tại thủ đô Hà nội, Việt Nam. Bên cạnh đó, phân tích kiểu gen của quần thể muỗi được thực hiện để cung cấp thông tin rõ ràng về khả năng lan truyền của muỗi với xuất huyết dengue và chikungunya ở Việt Nam. Kết quả cho thấy rằng sự phát hiện vi rút chikungunya ở muỗi *Ae. aegypti* nên được coi là cảnh báo vi rút chikungunya xuất hiện tại Việt Nam và có thể lưu hành cùng với bốn тип huyết thanh khác nhau là một vấn đề của sức khỏe cộng đồng và xã hội.
Résumé étendu en français

Depuis la seconde moitié du 20ème Siècle, avec les progrès de la médecine, en particulier dans le domaine de la vaccination, des antibiotiques, et avec l’amélioration des conditions de vie, la disparition des maladies infectieuses était espérée. Il n’en est toutefois rien. Dans les pays développés les efforts se sont concentrés sur les maladies non infectieuses, délaissant les maladies infectieuses. Ces maladies infectieuses, paludisme, SIDA, tuberculose, dengue, chikungunya, ont continué à s’étendre dans les pays en développement mais émergent aussi en zone tempérée, et en particulier en Europe, à la faveur des changements environnementaux et d’une société globalisée.

Parmi ces maladies, la dengue est l’une des plus dynamiques en termes de propagation. Elle est particulièrement présente en Asie du Sud Est qui est sa zone d’origine. Elle est transmise par des moustiques du genre Aedes particulièrement adaptés à un environnement anthropisé. La dengue demeure un problème majeur de santé publique malgré des efforts de lutte antivectorielle et cela pour plusieurs raisons : 1) Il n’y a actuellement aucun traitement ni aucun vaccin connu, 2) Son incidence annuelle globale est estimée à 50 millions de cas entraînant plusieurs dizaines de milliers de morts, 3) Plus de 2,5 milliards de personnes sont à risque, 4) La maladie existe également sous deux formes sévères, la dengue hémorragique (DHF) qui peut évoluer en syndrome de choc (DSS) dont l’issue peut être mortelle, 5) Depuis les années 1950, l’incidence des formes graves (DHF/DSS) a été multipliée par 30, 6) L’infection est souvent asymptomatique, ce qui conduit à de mauvais diagnostics et une sous-estimation du nombre de cas. La dengue est causée par 4 virus ou sérotypes distincts, DENV1, DENV2, DENV3 etDENV4. Un cinquième serotype, DENV5, a récemment été isolé. Un patient infecté par un sérotype devient résistant à ce sérotype (immunité homologue) mais redevient sensible aux autres sérotypes après un délai d’environ12 semaines et présente alors un risque accru de développer une forme sévère suite à une seconde infection.

Le chikungunya est une autre maladie arbovirale transmise par les mêmes vecteurs que la dengue. Le chikungunya et la dengue sont également très similaires du point de vue

La dengue et le chikungunya sont parmi les maladies les plus difficiles à distinguer, en particulier en phase précoce, du fait de symptômes similaires, de co-infections et de la transmission par les mêmes moustiques péridomestiques du genre Aedes. Aedes aegypti est considéré comme le vecteur principal en zone urbaine avec Aedes albopictus et d’autres moustiques anthropophiles du genre Aedes comme vecteur secondaires.


La dynamique de ces deux maladies n’est toutefois pas claire et de nombreuses informations manquent encore sur les facteurs d’influence et les mécanismes. Ces connaissances sont essentielles pour comprendre les dynamiques en jeu et améliorer les capacités de gestion et maîtrise de ces maladies. Si la dengue est depuis longtemps
hyperendémique au Vietnam, ce n’est pas encore le cas du chikungunya qui est très présent au Cambodge et au Laos et présente donc un risque d’émergence. Les échanges très importants entre le Vietnam, le Cambodge et le Laos, tant au niveau des biens que des personnes, constituent donc une voie d’entrée très plausible.

L’objectif de ce travail de thèse était donc de conduire un travail de détection et de surveillance de la dengue et du chikungunya à la fois au niveau clinique chez des patients hospitalisés avec des symptômes fébriles aigus. Ces études se sont concentrées à la frontière avec le Cambodge et le Laos. Ce travail a été réalisé en partie au Vietnam dans le cadre du NIHE et en partie en France au CPBS (UMR 5236 UM-CNRS).

Les objectifs étaient les suivants :

1. Établir une surveillance et une étude épidémiologique et entomologiques dans des zones frontalières avec le Laos et le Cambodge.


3. Evaluer la présence et la dynamique de circulation du chikungunya au Vietnam


5. Etudier le rôle des diverses populations de moustiques dans la transmission de la dengue et du chikungunya en période d’épidémie et hors période d’épidémie.


7. Evaluer le système hospitalier de surveillance

8. Analyser la structure génétique de populations de moustiques potentiellement vectrices.
Cette thèse est donc présentée sous forme d’articles organisés en chapitres. Ces chapitres et articles sont les suivants :

**Partie 1: Etude bibliographique**

**Pham Thi Kim Lien**, Roger Frutos. Joint arboviral infections: risk and prospective. (Article en préparation)

**Partie 2 : Études de terrain et de laboratoire**

**Chapitre 1 - Role of Aedes species in the transmission of dengue in urban areas in North Vietnam**


L’objectif de ce travail était d’évaluer les correlations entre les cas de dengue et les densités de population de moustiques du genre Aedes durant l’épidémie de dengue de Hanoï en 2011. 24 foyers épidémiques ont été analysés sur 8 districts entre Août et Décembre 2011. 140 patients ont été hospitalisés suite à un diagnostic de dengue avec une prédominance masculine (59.3%) et une classe d’âge comprise entre 15 et 34 ans. Seuls DENV1 (11.27%) et DENV2 (88.79%) ont été détectés à partir des échantillons cliniques. L’échantillonnage des moustiques conduit dans et autour des habitations des patients a montré la prédominance d’A. aegypti (95.15%) par rapport à A. albopictus (4.85%). En
conclusion, il y a une correlation positive entre les densités de population d’A. aegypti, le nombre de cas humains et la durée des épidémies. Ceci n’a pas été observé avec A. albopictus. Trois lots d’A. aegypti ont été trouvé positifs à la dengue. Deux avec DENV1 et un avec DENV2.

Chapitre 2 – Surveillance of dengue and chikungunya virus infection in Dong Thap


Cette étude visait à établir une surveillance dans la province de Dong Thap, qui est frontière avec le Cambodge, afin d’évaluer la présence de virus de la dengue et du chikungunya parmi les patients hospitalisés à l’hôpital général de Dong Thap. Une analyse descriptive a été conduite sur 131 patients hospitalisés avec une fièvre aiguë et des symptômes compatibles avec la dengue et le chikungunya. L’étude a été conduite de Janvier 2012 à Février 2013. Le tableau clinique complet a été établi, ainsi que la détection sérologique et moléculaire. L’analyse sérologique a été conduite de façon séquentielle sur des échantillons de sang collectés à l’admission et sept jours après admission. Les virus de la dengue et du chikungunya ont été recherché par ELISA et PCR. 101 patients sur 131(77%) ont été confirmés positifs pour la dengue. Les quatre sérotypes ont été détectés avec une prédominance de DENV2 et DENV4. Aucun virus du chikungunya n’a été détecté. Un différentiel d’efficacité a été observé. L’efficacité de détection sérologique sur les mêmes patients était de 29% à l’admission et de 53% après 7 jours. 30 patients sur 131 (23%) étaient négatifs pour la dengue et le chikungunya. En conclusion, la dengue est à
risque de sous-estimation et le chikungunya n’est pas systématiquement détecté. Des changements devraient être opérés dans les procédures de surveillance afin de permettre un meilleur suivi de ces maladies.

Chapitre 3 - Dengue virus, chikungunya virus and risk factors in several provinces of Vietnam

Pham Thi Kim Lien, Laurence Briant, Laurent Gavotte, Pierrick Labbe, Marco Perriot-Sanguinet, Laurent Gavotte, Emmanuel Cornillot, Vu Trong Duoc, Nguyen Thi Yen, Tran Vu Phong, Nguyen Van Soai, Tran Duc Dong, Tran Chi Cuong, Phan Thi Nga, Tran Nhu Duong, Roger Frutos. Aedes mosquitoes mobility, diversity and risk factors for the diffusion of dengue and chikungunya in Vietnam. In preparation for submission to Emerging Infectious Diseases

Une surveillance active a été conduite au Vietnam pour évaluer la présence de la dengue et du chikungunya chez des patients hospitalisés avec une fièvre aiguë dans cinq provinces frontières avec le Laos et le Cambodge. Ce travail, conduit de 2012 à 2014, a été complété par une évaluation des populations de moustiques collectées dans la même zone. Un total de 558 sérums humains a été prélevé ainsi que 1104 moustiques adultes (991 A. aegypti et 113 A. albopictus) et 10995 larves (8542 A. aegypti et 2453 A. albopictus) collectés à partir de 2250 foyers. Le virus de la dengue a été trouvé sur 17 (3%) serums humains. Le virus du chikungunya n’a pas été détecté dans les échantillons humains. Des densités de population variables ont été trouvées, la plus élevée étant dans la province sud de Long An frontière avec le Cambodge. Le virus de la dengue a été détecté essentiellement chez A. albopictus. Le virus du chikungunya a été détecté chez A. aegypti. L’analyse phylogénétique des moustiques adultes collectés a montré une large diversité de génotypes, tous ayant été décrits dans d’autres parties du globe. De nouveaux haplotypes ont été détectés. Un moustique de l’espèce Culex vishnui a été trouvé positif pour la dengue, faisant de cette espèce un vecteur potentiel.
Ce travail sur la surveillance et la dynamique de la dengue et du chikungunya au Vietnam apporte un regard nouveau sur la situation actuelle et sur un certain nombre d’idées préconçues. En premier lieu cette étude est à notre connaissance la première analyse comparative à être conduite à une telle échelle sur le pays. Toutes les études précédentes concernaient des événements et épidémies à l’échelle locale et bien que correctes les conclusions ne reflètent qu’une vision locale et partielle de la dynamique. Une vision plus large est nécessaire pour mieux comprendre la dynamique de ces maladies.

La première conclusion de ce travail est qu’il est très difficile de tirer des conclusions sur le principal vecteur de la dengue. Dans ce travail, deux conclusions opposées ont été exprimées en fonction du lieu et peut être de la période. Durant l’épidémie de dengue de Hanoi en 2011, *A. aegypti* a été clairement identifié comme responsable de la propagation de la maladie. Une corrélation a été établie entre les densités de population locales d’*A. aegypti* et le nombre de cas cliniques. *A. albopictus* ne jouait aucun rôle. Quand une analyse globale a été réalisée dans plusieurs provinces du Nord, Centre et Sud Vietnam, le vecteur principal est apparu être *A. albopictus*. Encore plus important, les haplotypes impliqués ont été décrits dans d’autres parties du monde et un haplotype en particulier a été décrit récemment comme une population invasive en Europe. Plusieurs hypothèses peuvent émerger de cette apparente contradiction. La différence pourrait s’expliquer par la situation spécifique de Hanoi qui est une métropole urbaine à forte densité de population, un environnement favorable à *A. aegypti* par rapport à *A. albopictus*. *A. aegypti* est en effet plus anthropophile qu’*A. albopictus* et il est logiquement plus attendu dans une zone urbaine intense comme la capitale. L’étude conduite au sein de plusieurs provinces a montré à l’inverse qu’*A. albopictus* était le vecteur principal mais cette étude a été conduite en zone rurale où ce dernier est plus compétitif. Une autre explication pourrait être liée à la date des études. L’étude sur l’épidémie d’Hanoi a été conduite en 2011 alors que celle sur les diverses provinces a été réalisée entre 2012 et 2014. Il n’est donc pas possible d’exclure un remplacement d’espèce dominante. Toutefois, cette hypothèse n’apparaît pas très solide étant donné que dans l’étude sur plusieurs province, *A. aegypti* était très largement l’espèce dominante. Une dernière explication pourrait être trouvée dans la manière dont ces analyses ont été construites, ce qui représente aussi une forme d’autocritique. La conclusion issue de l’étude sur Hanoi était basée essentiellement
sur une corrélation entre densité et période de pic des populations de moustiques et le nombre de cas cliniques. Cette étude était basée sur un nombre d’échantillon faible. Dans l’étude sur plusieurs provinces, un plus grand nombre d’échantillons a été analysé et *A. albopictus* a été identifié comme le vecteur principal alors que sa densité de population était nettement plus faible que celle d’*A. aegypti*. Ceci est particulièrement vrai dans la province de Long An où *A. albopictus* représentait 0.9 % des captures et 50% des moustiques infectés. Avec un plus faible échantillon, cette étude aurait pu conduire à la conclusion d’un rôle prédominant d’*A. aegypti*.

Ce travail de thèse montre le besoin d’une approche globale et coordonnée lors de l’analyse de la dynamique de la dengue et du chikungunya. De telles études ne peuvent pas être conduites à partir d’événements ponctuels et localisés du fait que la somme d’études ponctuelles ne conduit pas nécessairement une vision globale exacte. Les études de surveillance devraient être conçues au niveau national et basée sur un plan maître incluant à la fois des études cliniques et entomologiques avec détection de virus dans tous les échantillons. Le génotypage des populations de moustiques devrait être conduit de façon obligatoire ainsi que le génotypage des virus isolés d’échantillons humains et entomologiques afin de conduire les analyses de dynamique au niveau des lignées virales. La lignée est le véritable niveau de granulométrie à considérer. L’espèce et le sérotype ne sont pas suffisamment précis pour permettre une analyse de la circulation et une cartographie d’association. Une première recommandation issue de ce travail serait donc de développer une telle approche intégrée et de la proposer au NIHE ainsi qu’au niveau national. Ceci doit inclure une base de données et un système de gestion des bases de données homogènes et intégrés permettant une analyse spatio-temporelle.

Ceci est particulièrement pertinent si l’on considère une autre conclusion de ce travail de thèse, à savoir que les moustiques impliqués dans la vection ne sont pas des populations locales mais des populations circulant à l’échelon du globe. Une analyse de la dynamique ne doit donc pas se concentrer sur les populations locales de moustiques, bien qu’elles puissent néanmoins jouer un rôle, mais plutôt sur le monitoring régulier des populations de moustiques et en particulier aux points d’entrée comme les ports. De telles procédures devraient aussi être développées et cela pourrait être une autre perspective de
ce travail. Génotypage, bases de données adaptées et analyses comparative des séquences de moustiques et de virus devront être développées ainsi que des analyses géographiques et des mouvements commerciaux internationaux.

Un dernier aspect mis en évidence par ce travail est l’adaptation limitée des procédures actuelles de surveillance et de dépistage mises en œuvre à l’hôpital et dans les services de santé publique. Comme cela a été montré dans le cas de l’hôpital de Dong Thap, les tests sérologiques réalisés à l’admission sous-estiment le nombre de patients positifs pour la dengue. De plus, ils ne permettent pas l’identification des lignées virales. Le chikungunya n’est en outre pas dépisté du tout. Il serait trop onéreux et difficilement réalisable de mettre en place un test sérologique multi-étapes avec au final des résultats peu satisfaisants. La dernière recommandation et perspective issues de ce travail seraient donc la mise en place d’un test PCR multiplex pouvant détecter les quatre sérotypes de dengue ainsi que les deux variants, ancien et réémergent du chikungunya. Ce test devrait être associé au séquençage des échantillons positifs. Le cout de la PCR et du séquençage est désormais très compétitif et le bénéfice attendu pour la santé publique compense très largement l’investissement en surveillance. Ceci devrait être lié au même système intégré de bases de données dynamiques que pour la surveillance des moustiques. Un projet devra être soumis en ce sens au NIHE et aux instances nationales.

En conclusion, ce travail de thèse a mis en évidence des points important à aborder de façon coordonnée afin de développer un système de surveillance efficace pour la dengue et le chikungunya au Vietnam. Développer ces systèmes et outils représentera un défi stimulant à relever et une valorisation intéressante de ce travail.
SUMMARY

Arthropod-borne viral infections (or arboviral infections) are common causes of fever syndromes worldwide, more than 130 arboviruses are known to cause disease in humans. Dengue fever (DF) caused by *Flavivirus* belong to the family *Flaviviridae*, and chikungunya is caused by an *Alphavirus* in the family *Togaviridae*. Both dengue and chikungunya diseases are transmitted by mosquitoes mainly *Aedes aegypti* (*Ae. aegypti*) and *Aedes albopictus* (*Ae. albopictus*) and can cause potentially severe and or debilitating chronic disease. Over the past 50 years, dengue has spread inexorably, with nine countries reporting dengue transmission prior to 1970 compared to over 144 now, and incidence having increased 30 fold. While dengue is the commonest and the most rapidly spreading mosquito-borne viral disease in the world, chikungunya (CHIK) has recently re-emerged after an interval of several decades to affect and place at risk millions of people in the Indian Ocean areas, Africa, Southeast Asia and more recently has spread to the Caribbean region. There are evidence countries in Asia, Africa and the Pacific of patients exhibiting co-infection with dengue and chikungunya simultaneously. Without a licensed vaccine, therapeutic drugs and effective of vector transmission, the increasing number of case dengue virus (DENV), chikungunya virus (CHIKV) is associated with expanding geographic rage and increasing intensity of transmission in affected areas.

Vietnam is one of five countries in the Southeast Asia with the highest dengue burden. Cambodia and Laos countries share a long and extensive border with Vietnam that have endemic for dengue, reported increasing chikungunya activity in Laos and Cambodian provinces bordering Vietnam. Dengue is highly endemics in tropical southern Vietnam, while increasing larger seasonal epidemics have occurred in northern Vietnam over the last decade. Biomolecular level used to describes DENV serotypes. We have revealed that DENV serotypes circulating in Vietnam are similar to those observed in neighboring countries - in particular Cambodia and China. All four dengue virus serotypes founded circulating in Vietnam with dominant one varying through in southern and northern.

Although CHIKV affected areas often overlap with DENV - endemic areas, however, simultaneous outbreaks are rare. So far, no case of chikungunya in human reported in Vietnam, excepted 10 cases in 1967 of American soldiers in Vietnam. This
study is the first to prospective investigate the circulation of the CHIKV and detected two Ae. Aegypti mosquitoes infected with CHIKV in the south of Vietnam.

This thesis manuscript reports data obtained by multidisciplinary and integrative approaches aiming to better understand dengue and chikungunya virus situation in several provinces shares the border with Laos and Cambodia, and found that the proportion of Stegomyia index of two vectors Ae. aegypti and Ae. albopictus, with the potential effects of DENV and CHIKV vector differed at the communes belong five districts in the north, center and south of Vietnam. Additionally, we described that a significant the role of DENV as cause of febrile illness in human, and also identified high proportion of dengue infection among patients in Dong Thap hospital, in south of Vietnam. On the other hand, to better understand on the positive correlation between the population density of Ae. aegypti and the number of DENV human cases of outbreaks in Hanoi capital, north of Vietnam. Beside, an integrative analysis encompassing the genetic study of viral lineages on human patents and in mosquitoes along with the genotyping of mosquito population should be undertaken to provide clear information on the dynamic of dengue and chikungunya in Vietnam. Our result suggested that the detected CHIKV in Ae. aegypti mosquito should be considered as warned of CHIKV appear in Vietnam and may be with DENV consists of four distinct serotypes combination remains a major public health problem.
GENERAL INTRODUCTION

From the second half of the 20th century, with achievements of medical research in terms of vaccination, antibiotics and improvement of life and health conditions of mankind, it was expected that infectious diseases were going to disappear. However, in developed countries the efforts have been concentrated on illnesses as cancer. Consequently, at the dawn of the new century, infectious diseases are still causing suffering and mortality in developing countries. With the disease as Malaria, AIDS, Mycobacteria tuberculosis and other diseases will have marked the memory of humanity forever.

Among these diseases, dengue fever, especially known in Southeast Asia, are hitting countries with tropical and warm climates. It is transmitted to the man by the mosquito of the genus Aedes (Ae.) is the principal vector of dengue and adapted extremely well to the urban environment. Dengue remains a major public health problem in tropical and subtropical countries despite lots of effort to control the mosquito vector (1) with an estimated global annual incidence of 50 million cases leading to ten of thousands of deaths (2) and more than 2.5 billion people being at risk of infection. Since the 1950s, the incidence of DHF/DSS has increased over 30 fold (3), with more than countries affected by outbreaks of dengue (4) Infection with any of DENV serotype may be asymptomatic in the majority of case or may result in a wide spectrum of clinical symptom (5). Dengue fever exists in two forms: the classic dengue or Dengue Fever (DF) and the Dengue Hemorrhagic Fever (DHF) which may evolve toward a severe form known as Dengue Shock Syndrome (DSS). The major problem with dengue is the fact that the disease is caused by five distinct serotypes known as DEN1, DEN2, DEN3, DEN4 (6) and new DENV5 was detected in Thailand in 2013 (7). A person infected by one of the five serotypes will never be infected again by the same serotype (homologus immunity), but loses immunity to the three other serotypes (heterologus immunity) in about 12 weeks and then becomes more susceptible to developing dengue hemorrhagic fever.

The latter distinguishes chikungunya virus (CHIKV) from dengue fever, which otherwise shares the same vectors, incubation period, clinical course, symptoms, and geographical distribution. The word chikungunya, which is used for both the virus and the disease, means “to walk bent over” in African dialect Swahili or Makonde, and refers to
the effect of the incapacitating arthralgia. The virus was first isolated in 1952 in Tanzania (8). Human chikungunya virus infection has been documented in Burma, Thailand, Cambodia, Viet Nam, India, Sri Lanka, and the Philippines (9). Recent chikungunya outbreaks caused several million clinical cases in the Indian Ocean Islands and India. Neither Europe nor the Americas have had outbreaks of chikungunya virus so far (9) (10) and more recently has spread to the Caribbean region (11).

Dengue and Chikungunya are among the most difficult diseases to distinguish, especially because simultaneous co-infection can occur (12)(13)(14)(15)(16)(17). Chikungunya and dengue viruses are frequently transmitted to humans by peridomestic Aedes mosquitoes. *Ae. aegypti* has been considered to be the principal vector in the urban transmission cycle, with *Ae. albopictus* and other anthropophilic *Aedes* spp. serving as secondary vectors (18)(19).

Vietnam is located in South Eastern Asia, bordering the Gulf of Thailand, Gulf of Tonkin, and shares the border with South China Sea, China, Laos, and Cambodia. The climate is tropical in south; monsoonal in north with 4 seasons are spring, summer, autumn and winter. Vietnam faced with many health problems including fever/ dengue haemorrhagic fever (DF/DHF). In 1958, dengue was first detected in the North, and in 1960 was described in the South of Vietnam (20). Case occur year round in the South, and during the rainy season elsewhere. The incidence of DHF has increased from the first recorded outbreak in 1963, major epidemic occurred in 1969, 1983, and 1987 with a widespread epidemic in 1998 affecting 42 out of 61 provinces and resulting in 232,793 cases and 447 deaths (21). An estimated average reported morbidity and mortality between 1996 and 2005 was 75,407 cases and 145 deaths per year (22). In 2009, 27,000 cases (26 fatal), and in 2012 have 18,052 cases, 9 fatal, were reported during January to June (23). The outbreaks in 2013 were reported 25,300 cases and 16 fatal in August. (23)

Since 1975, chikungunya virus is first detected in Vietnam according WHO reported (24). To date, no cases of chikungunya have been reported in Vietnam, since 1967 when 10 cases were reported in American soldiers in Vietnam (25) and other study of anti-chikungunya antibodies in Vietnamese children in the South of Vietnam (26). In other research on anti-chikungunya antibodies in the North, Viet Nam show that, 60 percent of patients with classic dengue symptoms have tested negative for dengue virus. according to Vu Sinh Nam, Preventive Health and Environment Department, Ministry of health, and 4
of 17 provinces: Ha Noi, Nghe An, Ha Nam, Nam Dinh were positive to chikungunya virus with proportion 15/324 patients who have had classic dengue symptoms. Detected of chikungunya virus during dengue outbreak in the north, Viet Nam (27).

To find out suitability for surveillance chikungunya and dengue viruses infection in Viet Nam, the knowledge about mechanism of Chikungunya and Dengue virus interaction has essential activities that can help in the prevention of vector - born disease to improve the management, surveillance, control of dengue and chikungunya virus infection in Vietnam. On the other hand, the current knowledge on early events of chikungunya and dengue transmission from mosquitoes to human is limited. Besides, there are several reasons to believe that dengue and chikungunya may be co circulating in Vietnam as cases of CHIKV have been reported in neighbouring human populations. Cambodia reported the re - emergence of CHIKV in 2011 with 24 patients identified when samples were tested for Flaviviruses and Alphaviruses (28). In 2012, chikungunya outbreaks were reported in Laos with 197 cases in Moonlpamok and Khong Districts of Chamasak province (29). Vietnam shares borders with Cambodia and Laos, its therefore possible that cross - border transmission into Vietnam may occur as result of travel and traffic between the neighbouring countries from infected people or mosquitoes.

Our aim is therefore to perform an epidemiological survey of dengue and chikungunya in several provinces in Vietnam shares the border to Cambodia and Laos during the 2011 - 2014 periods. We will also investigate the interaction of mosquito to human transmission and the risk factors transmission dengue and chikungunya viruses. This part of the study is coordinated with the Center of National Research Scientific (CNRS), and Montpellier University 2, Montpellier, France.

The specific objective of the research aims:

9. To describe the surveillance data of chikungunya virus from several provinces presence in the north, center and south in Vietnam shares border with Laos and Cambodia.
10. To better understand the monitor Dengue and identify the virus strains circulating in Vietnam.
11. To obtain and analysis, of some dengue strains circulating in the North, with dengue viruses isolated in other regions in Vietnam.
12. To describe the spread of chikungunya and dengue viruses with the role of mosquitoes transmission in Ha noi, Vietnam.

13. To identify the molecular epidemiology of vector transmission chikungunya and dengue viruses in Viet Nam.

The outline will be displayed in form of chapters with results presented as a form of published, submitted or in preparation articles. The articles included in this thesis are listed below:

**FIRST PART**

Pham Thi Kim Lien, Roger Frutos. Joint arboviral infections: risk and prospective. (in preparation)

**SECOND PART**

CHAPTER 1

Pham Thi Kim Lien, Vu Trong Duoc, Laurent Gavotte, Emmanuel Cornillot, Phan Thi Nga, Laurence Briant, Roger Frutos, Tran Nhu Duong. Role of *Aedes aegypti* and *Aedes albopictus* during the 2011 dengue fever outbreaks in Hanoi, Vietnam. Asian Pacific Journal of Tropical Medicine, 2015; 8 (7); 543-548.

CHAPTER 2


CHAPTER 3

Pham Thi Kim Lien, Laurence Briant, Laurent Gavotte, Pierrick Labbe, Marco Perriat-Sanguinet, Laurent Gavotte, Emmanuel Cornillot, Vu Trong Duoc, Nguyen Thi Yen, Tran Vu Phong, Nguyen Van Soai, Tran Duc Dong, Tran Chi Cuong, Phan Thi Nga, Tran Nhu Duong, Roger Frutos. *Aedes* mosquitoes mobility, diversity and risk factors for the diffusion of dengue and chikungunya in Vietnam. In preparation for submission to Emerging Infectious Diseases
PART I
LITERATURE REVIEW
1. Arboviruses

Arthropod-borne viruses (arboviruses) are viruses that can be transmitted to human by arthropod vectors. The WHO definition is as follows: “Viruses maintained in nature principally, or to an important extent, through biological transmission between susceptible vertebrate hosts by haematophagous arthropods or through transovarian and possibly venereal transmission in arthropods.” (30).

Arboviruses that cause human encephalitis/animal or zoonotic disease have been identified, are members of four virus families: the *Togaviridae* (genus Alphavirus), *Flaviviridae*, *Bunyaviridae* and *Reoviride*, contain most of the arbovirus that cause human/animal disease (31)(32)(33). The term of arboviruses is not taxonomic indicator, it describers their requirement for vertor in their transmission cycle (34)(33). According to International catalogue of Arbovirus, 1992,535 species belonging to 14 virus families were registered (33). More than 130 arboviruses are known to cause human disease.

Human and animals infected by arboviruses, may suffer diseases ranging from sub-clinical or mild through febrile to encephalitic or hemorrhagic with a significant proportion of facilities. Arboviruses infections can cause four types of illness: 1) Illnesses of the central nervous system, ranging in seriousness from mild viral meningitis to encephalitis (inflammation of the brain), with coma, paralysis, and death; 2) Mild fever illnesses with or without rash; 3) Hemorrhagic fevers that can be serious and life-threatening; 4) Arthritis and rash, with or without fever (35)(36).

Three of a large number of neglected human pathogenic arthtopod- borne virus are chikungunya virus (CHIKV), dengue virus (DENV), and West Nile virus (WNV) whose combined figures for morbidity and mortality far exceed those for Ebola, severe acute respiratory syndrome and Middle East respiratory syndrome viruses (36).

Approximately 300 type of mosquitoes could transmit arbovirus, special *Aedes* and *Culex* mosquitoes are the species most frequently associated with arbovirus transmission, respectively more than 105 - 115 types of arbovirus (37) (33). Ticks are also prevalent vectors, 116 difference species are currently know to transmite arboviruses, in addition 25 midge species mainly 24 types of *Culicoides* and *Laisiohelela*. Sandflies, blackflies,
stinkbugs, lice, mites, gadfly, and bedbugs can also transmit arboviruses (38). This diversity of species and the wide distribution of these transmission vectors explain why arboviruses are so successful in dispersing globally via the mechanisms highlighted earlier (39)(33). A high proportion of Arbovirus associated with human and animal disease circulate in tropical and subtropical regions, where mosquitoes, and other flying insects, tend to be abundant. Also, many arboviruses circulate among wildlife species in temperate regions of the world. They have evolved a wide variety of strategies to ensure their long term success, dispersal and survival. Arbovirus adapt readily to new susceptible hosts by alteration of receptor specificity, transmission efficiency, antigenicity, ecological and environmental conditions. Changing anthropological behaviour, climate change and high mutation frequency are important determinants of arbovirus emergence (36).

Up to date, in the 21st century, develop vaccine and antiviral drugs to prevent or treat humans against infection by pathogenic aboviruses will resolve the challenge associated with emerging arboviruses.

2. Different of Arbovirus families

2.1. Family Flaviviridae

2.1.1. Classification

The International Committee on Taxonomy of Viruses (ICTV) began to devise and implement rules for the naming and classification of viruses early in the 1970s, an effort that continues to the present day. According to the ICTV of virus Flaviviruses constitute of three genera within the virus family Flaviviridae, and others two are the genera Pestivirus from Latin pestis is “Plague” and Hepacivirus from Greek hepatos is “liver”. The family Flaviviridae contains 58 species within three genera to include Flavivirus (53 species), Herpacivirus (1 species), and Pestivirus (4 species). Fourteen species within the genus Flavivirus and all species within the Herpacivirus and Pestivirus genera are not known to be transmitted by arthropod vectors. (Beth K. Schweitzeer, 2009) (40).
Figure 1: Three genera of the *Flaviviridae* family in the Phylogenetic tree.

The Flaviviruses are primarily transmitted by arthropods and consist of more than 73 viruses including yellow fever virus, Japanese encephalitis virus, Dengue virus, West Nile virus, tick borne encephalitis, (41)(42). The first identified human virus in the flavivirus prototype is Yellow fever virus (YFV), this is name derived from Latin word “flavus”, meaning yellow, evoking the jaundice caused by YFV (43).

In the genus Flavivirus, viruses share complex antigenic inter relationships, they can separate into four ecological or phylogenetic group with regard to their vector association: mosquito - borne group, a tick - borne group, and non- vectored viruses. (See figure 2) Subtypes are written in parentheses after virus names. New world viruses are printed in bold and underlined (43).
Figure 2: Devided from the GenBank library, phylogenetic tree of the flaviviruses derived from partial Non-structural protein NS-S (NSS) sequences.
2.1.2 Genome structure

The *Flaviviridae* genome contains a single, consists of a linear, positive-sense RNA molecule of about 10.8 kb in size, and the genome is not segmented. The complete genome is 9500 - 12500 nucleotides long, Flavivirus virion are 50nm in diameter, spherical, and enveloped (44). The genome has a 5’- end carries a methylated nucleotide cap or genome - linked protein. It also has a 3’ polyadenylated tail, polyprotein from genomic RNA cleaved, three structural proteins and some non-structural proteins. The genome undergoes cytoplasmic replication (45). The translation initiation is cap - dependent in *Flaviviruses* (44).

![Diagram of flavivirus virion](image)

**Note:** M is protein, E is protein envelope, ORF is openreading frame, ssRNA is Singgle Stranded Ribonucleic Acid.

**Figure 3:** Schematic structure of flavivirus virion (Philippe Buchy).

As study of Cleaves in 1981, the flavivirus genome has one open reading frame encoding a sing ger polyprotein at the origin of structural and non tructural proteins (45).
Figure 4: The single open reading frame is depicted with the structural and non-structural protein coding region (colored is blue and green respectively). The 5′cap and the 5′ and 3′ untranslated region (UTR). The single open reading frame encodes an immature polyprotein precursor that is co and post translationally cleaved into three structural proteins (in blue) and seven nonstructural proteins (in green) (46).

Figure 5: The detail of cleavage sites for cellular proteases, NS2B/NS3 and unknown protease are indicated (47).
2.1.3 Vector

Ticks and mosquitoes are too major group of arthropod vectors of Flaviviruses, of the known Flaviviruses, approximately 50% are recognized human pathogens causing fever, encephalitis, or hemorrhagic disease, however, for many of others, the pathogenic potential has not been well studied (Gubler Dj, Kuno G, 2007)(48) (49). Important mosquito was borne Flaviviruses include dengue virus serotypes 1 - 4, Yellow fever virus (YFV), West Nile virus (WNV), Japanese encephalitis virus (JEV) and St.Louis encephalitis virus (SLEV). The mosquito - born flaviviruses comprise two distinct epidemiology groups: neutrotropic viruses, often associated with encephalitic disease in human or livestock, *culex* spp. Mosquito vectors, and birth reservoirs, and nonneutrotropic viruses are associated with hemorrhagic disease in humans, *Aedes spp* mosquito vector, and primate host (50).

**Ticks**

In nature, tick borne flaviviruses are maintained through a transmission cycle involving an ixodid tick vector and a vertebrate host (51). Tick transmitted flaviviruses comprise two distinct groups: mammalian and seabird virus groups. It is transmitted by the bite of several species of infected ticks, including *Ixodes scapularis, Ixodes ricinus* and *Ixodes persulcatus* (52) or very rarely through the non - pasteurized milk of infected cows.

![Figure 6: Transmission cycle for tick-born encephalistic virus.](image-url)
Tick-borne encephalitis virus (TBEV), which includes three subtypes, European, Far Eastern, and Siberian, was the most important role in human epidemiology, particularly in the old ‘‘Eastern bloc’’ countries, producing a wide range of diseases including subclinical infections, biphasic fever, encephalitis, and chronic disease. The vector of TBEV in European is *Ixodes ricinus*, and *I persulcatus* for the other two subtypes (53) (54)(55) (56)(57) (58) (59) (60). *I ricinus* is detected in the most of Europe, and the distribution extends to Turkey, Northern Iran, and in the Southeast of Caucasus (61). *I persulcatus* was found in the belt extending from Eastern Europe to China and Japan. Both tick species cocirculate a restricted area in northeastern Europe, Russian Karelia, St Petersburg, and eastern Estonia and Latvia. An ectopic focus of TBE-Sib carried by *I persulcatus* has been discovered in western Finland. (62) (63)(64).

The seabird tick - borne virus group has not been shown to induce disease in humans or in seabirds and the reasons why these relatively closely related viruses differ so significantly in this particular characteristic have not been investigated. However, human contact with seabirds is limited (65).

*Mosquitoes*

*Culex*

The most dangerous and most widely distributed mosquito in the world is *Culex* mosquitoes, *Culex* mosquito feeding normally happens at night. After feeding, the *Culex* mosquito will find somewhere cold and damp to rest and digest. Digestion of a meal can take 2 to 7 days with 1 to 3 meals needed to produce a clutch of eggs. The female mosquitoes prefer to lay their eggs in standing water that contains plenty of organic matter (66).

The most importance of *Culex* vectors are member of *Culex pipiens* complex, known as the northern house mosquito. Normally, *Culex pipiens* is considered to be a bird feeder but some urban strains have a predilection for mammalian hosts and feed readily on humans. According to a classification system for Northeastern mosquito, the life cycle of *Culex pipiens* represents a variation of the *multivoltine* life cycle: non - desiccation resistant eggs laid directly on water, larvae develop in polluted water habitats, multiple generations each year; overwinters as a mated female.
Figure 7: Life cycle of *Culex* mosquito

The second of *Culex* vectors are *C.aurtralicus*, *C.triaeniorhynchus*, *C.salinatius*, *C.tarsalis*, *C.quinequefasciatus*, *C.nigripalus*, *C.annulirostris*. The major Asian vector of Japanese encephalitis (JE) is *Culex triaeniorhynchus* (67). In Australia, the main vector transmission to human of Murray Valeley (MVE) and Kunjin (KUN) viruses is *Culex annulirostris* (68)(69).

**Transmission cycles**

In Human, cycle of *Culex* mosquito is multipliers of the virus, and serving as a source of the virus for uninfected mosquitoes. Most female mosquitoes have to feed on human or an animal and get a sufficient blood meal before she can develop eggs, and *Culex* mosquito usually lay their eggs at night.

**Aedes aegypti and Aedes Albopictus**

*Aedes aegypti*

*Ae. aegypti* is believed originated in the jungle of Africa where a sylvatic, where ancestral from (4)(70), and *Ae. aegypti formosus* is East and Central Africa (71). The domestic from *Ae. aegypti* was most likely spread throughout the rest of the world via slave and
trading ships during the seventeenth to nineteenth centuries (72). After that, *Ae. aegypti* could be found in the tropical and subtropical regions of the world. According to Moritz UG Kraemer, 2015 prediction the distribution of the top ten countries in terms of occurrence records for each continent for *Ae. aegypti* and *Ae. albopictus* (73) are shown in table 1.

Table 1: The geographic distribution of spatially unique occurrence for the Americas, Europe/ Africa, and Asia/ Oceania (source: Moritz UG Kraemer, 2015) (73)

<table>
<thead>
<tr>
<th></th>
<th>Americas</th>
<th>Europe/Africa</th>
<th>Asia/Oceania</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ae. aegypti</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brazil</td>
<td>5,044</td>
<td>Senegal</td>
<td>112</td>
</tr>
<tr>
<td>USA</td>
<td>436</td>
<td>Cameroon</td>
<td>55</td>
</tr>
<tr>
<td>Mexico</td>
<td>411</td>
<td>Kenya</td>
<td>52</td>
</tr>
<tr>
<td>Cuba</td>
<td>177</td>
<td>United Republic of Tanzania</td>
<td>44</td>
</tr>
<tr>
<td>Argentina</td>
<td>170</td>
<td>Côte d’loire</td>
<td>40</td>
</tr>
<tr>
<td>Trinidad &amp; Tobago</td>
<td>152</td>
<td>Nigeria</td>
<td>35</td>
</tr>
<tr>
<td>Venezuela</td>
<td>130</td>
<td>Madagascar</td>
<td>28</td>
</tr>
<tr>
<td>Colombia</td>
<td>128</td>
<td>Gabon</td>
<td>27</td>
</tr>
<tr>
<td>Puerto Rico</td>
<td>120</td>
<td>Mayotte</td>
<td>20</td>
</tr>
<tr>
<td>Peru</td>
<td>89</td>
<td>Sierra Leone</td>
<td>20</td>
</tr>
<tr>
<td><strong>Ae. albopictus</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brazil</td>
<td>3,441</td>
<td>Italy</td>
<td>203</td>
</tr>
<tr>
<td>USA</td>
<td>1,594</td>
<td>Madagascar</td>
<td>58</td>
</tr>
<tr>
<td>Mexico</td>
<td>50</td>
<td>Cameroon</td>
<td>42</td>
</tr>
<tr>
<td>Cayman Islands</td>
<td>15</td>
<td>France</td>
<td>37</td>
</tr>
<tr>
<td>Haiti</td>
<td>13</td>
<td>Gabon</td>
<td>27</td>
</tr>
<tr>
<td>Guatemala</td>
<td>12</td>
<td>Albania</td>
<td>22</td>
</tr>
<tr>
<td>Venezuela</td>
<td>7</td>
<td>Mayotte</td>
<td>21</td>
</tr>
<tr>
<td>Colombia</td>
<td>3</td>
<td>Greece</td>
<td>18</td>
</tr>
<tr>
<td>Cuba</td>
<td>3</td>
<td>Israel</td>
<td>17</td>
</tr>
<tr>
<td>Puerto Rico</td>
<td>3</td>
<td>Lebanon</td>
<td>15</td>
</tr>
</tbody>
</table>
Currently, *Ae. aegypti* is presented and frequently abundant in most tropical and subtropical countries of the world (73). It seems probable that the geographical distribution of *Ae. aegypti* will continue to expand, with incursion in previously uncolonised areas resulting in risk of vector-born disease transmission to previously unaffected populations (74).

**Ae. albopictus**

*Ae. albopictus* is believed to have originated in South-East Asia, islands of the Western Pacific and Indian Ocean, has spread during recent decades to Africa, the mid-east, Europe and the Americas (75).

Prior to 1979, *Ae. albopictus* was present from China, northern Japan to tropical Asia and in the Western Pacific, but has spread to much of the rest of the world in recent decades, in 1983 *Ae. albopictus* was found in Memphis, Tennessee, United States, and 1995, confirmed with its discovery in Houston, Texas, United States. (76) (77).

*Ae. albopictus* has been one of the fastest spreading animal species over the past two decades in central and South America (4). In addition to the ecological problems inherent in rapid spread of any species of particular importance are the serious public health risks posed by the introduction and establishment of an aggressive pest and efficient disease vector (78).

**Transmission cycles**

Infected humans are the main carriers and multipliers of the virus, and serving as a source of the virus for uninfected mosquitoes. The virus circulates in the blood of infected humans for two to seven days, at approximately the same time that they have a fever. *Aedes* mosquitoes may acquire the virus when they feed on an individual during this period. The transmission cycle may also involve jungle primates that act as a reservoir for the virus in parts of South East Asia and Africa (79)(80).
2.1.4 Flavivirus replication cycle

In the host cell, Flavivirus enter by receptor-mediated endocytosis (82). In human target cell have two types of cell receptor appear to be involved in facilitating entry of Dengue virus depending on the cell (83). The first type corresponds to several primary receptors of low affinity and specificity including aminoglycan-type adhesion molecules such as heparin sulfate that are expressed in many cell types (84) (85). The second type corresponds to lectin-type receptors such as the Dendric cell-specific intercellular adhesion molecule 3-grabbing non-antigen (DC-SIGN) expressed in some antigen-presenting cells such as immature dendritic cell (82).
2.1.5 Main disease

Yellow fever

Yellow fever (YF) is an acute viral haemorrhagic disease transmitted by infected *Ae. aegypti* (87), and other species mosquitoes (88). YF was found in tropical and subtropical areas in South America and Africa, but not in Asia (89). The origin of the disease is most likely to be Africa, from where it was introduced to South America through
the slave trade in the 16th century. Since the 17th century, several major epidemics of the disease recorded in the Americas, Africa and Europe. In the 19th century, YF was deemed one of the most dangerous infectious diseases (90). According to the World Health Organization (WHO) estimates, there are approximately 200,000 cases of YF worldwide each year, and 30,000 deaths. About 90% of all cases occur in Africa. The virus is endemic in tropical areas of Africa and Latin America, with a combined population of over 900 million people (91).

The "yellow" in the name refers to the jaundice that affects some patients. The signs and YF symptoms in some people have no symptom but in the more severe case is fever, nausea, vomiting, neck and back pain and it generally subsides after several days.

There is no cure for yellow fever. Up to 50% of severely affected persons without treatment will die from yellow fever. Treatment is symptomatic, aimed at reducing the symptoms for the comfort of the patient (WHO).

In the middle of the 20th century a safe and effective live, and attenuated vaccine was created (92). However, since the 1980s the number of YF cases has increased, making it a reemerging disease. Besides vaccination, control of the YF mosquito *Ae. aegypti* and other species mosquitoes is of major importance in prevention YF virus (WHO).

**St. Louis encephalitis**

St. Louis Encephalitis (SLE) is a disease transmitted caused by the *Culex* mosquito. In 1993, SLE virus was first isolated from a brain suspension obtained from a case of acute encephalitis during a large urban outbreak of the disease in St Louis, Missouri, and the neighboring St. Louis County, the epidemics have occurred sporadically and unpredictably in the subsequent decades. Prior to the introduction of West Nile Virus to the United States in 1999, SLE was the most common mosquito transmitted pathogen in the United State, major SLE epidemics occurred in Florida in 1959, 1961, 1962, 1977 and 1990. A large outbreak occurred in the Ohio - Mississippi River Basin in 1975, a year when close to 2000 cases were reported nationwide. Occasional cases have been reported from Canada and Mexico. SLE virus is an emerging arbovirus in South America, with febrile illness and encephalitis cases reported in Argentina in 2002 and 2005, and in Brazil in 2004 and 2006 (93)(94).

In general people who are infected with SLE have very mild illness or may never become sick, mild infection are characterized by fever and headache, without other
apparent symptoms, but the symptoms of severe disease can include: headache, nausea, high fever, neck stiffness, confusion, coma, shaking, seizures and/or paralysis (95).

There is no effective antiviral medication for the treatment of SLE. Treatment for SLE is largely supportive and includes rest and medications to control vomiting (96).

Prevent to SLE virus infected is the easiest and best way to avoid mosquito bites. There is no commercially available human vaccine for SLE (97)(98).

**Japanese encephalitis**

Japanese encephalitis (JE) virus disease transmitted cause by the mosquito *Culex tritaeniorhynchus*, It was first recognised in Japan in the late 1800s (99), represents the most significant etiology of arboviral encephalitis worldwide. JE is a neurologic infection closely related to St. Louis encephalitis and West Nile encephalitis. JE disease is most prevalent in Southeast Asia, the Far East and the Pacific islands (100). Intensification and expansion of irrigated rice production systems in South and South East Asia over the past 20 years have had an important impact on the disease burden. According to the World Health Organization, at least 30,000 - 50,000 people in Asia develop visible symptoms of Japanese encephalitis each year. Around 1 in 200 people develop more serious symptom, which can lead to permanence brain damage or death. It occurs from the islands of the Western Pacific in the east to the Pakistani border in the west, and from Korea in the north to Papua New Guinea in the south. Countries which have had major epidemics in the past, but which have controlled the disease primarily by vaccination, include China, Korea, Japan, Taiwan and Thailand. Other countries that still have periodic epidemics include Viet Nam, Cambodia, Myanmar, India, Nepal, and Malaysia.

Infected mosquitoes then transmit the Japanese encephalitis virus to humans and animals during the feeding process. Mild infections occur without apparent symptoms other than fever with headache. More severe infection marked by quick onset, headache, high fever, neck stiffness, stupor, disorientation, coma, tremors, occasional convulsions (especially in infants) and spastic (but rarely flaccid) paralysis. Most infections are asymptomatic, but when encephalitis develops, the case - fatality rate can be as high as 30%. Neuropsychiatric sequelae reported in 50% of survivors.

In May 2009 and 2011 a new an effective inactivated vaccine is available for Japanese encephalitis, but it is expensive and requires one primary vaccination followed by two boosters.(101)(102)(103). According to WHO, in 2014 there are three types of
inactivated vaccines and one type of live attenuated vaccine currently used in the world: 1) mouse brain - derived, purified vaccine, which is based on either the Nakayama - NIH or Beijing -1 [P-1] strains; 2) primary hamster kidney (PHK) cell - derived, purified vaccine, based on the Beijing-3 [P-3] strain; 3) Vero - cell derived purified vaccine based on the P-1, P-3 or SA14-14-2 strains as virus seeds; and 4) PHK cell derived live attenuated vaccine based on the SA14-14-2 strain of the JE virus.

Dengue

Dengue viruses transmitted principally in a cycle involving humans and mosquito vectors, the *Ae. aegypti* or more rarely the *Ae. albopictus* mosquito. The first case was reported the existence of dengue - like disease in 1779 but it was most likely present long before in first appeared in literature. Dengue virus is major threat to health in tropical and sub - tropical countries, mostly found at Africa, Asia, Caribbean countries, Central and South America, Mexico, The Pacific. Severe dengue, previously known as Dengue Haemorrhagic Fever (DHF) was first recognized in the 1950s during dengue epidemics in the Philippines and Thailand. Before 1970, only nine countries had experienced severe dengue epidemics. The disease is now endemic in 144 countries in Africa, the Americas, the Eastern Mediterranean, South - East Asia and the Western Pacific. South - East Asia and the Western Pacific regions are the most seriously affected (3).

Dengue fever is a severe, flu - like illness that affects infants, young children and adults, but seldom causes death. For severe dengue, medical care by physicians and nurses experienced with the effects and progression of the disease can save lives. At present, the only method to control or prevent the transmission of dengue virus is avoid mosquito bites. Developing a vaccine against dengue or severe dengue has been challenging although there has been recent progress in vaccine development. To date, there is no vaccine to protect against dengue.

2.2. Family Togaviridae (genus Alphavirus)

2.2.1. Classification

The Togaviruses was originally classified together with several groups of viruses predominantly transmitted by insect, more recent analyses in Taxonomic structure of the
family have defined them into a distinct family with two genera: the alphaviruses and the rubiviruses (104). The alphaviruses has been classified into seven antigenically related complexes (105), this genera with about 40 recognized members, while the Rubivirus genus is composed of a single member is rubella virus.

2.2.2. Genome structure

Virions contain one molecular of linear positive-sense single stranded RNA. Total genome length is 9700 - 11800 nt. The RNA of the virus is pure stranded and capped at its 5’ end as well as having a polyadenylene 3’ tail. The virus is enveloped and forms spherical particles from 65 - 70 nm diameter, the capsid within is icosahedral, constructed of 240 monomers. This structure allows the virus to act as mRNA within the host cell and easy to replicate. Genome first translated into four non-structural proteins (nsP1- nsP2- nsP3- nsP4) and structural proteins (E1- E2 - E3) (106) (107).

Figure 10: Genome structure of Togavirus (Source NCBI) (108)

Togaviruses have an icosahedral capsid and have a surrounding envelope composed of two glycoprotiens. These glycoprotiens can be used to distinguish between species of the virus. It has been theorized that one of these protiens has a role in binding the virus to the host cell, allowing it to gain entry through receptors mediated endocytosis.
2.2.3. Vector

The most common is transmitted by arthropod vectors, most usually is *Ae. aegypti* and *Ae. albopictus* mosquitoes, vertebrate host is birds, rodents, rabbit. The mosquitoes was first found in the New World in 1985 when it was isolated in Houston, Texas. It probably traveled there from northern Asia in ships carrying scrap tires. To further complicate matters, not only is *Ae. albopictus* now a good host for chikungunya virus, but also the mosquito is spreading across the globe from eastern Asia to Europe and the United States (109) (110). The cycles of wild bird and mosquito interactions and infectivity allow the virus to remain endemic. No cases of bird transmission of the disease have been reported, making mosquitoes the primary vector and birds simply reservoirs (111).

2.2.4. Togaviridae replication cycle

In the host, the most important feature of togavirus replication is that it has a dicistronic genome. Two mRNAs are used, one to produce non-structural proteins and another to produce structural proteins. In fact, there is 4 times as much subgenomic RNA as genomic RNA in cells infected with togavirus. Two classes of proteins are synthesized from different mRNAs, which allows temporal regulation and qualitative replication. Genomic RNA can do first is make non-structural proteins (such as replicase) by synthesizing the minus strand, second is make structural proteins through synthesis of subgenomic RNA and synthesize positive strand RNA (112).

The virion has glycoproteins: Envelop 1 (E1) and envelop 2 (E2) that recognize and bind to the host cell membrane. The virion binds and is completely released inside of the host cell through endocytosis. The virion is taken in and binds to an endosome. The endosome has an ATP dependent H+ pumps that use ATP to pump into the endosome hydrogen ions, which decreases the pH and degrades the outer layer thus exposing and releasing the viral genome to the cytoplasm. The first process that the genome does is to translate the nonstructural proteins. This is possible because the genome is already in a positive-sense single stranded RNA, therefore the genome uses the host's ribosomes and tRNA to produce the nonstructural proteins. These proteins are produced as a single polypeptide that was then cleaved into four nonstructural proteins. These proteins are
important in forming a complex that was involved in transcribing the viral RNA into a complementary negative - sense single stranded RNA template. The negative - sense RNA template is used to replicate into positive - sense single stranded RNA. Also, from the 3' end (of the positive-sense RNA) to approximately the 1/3 mark on the genome was used to produce structural proteins that encodes: capsid proteins, E1's, and E2's. These structural proteins and +ssRNA are transported to the endoplasmis reticulum (ER) where they are modified, and bud from the ER to go to the golgi apparatus were they are packaged into virions. The virion is then released from the golgi apparatus to leave the cell, and in doing so it acquires its lipid membrane from budding from the host cell (113).

Figure 11: Replication cycle of Togaviridae (114)
2.2.5. Main diseases

Chikungunya

Chikungunya virus was first isolated from the blood of a febrile patient in Tanzania in 1952 (115), and there have been recent outbreaks of chikungunya in Africa, Asia and the Indian subcontinent. In recent decades mosquito vectors of chikungunya have spread to Europe and the Americas. Between 1960 and 1982, outbreaks of chikungunya fever was reported from Africa and Asia. In Asia, virus strains have been isolated in Bangkok in 1960s; various parts of India including Vellore, Calcutta and Maharastha in 1964; in Sri Lanka in 1969; Vietnam in 1975; Myanmar in 1975 and Indonesia in 1982. In 2007, disease transmission was reported for the first time in Europe. Prior to 2013, chikungunya virus outbreak had been identified in countries in Africa Asia Europe, and the Indian and Pacific Oceans. In late 2013, the first local transmission of CHIKV in the Americas was identified in Caribbean countries and territories. Since then, location transmission has been identified in 44 countries (116).

Figure 12: Countries and territories where chikungunya cases reported (116)
The disease resembles dengue fever, and is characterized by severe, sometimes persistent, joint pain (arthritis), as well as fever and rash. It is rarely life-threatening. Nevertheless, widespread occurrence of diseases causes substantial morbidity and economic loss.

There is no cure for the disease. Treatment is focused on relieving the symptoms. No vaccine is available against this virus infection. Prevention is entirely dependent upon taking steps to avoid mosquito bites and elimination of mosquito breeding sites (3).

**Eastern Equine encephalitis**

Since 1830's, Eastern Equine Encephalitis (EEE) is thought to have been the cause of virus in North American horses. EEE virus not received its name until a major outbreak occurred in horses in coastal areas of Delaware, Maryland, New Jersey, and Virginia in 1933. (The U.S. Department of Agriculture, 2008). So, the virus may have been present in its endemic form long time before, it is maintained in nature through a bird - mosquito cycle, there are two mosquito species primarily involved in this portion of the cycle, they are *Culiseta melanura* and *Cs. morsitans* and *Coquillettidia perturbans*, *Ochlerotatus canadensis*, *Oc.sollicitans*… (117). In 1934, mosquito species of *Aedes* and *Culex* could become infected with and transmit EEE virus from one vertebrate to another.

Most people bitten by an infected mosquito will not develop any symptoms. Severe cases of EEE virus infection, involving encephalitis (an inflammation of the brain) begin with the sudden onset of headache, high fever, chills, and vomiting. The illness may then progress into disorientation, seizures and coma. Approximately a third of patients who develop EEE die, and many of those who survive have mild to severe brain damage (118)(119).

There is no vaccine or drug against Eastern equine encephalitis virus (EEEV) for humans. Reducing exposure to mosquitoes is the best defense against infection with EEEV and other mosquito - borne viruses (120)(121).

**Western Equine encephalitis**

The western equine encephalitis (WEE) was first isolated in California in 1930 from the brain of a horse with encephalitis, and remains an important cause of encephalitis in horses and humans in North America, but most cases have been reported from the plains regions of the western and central United States since 1964 and in Canada (122). The main mosquito is transmission is *Cx. tarsalis*, and WEE virus are still present over a widespread
geographic range, has a complex life cycle involving birds and *Culex tarsalis* mosquito. *Cx tarsalis* is a mosquito that often found on the West Coast of the United States and that prefers warm, moist environments. Other mosquitoes eg, *Aedes* species and, occasionally, small, wild mammals also have been known to spread the virus (123).

Infection can cause a range of illnesses, from no symptoms to fatal disease. People with mild often have only a headache or sometimes have a fever. People with more severe WEE can have sudden high fever, headache, drowsiness, irritability, nausea, and vomiting, followed by confusion, weakness, and coma. Young infants often have seizures symptom (124).

Nowadays, a vaccine is available for horses but not for humans (125). While there is no specific treatment for WEE, prevention involves controlling mosquitoes and avoiding mosquito bites (124).

**Venezuelan equine encephalitis**

Venezuelan equine encephalitis (VEE) virus was first identified in horses in 1935 after outbreaks in Columbia, Venezuela and Trinidad, and isolated in 1938 (126)(127)(128). The outbreaks usually occur after a season of heavy rains, due to increases in the mosquito population (72) (129)(126)(130). In the 1960’s and 1995 some outbreak were occurred Colombia and in Venezuela and Mexico. The epizootic and enzootic strains of the VEE virus range from northern Argentina to Florida and parts of the Rocky Mountains; however, it is most prevalent in northern South America (126) (127).

The VEE virus is typically spread by mosquitoes, although certain types of ticks and mites can spread the virus as well. The *Culex (Melanoconion)* mosquito is normally responsible for the dispersal of the enzootic strain of the VEE virus (126)(128), and transmission by *Ochlerotatus taeniorhynchus, Psorophora confiniss, Psorophora columbiae, Ochleratus sollicitans, Mansonia titillans* and *Anophilis aquasalis* are some of the species of mosquitoes known to carry the epizootic varieties of the VEE virus (126) (131)(130).

The most common symptoms are confusion, there is a sudden onset of flu - like symptoms including a severe headache, chills, fever, retro - orbital pain (pain behind the eyes), congestion, nausea and vomiting. In severe case the virus invades the central nervous system leading to encephalitis disorientation, convulsions, paralysis and coma. Adults are relatively resistant to the disease with <10% dying, but 20-30% of children
affected may die (International Classification of Disease Codes for Venezuelan Equine Encephalitis, 1999) (132).

There is no specific drug for treatment of VEEV infection. Currently, there is a vaccine available for both humans and horses. The live attenuated vaccine known as TC-83 is a strain of VEEV that was pass 83 times in guinea pig heart cells (126)(133).

2.3. Family Bunyaviridae
2.3.1. Classification

Formally, the family *Bunyaviridae* was established in 1975 and now contains four genera of animal-infecting viruses are Orthobunyavirus, Phlebovirus, Nairovirus, and Hantavirus genera and one genus of plant-infecting viruses is Tospovirus (134) (135). The *Bunyaviridae* family of segmented negative strand RNA viruses (136). The family includes a number of significant human pathogens such as La Crosse virus (LACV), Hantaan virus (HTNV), Sin Nombre virus (SNV), Rift Valley fever virus (RVFV), and Crimean - Congo hemorrhagic fever virus (CCHFV) (137)(138) (139).

Several members of the *Bunyaviridae* family also transmitted by mosquitoes, such as the Rift Valley fever virus and the California encephalitis virus, while in the others, such as the Crimean - Congo hemorrhagic fever (CCHF) virus, they are transmitted by ticks. Several of these viruses are the agents of viral haemorrhagic fevers.

2.3.2. Genome structure

According to the International Committee on Taxonomy of Virus, the Bunyavirus genome is monomeric and consists of three segments. These segments are labeled large (L), medium (M) and small (S) RNA segment (140). These RNA segments are single-stranded, and exist in a helical formation within the virion. On the other hand, they exhibit a pseudo-circular structure due to each segment's complementary ends. The L segment is 6300 - 12000 nucleotides long and encodes the viral RNA polymerase. Dependent RNA-polymerase, necessary for viral RNA replication and mRNA synthesis. The M segment is 3500 - 6000 nucleotides long and encodes two glycoproteins as a single gene product that is usually co-translationally cleaved. The L and M segment are negative sense. The S
segment is 1000 - 2200 nucleotides long and encodes the nucleocapsid protein. Total genome size is around from 10500 - 22700 nucleotides long. For the Genera of Phlebovirus and Tospovirus, the S segment is ambisense, that are some of the genes on the RNA strand are negative sense and others are positive sense. The S segment codes for the viral nucleoprotein in the negative sense and a nonstructural protein in ambisense. The terminal sequences of each segment are base paired. Because of the RNAs form non-covalently closed circles (141).

![Figure 13: Schematic representation of a generic bunyavirus virion, and negative-sense or ambisense gene expression strategies (142).](image)

Each Bunyavirus genome segment directs two RNA synthetic activities: the first is transcription of a single mRNA, and second is replication to generate an antigenome which acts as an intermediate for synthesis of further genomic strands. The nucleotide sequences at the 3'-terminus and the 5'-terminus are complimentary, forming panhandle structures. The 5'-terminus is not capped (143)(144)(145).

2.3.3. Bunyaviridae replication cycle

Replication begins with the attachment of viral proteins to host receptors and entry of virus by endocytosis. In the cell surfaces, viral proteins are used to bind to receptors. They are transit through the endoplasmic reticulum (ER), and Golgi apparatus, mature
virions bud from the Golgi apparatus into vesicles which are transported to the cell surface, while Bunyavirus RNA replicates in the cytoplasm via RNA and dependent RNA polymerase, transcription occurs in the cytoplasm of the cell rather than in the nucleus. As a result, it is hypothesized that caps are stolen from mRNAs that are derived from host messages within the cytoplasm. Secondary transcription, three mRNA species are transcribed from the three segments, which occurs after replication, increases the amount of L, S and M mRNA segments. Most of the segments found in the cell due to secondary transcription are S. The least amount of segments was M, with an intermediate amount of L segments formed. The L and S segments of the genome translated by free ribosomes. M segments translated by membrane bound ribosomes. The L, S, and M segments are responsible for different structural and non-structural proteins. The viral progeny assembled within the Golgi apparatus of the cell. All of the viruses given glycoproteins and undergo terminal glycolysisation. In addition, the viral progeny adopt pieces of host membrane to form the envelope (146).

2.3.4. Vector

The Bunyaviridae are a large group of viruses that infect a diversity of arthropod vectors and animal hosts, virus is transmission through mosquito, ticks, sandflies and midgus (Chin J, 2000; Plyusnin, 2011) (147) (148) (149).

Mosquitoes

Ae. Triseriatus and Ae. Trivittatus

Ae. Triseriatus is commonly called the tree holes mosquito, or eastern tree holes mosquito, is a species of mosquito found in the western hemisphere in wooded regions of eastern and central North America. It is quite prevalent, ranging from New Brunswick to the Florida Keys and stretching as far west as central Texas (150) (151). Female Ae. triseriatus only mate once, and sperm are transferred into a structure known as the spermathecae. The female mosquito lays her eggs slightly above the water level, if water is present in the hole. Females require a blood by biting human for each batch of eggs produced, and can produce eggs throughout their lives (152) (153)(154). Ae. triseriatus has been identified as a vector of Eastern Equine Encephalitis and linked to the spread of La Crosse Encephalitis (155)(156).
Ae. Trivittatus is the inland floodwater mosquito has been recorded in Canada from Ontario (157) and Nova Scotia (158). In 1971, the female mosquito was take in North - East of Pinawa, larvae was found in floodwater pool in meadows, swamps, and woodlands. Ae. trivittatus is the most widely distributed in the United States, it occurs Southern Canada and generally over the Eastern half of the United States and as far west as Montana and Colorado (159). To most people who encounter Ae. trivittatus, the bite is much more painful and irritating than other mosquitoes encountered. Ae. trivittatus are persistent aggressive biters often attacking the human in a swarm - like manner (160).

Ticks

Ixodid (hard) ticks, especially those of the genus, are both a reservoir and a vector for the Bunyavirus virus. Numerous wild and domestic animals, such as cattle, goats, sheep and hares, serve as amplifying hosts for the virus. Transmission to humans occurs through contact with infected animal blood or ticks, virus can be transmitted from one infected human to another by contact with infectious blood or body fluids (Tick-borne bunyavirus fever). I uriae are thought to replicate in the arthropod vectorand be transmitted to the vertebrate host (seabird) when the ticks feed on susceptible hosts. The virus then replicates in the seabird producing viraemi, infecting more ticks will also feed human. (161)(162)(163).

2.3.5. Main disease

La Crosse encephalitis

La Crosse encephalitis (LAC) was discover in La Crosse, Wisconsin in 1963. Since then, the virus has been identify in several Midwestern and Mid - Atlantic states. In 1964, LAC reported in US and India (164). Different mosquitoes can carry the virus including Aedes, Culex, and Culiseta but common in nature is virus vertical transmission by Ae. trivittatus mosquitoes (149).

Although the vast majority of cases are not serious, LAC can cause severe illness, especially in children under age 16 (165). Similar to SLE virus, LAC virus does not cause disease in horses (166).

Many people infected with LACV have no apparent symptoms. Among people who become ill, initial symptoms include fever, headache, nausea, vomiting, and tiredness.
Some of those who become ill develop severe neuroinvasive disease (disease that affects the nervous system). Severe LACV disease often involves encephalitis (an inflammation of the brain) and can include seizures, coma, and paralysis. Severe disease occurs most often in children under the age of 16. In rare cases, long-term disability or death can result from LAC. There is no specific treatment for LACV infection - care is based on symptoms (167). The best way to reduce your risk of infection with LACV or other mosquito-borne viruses is to prevent mosquito bites (168).

Reoviruses

Reoviruses, which also called orthoreoviruses to avoid confusion with the family Reoviridae. In 1959, Sabin proposed the name reovirus to reflect the fact that viruses of this group had been isolated from the respiratory and enteric tracts and was orphan (reo) viruses without known associated disease. According from Intestinal Health Center for Poultry, Reovirus was first isolated from chickens in the 1950s. In human orthoreovirus was isolated in 1953, Reovirus infections occur frequently, but most are mild or subclinical. The role of these viruses in human disease is not clear, but they are not consider important agents of human disease, however, during the last two decades, few cases of human disease have been report. These viruses also have been evaluate extensively in studies involving laboratory animals (35).

No specific treatment or prevention measures have recommended for reovirus infections in humans because of the lack of definitive association with disease.

Colorado tick fever

Colorado tick fever (CTF) virus, also known as Mountain tick fever or American mountain fever, is a viral disease caused by infection with the CTF virus. CTF is transmitte to humans most commonly by the bite of an infected adult wood tick, Dermacentor andersoni, CTF occurs primarily in the Rocky Mountain region of the western United States as well as the Canadian provinces of British Columbia and Alberta, in 1930. More than 90% of all CTF cases in the United States are reported from Colorado, Utah and Montana (169).

The initial symptoms of the disease often include fever, chills, headache, muscular, skeletal pain, and malaise. Other symptoms may include nausea, vomiting, stomach pain, light sensitivity and sore throat. In rare cases, patients experience illnesses of the central nervous system (CNS) ranging from mild to encephalitis with coma and death. CNS
illnesses commonly characterized by severe headache, sensory impairment, neck stiffness and light sensitivity.

No specific treatment for CTF is available. Management of CTF includes treatment of fever and pain with analgesics and acetaminophen, along with standard infection control procedures. Patients infected with CTF should advise blood collection agencies of their illness prior to donation, due to the risk of transmitting CTF through blood transfusion (57).

3. **Flavivirus and Dengue**

3.1. **Classification**

Dengue fever is caused by five closely related virus serotypes of the genus *Flavivirus*, family *Flaviviridae*; however, the differences between each serotype are sufficient to prevent epidemics of multiple serotypes (DENV1, 2, 3, 4, 5). *Flaviviridae* have single-stranded RNA of 9.6 - 12.3 kilobase in length with positive polarity that are monopartite and linear and a methylated nucleotide cap on the 5' end. The virus particles have spherical envelopes of about 40-60 nm in diameter (170). As other virus, the evidence for strain differences among DENVs was first detected serologically using antibodies made by inoculating laboratory animals (171). Later, nucleic acid sequencing allowed for the classification of DENV into genetically distinct groups or genotypes within each serotype (172). Various phylogenetic analysis based on complete E nucleotide or partial E/NS1 (173)(174) indicated that DENV-1 are grouped in four genotypes: 1) genotype 1, representing strains from Southeast Asia, China, and East Africa; 2) genotype 2, representing strains from Thailand collected in the 1950s and 1960s; 3) genotype 3, representing sylvatic strains collected in Malaysia; 4) genotype 4, representing strains from the West Pacific islands and Australia, and representing all strains collected in the America, West Africa and Asia (175)(176).

Second, in DENV - 2, based on E nucleotide sequences of phylogenetic analysis, DENV - 2 comprises five genotypes: 1) the Asia genotype included are genotype 1 representing strains from Vietnam, Thailand, Malaysia, Cambodia, and genotype 2 representing strains from Vietnam, China, Taiwan, Sri Lanka and the Philippines; 2) the cosmopolitan genotype, representing strains in Australia, East and West Africa, the Pacific
and India ocean islands, the Indian Subcontinent and Middle East; 3) the American genotype is presenting strains from Latin American and older strain from Caribbean, the India subcontinent and Pacific Islands in the 1950s and 1960s; 4) the Southeast Asia and America genotype, representing strains from Thailand, Cambodia and Vietnam and strains collected in the Americas over last 30 years; and 5) the sylvatic genotype, representing strains collected from humans, mosquitoes in forest or sentinel monkey in West Afiric and Southeast Asia (177).

Isolated DENV-3 based on prM/E nucleotide and then complete genome sequences (178) in to four genotypes are 1) genotype 1 is presenting from Indonexia, Malaysia, Phillipnes and recent isolates from South Pacific Islands; 2) genotype 2, from Vietam, Cambodia, Thailand and Bangladesh; 3) genotype 3, from India, Sri Lanka, Africa and Samoa, however, the complete genome phylogenetic analysis within this genotype includes the 1962 strainsfrom Thailand (179); and 4) Gennotype 4, from Puerto Rico, Latin and Central America. Sylvatic strains of DENV-3 are believed to exist in Malaysia based on the seroconversion of sentinel monkeys (176).

DENV- 4 strains exhibitided greater sequence conservation than the other DENV serotypes (92%) and 96 -100% conservation in E protein amino acids. Currently, DENV-4 phylogeny complete E gene sequences delineate four genotypes base on the E gene or complete genome sequence (180)(181) (182)(183)(184) are: 1) genotype 1, representing strains from Thailand, Cambodia, the Philippines, Sri Lanka, and Japan; 2) genotype 2, from Indonesia, Malaysia, Tahiti, the Caribbean and the Americas; 3) genotype 3, representing recently sampled Thailand strains, that are distinct from other Thailand strains (181); and 4) genotype 4 representing the sylvatic strains of DENV - 4 from Malaysia.

The fifth and latest addition to the existing serotypes of dengue viruses is DENV - 5 which has been announced in Thailand, October, 2013 (185), is sylvatic strains. Phylogenetic evalutation revealed that DENV - 5 is genetically similar to other four serotypes, thereby hinting to a common ancestral origine (186).

3.2. Genetic evolution

In DENV, genetic variability most obviously manifest in the existence of four (or five) antigenically distinct serotypes. The introduction of comparative gene sequence
analysis, it has been possible to dissect the genetic structure of DENV populations and to reveal the processes governing viral evolution (81)(187)(188).

3.3. Vectors

3.1.1 *Aedes aegypti* and *Aedes albopictus*

The various serotype of the dengue virus transmitted to human through the bites of infected *Aedes* mosquitoes. The principal vector of DENV is the *Ae. aegypti* mosquito, an anthropophilic species that has adapted extremely well to the urban environment and is found both indoors and outdoors in close proximity to human dwelling and can complete their whole cycle life here, they prefer to feed during the day (189). *Ae. aegypti* is an efficient vector of DENV because of its preference for laying its eggs in artificial, rather natural container, biting human, and remaining indoors, where it has acces to its favorite host (190).

The Asian tiger mosquito, *Ae. albopictus* is a secondary of DENV in SEA, the Western Pacific, and increasing in Central and South America (76), the *Ae. albopictus* mosquito appears to be following the same adaptation pattern as *Ae. aegypti* in becoming an increasing urban species. Compared to *Ae. aegypti*, which is the most important vector of Dengue, *Ae. albopictus* is a less competent vector of arboviruses, and the epidemics it causes are milder. However, *Ae. albopictus* is becoming an increasingly important vector because of its rapidly changing global distribution (191). Before 1979, *Ae. albopictus* was found only in Asia and in the Western Pacific, but it has spread too much of the rest of the world in recent decades (76), spreading through the United state in 198 (192)(193)(194). A mutation increasing the fitness in *Ae. albopictus* was identified for another mosquito-borne virus, the Chikungunya virus, during an epidemic on La Réunion in 2005; a virus strain with the same mutation also caused an outbreak in north-eastern Italy (195) (191) and recently in Caribbean (196)(197)(198).
3.1.2 Transmission cycle

Sylvatic DENV cycle

DENV exist in two separate cycles in nature, circulating in either non-human primates or humans. The endemic in humans today most likely evolved from non-human primate dengue viruses a few hundred years ago and have since established themselves as four distinct serotypes in human populations, causing periodic epidemics and severe disease (199) and principle on Aedes spp. as vector. The ancestral forms of DENV are believed to be viruses that circulate in forest habitats, presumably among nonhuman primates (173). There DENV sylvatic cycle have been demonstrated in Asia, where serological evidence as well as virus isolation suggest transmission of sylvatic strains of DEN-1, DEN-2, DEN-4 among Macaca and Presbytis monkeys vectored by Aedes niveus ((200)(201). The Sylvatic DEN-2 in West Africa shown to circulate regularly between Erythrocebus monkeys and various sylvatic Aedes spp., such as Ae. taylori, Ae. furcifer, Ae. vitattus and Ae. luteocephalus (202) Rodhain, 1991 (203) and was isolated from 5 humans in Eastern Senegal (Saluzzo et al., 1986; Zeller et al., 1992)(204) (205). All sylvatic isolates are generaltically distinct from all endemic isolates and are isolated evolutionarity (172)(206)(207).

Endemic/epidemic DENV cycles

Endemic / epidemic DENV circulated in both a sylvatic (enzootic) cycle involving non-human primates with various species of Aedes mosquitoes including Ae. fucifer, Ae. luteocephalus and Ae. taylori, in a human cycle principally vectored by Ae. aegypti and Ae. albopictus (208) (209). The efficiency of the endemic cycle is now completely independent both evolutionarily and ecologically from the ancestral, sylvatic cycles (210). Time estimates for evolution of the endemic/epidemic forms ranged from 100 to 1,500 years ago.

When a female Aedes bites a human for food, she injects saliva into wound where the anti - coagulants contained in her saliva facilitate feeding. The adult mosquitoes prefer to feed on human daylight hours (211), they prefers to stay indoors, do not travel great distance by themselves less than 200 meters. The pick of biting activity: early morning for 2-3 hours after daybreak and in the afternoon for several hours before dark (190). Female mosquitoes have habit disrupting the feeding process at the slightest movement and tend to
feed multiple times, she can feed on several person during a single blood meal and may transmission DENV to multiple person in a short time (212). After a person has bitten by an infective mosquito, the virus suffer an incubation average period of 4 - 7 days (or maybe 3 to 14 days), after which the person onset of fever accompanied by a variety of nonspecific signs and symptoms and DENV may circulate in the peripheral blood for as long as 10 days. If other Ae. aegypti mosquitoes bite the patient during this febrile viraemic stage, those mosquitoes may become infected and subsequently transmit the virus to other uninfected persons, after an extrinsic incubation period of 4 to 12 days (213)(214).

**Maintenance of DENV and vertical transmission of DENV in mosquitoes**

Several factors can influence the dynamic of virus transmission, including environmental and climate factors, host - pathogen interactions and population immunological factor. In the most countries, dengue displays a seasonal pattern related to temperature and rainfall (215). Climate directly influences the biology of the vectors and thereby their abundance and distribution, this has rise the question of how the virus overwinters, or persist during dry and cold seasons. One possibility is that a population of infected mosquitoes could survive throughout the interim and introduce the virus during the next season. Aedes mosquitoes remain DENV infected and the longest lifespan recorded to date is 174 days, although a more typical survival rete is 1 - 2 weeks (72) (216). A second possibility is passage of the virus the next generation of the mosquitoes via survival in an infected egg. Vertical transmission (transovarial transmission) has been demonstrated in the laboratory and in the wild (217). The significance of vertical transmission for maintenance of the virus is not well understood (218) (219). Some evidence shows that Ae. albopictus mosquitoes are more efficient at vertical transmission than Ae. aegypti, which would make them a candidate for maintaining DENV during interepidemic period (220). Thus, vertical transmission of DENV in mosquitoes is possible, where or not the mechanism is truly transovarial or mediated by infection of the mature egg at the time of oviposition (72)(216). Several research show that the asymptomatic case of dengue may be is silent transmission in humans by the reduced number of vectors maintains DENV circulation between epidemic season (221) (222)(223).
3.4. Dengue epidemiology

3.4.1. History and origin of Dengue

The origins of the word dengue are not clear, but one theory is that it is derived from the Swahili phrase "Ka-dinga pepo", meaning "cramp-like seizure caused by an evil spirit". The Swahili word "dinga" may possibly have its origin in the Spanish word "dengue" meaning fastidious or careful, which would describe the gait of a person suffering the bone pain of dengue fever. The earliest know clinical descriptions of a dengue like illnesses are from Chinese encyclopedia written during the Chin Dynasty. [Common Era (CE) 265–420 AD], Tang Dynasty (CE 610) and Northern Sung Dynasty (CE 992) (190). These reports described a disease called “water poison” cause by it is association with water - associated with flying insects. The next report of a similar appear almost seven countries later, describing an acute illness with prolong convalescence in the French West Indies and Panama during q635 and 1699 respectively (173). A century later, 1779 - 1788 the first reports of a possible dengue pandemic were described in Batavia (nowadays is Jkarta) (224), Cairo (225), Philadelphia (174), and Cadiz and Seville, Spain (225).

The viral etiology and the transmission by mosquitoes deciphered in the 20th century. The role of Ae. aegypti in transmission of dengue was confirmed in 1926 by the extensive and well - controlled experiments of Siler (226), followed by the incrimination of Ae. albopictus in 1931 (227). In 1943, the scientists of Japan was isolated dengue serotype 1 in Nagasaki, it is Mochizuki strain as well as other DENV-1 strain from affected patients in Japan (228). Then, Sabin isolated both DENV-1 (Hawaii strain) and DENV-2 (New Guinea C strain) from US Soldiers in 1944 (229) (230). The first well documented outbreak of dengue haemorrhagic fever took place in Manila in 1953/1954 (231), and was followed by a larger outbreak in Bangkok in 1958 (232). The viruses isolated from patient during the 1956 in Phillipines epidemic were members o the DENV-3 (H87 strain) and DENV-4 (H241 strain) (232). Since that time, DHF/DSS have become endemic in all countries in Southeast Asia with dramatic increase in case number and DENV considered an ‘emerging’ disease. At the same time the geographic range of DHF/DSS has expanded considerably, and since 1950s, the incidence of DHF/DSS has increased over 30 fold (219) (3). Nowadays, dengue spread to more than 140 countries in
Asia, the Pacific, the Americas, Africa, and the Caribbean. Estimated that there are 390 million dengue infections per year, of which 96 million manifest apparently with any level of disease severity by using cartographic approaches (6).

Until now, it is not clear where dengue originated from region. Gaunt et al, 2001 suggested an African origin, principally because many of the most divergent mosquitoes-born flaviviruses circulate exclusively in Africa and often infect primates, implying that DENV has an origin in Africa. To go further, *Ae. aegypti* is believed to have originated in Africa, although this species is only likely to have been adopted as a vector for human transmission in the relatively recent past. Conversely, ecological and phylogenetic evidence argues for an Asian origin of Dengue (233)(234) (235)(236) (210) (237)(238).

### 3.4.2. Global burden

Dengue is the most rapidly spreading mosquito-borne viral disease in the world. In the last 50 years, incidence has increased 30 fold with increasing geographic expansion to new countries and, in the present decade, from urban to rural settings in tropical and subtropical countries in Southeast Asia, the Pacific, the Americas, Africa, European and the Caribbean. (Figue 14)

![Distribution Map of Dengue](image)

**Figure 14:** Endemic or potentially endemic to 144 countries of Dengue transmission, 2015 (23)
Worldwide, approximately 2.5 billion people live in dengue endemic countries and annually, an estimated 50 million dengue infections occur, up to 500,000 case of the life-threatening dengue DHF/DSS, mainly among children, with the case fatality rate exceeding 5% in some area (219) (239). The average number of DF/DHF cases reported to the WHO has increased dramatically (240). For the period 2000 - 2004, the annual average was 923,896 cases, almost double the figure of 429,848 cases that reported for the period 1990 - 1999. Cases across the Americas, South-east Asia and Western Pacific have exceeded 1.2 million cases in 2008 and over 2.2 million in 2010 (based on official data submitted by Member States). Recently the number of reported cases has continued to increase (240). (See figure 15).

![Worldwide Dengue, cases - GIDEON](image)

Figure 15: Worldwide. Dengue, cases.

In 2010, 1.6 million cases of dengue were reported in the Americas alone, of which 49,000 cases were severe dengue (241).
Before 1970, only nine countries had experienced severe dengue epidemics. In 2001, a record 69 countries reported dengue activity to WHO (1). The disease is now endemic in countries of Africa, the Americas, the Eastern Mediterranean, South East Asia and the Western Pacific. South East Asia and the Western Pacific regions are the most seriously affected (241).
Figure 17: The change in distribution of dengue serotype. The figure shows the distribution in 1970 (A) and 2004(B) (240).

All four DENV serotypes are now circulating in Asia, Africa and the Americas, a dramatically different scenario from that which prevailed 20 - 30 years ago (Figure 17), only DENV 5 was in Thailand. By the 1980s, the American region was experiment major epidemic of dengue in countries that have been free of the disease for 35 to 130 years (190). New DENV strains and serotypes were introduced DENV-1 in 1977, a new train of DENV-2 in 1981, DENV-4 in 1981, and a new strain of DENV-3 in 1994. Moreover, many countries of the region evolved from nonendemicity or hypoendemicity (one
serotype present) to hyperendemicity (multiple serotype present), and epidemic DHF emerged, much as it had in Southeast Asia 25 years earlier (190).

**Epidemiology trend in several regions of the world**

**Epidemiology trend in the Pacific region**

Dengue has been described in the Pacific region for over 100 years (242). Over the past three decades, dengue fever has affected more and more countries in Pacific region (65) (243). In the World War II, dengue virus was introduced throughout Southeast Asia and Pacific Islands, Japan (244). During the 1990s, more than 1 million cases of dengue reported in weastern Pacific region. The Philippines, Malaysia, Cook Islands, French Polynesia, New Guinea, and Australia (72) (190) all reported cases early in the decade. In 1998 and 1999, there were 356,554 and 64,066 case of DF/ DHF with 1470 and 112 deaths (245). Dengue virus continues to circulate throughout the Pacific region and incidence of DHF may increase despite many of the inlands’geographic isolation, due to the ease international travel and global communities’desire for access to tropical settings.
Figure 18: Western Pacific region. Dengue cases (A), deaths (B).
Epidemiology trend in Southeast Asia

Dengue haemorrhagic fever (DHF), a potentially lethal complication of dengue fever, first recognized in the 1950s during dengue epidemics in the Philippines and Thailand. Today DHF affects most Asian countries and has become a leading cause of hospitalization and death among children in the region. In 1998, worldwide dengue epidemics accounted for 1.3 million cases of DF and DHF with 3442 deaths and Southeast Asia reported 218,859 dengue cases and 2075 deaths (65). Since 2000, epidemic dengue has spread to new areas and has increased in the already affected areas of the region. The main reason is by the rapid demographic increase, migration, anarchic urbanization, transportation, etc. The endemic transmission cycle of Dengue in SEA differs from that American and characterized by transmission activity all year around with peak during rainy season. Although all five serotypes are now found in circulation in Asia and four serotypes in Americas, the severe form of dengue is more than 17 fold higher in Asia. The most affected are group is between 5 to 9 years. However, in Singapore and Thailand, adult are affected with moderate clinical symptoms. Between 2001 and 2008, 1020333 cases were reported in Cambodia, Philippines, Vietnam and Malaysia with the high numbers of deaths (246) (3)
Figure 19: Southeast Asian region. Dengue, cases (A) deaths (B).
Vietnam is located in South-Eastern Asia, bordering the Gulf of Thailand, Gulf of Tonkin, and South China Sea, China, Laos, and Cambodia. The climate is tropical in south; monsoonal in north with 4 seasons are spring, summer, autumn and winter. The environment: Slash-and-burn agricultural practices contribute to deforestation and soil degradation. Water pollution and over fishing threaten marine life. Groundwater contamination limits potable water supply. Growing industrialization (and population migration) is rapidly in Hanoi and Ho Chi Minh City. The population growth rate is estimated 1.077% and the age structure is 25.2% 0-14 years; 69.3% 15-64 years; 5.5% 65 years and over. The Vietnamese population estimated 93,386,630 as of July 1, 2015 (247).

Figure 20: Vietnam map.

In Viet Nam, historical evidence suggests that outbreaks of dengue with four fatal case occurred during 1895 to 1909. Dengue was the first recorded case occurring in 1959 in the North (Ha noi and Hai phong), and first reported in 1960 in the South (approximately 50 fatal cases of DHF reported from Cai Be). Since then, dengue has become an endemics, the rate of morbidity per 100,000 populations has been increasing steadily from 32 in the year 2000 to 120 in 2009, with 105,370 cases reported in the whole country. In the southern regional morbidity is as high as 214.5 cases per 100,000
populations. July and October are peak months of dengue activity. In 2009, over 70% of all dengue cases and 85% of all deaths due to dengue in this period occurred in the southern provinces, 80% of all dengue deaths occurred in children under the age of 15 years (248).

Figure 21: Distribution of DF/DHF in Vietnam in 2009.

From 1 Jan - 19 Jun 2011, Vietnam reported 18 432 cases with 15 deaths, CFR 0.08%, 13 898 cases with 17 deaths in 2010 for the same period. High activity reported in the southern areas of Vietnam. During 5 months from Jan - May 2011, of the 15 634 cases with 12 deaths, 13 999 cases with 11 deaths occurred in the 20 provinces of southern of Vietnam (248). Up to November 2011, Vietnam was reported outbreaks occur with 49,011 cases, 46 fatal. Outbreaks to September in 2012 were reported 51,000 cases, 42 fatal, in 2013 outbreaks to August reported 25, 300 cases, 16 fatal (249).
Despite the existence of a National dengue control Program since 1998, dengue remains a major health problem in Vietnam. Over the past 15 years, the number of DENV cases has been increasing.
Epidemiology trend Europe, Mediterranean, and the Middle East

Between 1784 and 1788, in Cadiz and Seville, Spain, dengue was described in clinical illnesses. Disease occurred throughout the 1980s in the Middle East regions of the Suez in 1824, the Arabian coast in 1835, in Yemen from 1870 - 1873, and in Israel 1889 - 1990 (250). From 1927 - 1928, an extensive dengue outbreak occurred in Greece with more than one million case (251) (252) Retrospective serology investigations clearly implicate DENV-1 and possibly DENV-2 as causative agents (253) (254).

Every year, numerous dengue cases are imported by travelers and expatriates, almost infection are acquired in the hyperendemic areas of Latin America and Southeast Asia (255). In 2008, 116 cases were reported, mostly in European travelers, 43% had travelled to Europe from South East Asia, 14% from Latin America, 12% from the Indian subcontinent, 11% from the Caribbean and 4% from Africa, reflecting worldwide dengue activity and travel preferences (256). Recently, first autochthonic DENV infections have been describle in France (257) and in Croatia (258).

In 2009 and the first half of 2010, outbreaks of Dengue fever and haemorrhagic fever were reported from Saudi Arabia, Sudan and Yemen. So far outbreaks concentrated in the cities and urban areas along the Red Sea and Arabian Sea coasts and Pakistan (259).

Figure 23: European Union, Dengue cases
Epidemiology trend in the Americas

Mainly during the 1960s and early 1970s in American, dengue epidemics was characterized by the circulation of single serotype at any given time within a region. From 1977 - 1978 in Cuba occurred major epidemic of dengue fever caused by the DENV-1 serotype. This trend was changed following the introduction of Southeast Asia strain of DENV-2 into Cuba, probably from Vietnam in 1981 (260) (261), followed by an increase in the severity, during Cuban epidemic in 1981 (262) (263), 98% - 99% of the case infections. In 1989, an epidemic of DHF occurred in Venezuela, followed by a epidemic in Cuba in 1997 and both epidemic caused by the DENV-2 serotype (264). In 2007, according to Emerging and Reemerging Infectious Diseases Region of the Americas, in the period from 2001 - 2006 have 3,419,999 cases of dengue were reported in Americas, including 79,664 cases of dengue hemorrhagic and 982 deaths, with a case fatality rate of 1.2%, and the circulation of all four serotypes (DENV1, 2, 3, 4) which increase the risk for the appearance of the most serious forms of the disease (265)(266).
Figure 24: Americas region. DHF, cases (A) and deaths (B).
Epidemiology trend in Africa

Although the history of dengue in Africa is poorly documented, it is know that dengue has been on continent since the start of the 20th century. During the surveillance program started in 1964, DENV-1 and DENV-2 were isolated at the Virus Research Laboratory at the University of the Ibadan, Nigeria. DENV-1, DENV-2, are outbreaks in Comoros in various years in 1948, 1984, and 1993 (267). In 1983, the first evidence of autochthonous DENV-4 transmission in Senegal was detected (268), and DENV-3 transmission was identified in Mozambique in 1984 (269) (270)(271).

Despite poor surveillance for dengue in Africa, it is clear that epidemic dengue fever caused by all four dengue serotypes has increased dramatically since 1980, with most epidemics occurring in eastern Africa, and smaller extent in western Africa, though this situation may be changing in 2008 (218).

3.5. Diagnosis

Dengue has a wide spectrum of clinical presentations, often unpredictable clinical evolution and outcome (3). In clinical spectrum ranges from unapparent, may be mild febrile illness, non-severe to severe and fatal haemorrhagic diseases or vascular shock. Following WHO “Dengue Guideline for Diagnosis, Treatment, prevention and Control publish”, in 2009 while most patient recover following a self-limiting non-severe clinical course, estimated 1% proportion progress to severe disease, mostly characterized by palasma leakage with or without haemorrhagic.

3.5.1. Classification in clinical

In 1999, according to the WHO guideline dengue manifest in three forms are DF, DHF and undifferentiated fever, with plasma leakage that may lead to hypovolemic shock, DSS. This classification was repeatedly evaluation and could mistakenly classify dengue cases because it was often found inappropriate for clinical management of dengue (272). In 2008, a WHO expert group was organized and proposed a new classification range based on dengue disease entity which manifest in a broad spectrum of symptoms and often with unpredictable evolution and outcome. The important of this classification is early
recognition and understanding of the clinical problem during the different phases of the disease, leading to a rational to case management and a good clinical outcome. In 2009, a new classification of dengue proposed by WHO Tropical Disease Reaserch (TDR) was classifies dengue into dengue, dengue with warning signs (DW) and severe dengue (SD). For practical reasons, the group of non - severe dengue divided in two subgroups: patients with warning signs and those without (see figure 25).

**Suggested dengue case classification and levels of severity**

- **Dengue ± Warning Signs**
  - With warning signs
  - Without

- **Severe Dengue**
  - 1. Severe plasma leakage
  - 2. Severe haemorrhage
  - 3. Severe organ impairment

**Criteria for Dengue ± Warning Signs**
- **Probable Dengue**
  - Live in /travel to dengue endemic area. Fever and 2 of the following criteria:
  - Nausea, vomiting
  - Rash
  - Aches and pains
  - Tourniquet test positive
  - Leukopenia
  - Any warning sign

- **Laboratory-confirmed dengue**
  (Important when no sign of plasma leakage)

**Warning Signs**
- Abdominal pain or tenderness
- Persistent vomiting
- Clinical fluid accumulation
- Mucosal bleed
- Lethargy, restlessness
- Liver enlargement > 2cm
- Laboratory: Increase in HCT concurrent with rapid decrease in platelet count

*(requiring strict observation and medical intervention)*

**Criteria for Severe Dengue**
- **Severe Plasma Leakage**
  - Shock (DSS)
  - Fluid accumulation with respiratory distress
- **Severe bleeding**
  - As evaluated by clinician
- **Severe organ involvement**
  - Liver: AST or ALT >=1000
  - CNS: Impaired consciousness
  - Heart and other organs

Figure 25: Dengue case classification and levels of severity (219)

Current WHO classification is recommended for continuing use because the newly suggested TDR classification creates about 2 times the work - load to health care
personnel. More than 90% of DHF defined by WHO case definition are dengue confirmed. However, current WHO classification needs to be modified for more simple and friendly use. The suggested modification is to address plasma leakage as the major criteria. Unusual dengue is proposed to be added to the current WHO classification to cover those patients who do not fit with the current WHO classification (273).

3.5.2. Disease course

Dengue infection is a systemic and dynamic disease. It has a wide clinical spectrum that includes severe, non-severe clinical manifestation. After the incubation period, the illness begins abruptly and followed by the three phases: febrile, critical, and recovery (3). (Figure 26).

![Figure 26: The Course of Dengue disease (WHO, 2009)](image-url)
**Febrile phase**

Patients typically develop high-grade fever suddenly. This acute febrile phase usually lasts 2 - 7 days and is often accompanied by facial flushing, skin erythema, generalized body ache, myalgia, arthralgia and headache (274). Some patients may have sore throat, injected pharynx and conjunctival injection. Anorexia, nausea and vomiting are common. It can be difficult to distinguish dengue clinically from non-dengue febrile diseases in the early febrile phase. A positive tourniquet test in this phase increases the probability of dengue (275) (276). In addition, these clinical features are indistinguishable between severe and non severe dengue cases. Therefore monitoring for warning signs and other clinical parameters is crucial to recognizing progression to the critical phase.

Mild haemorrhagic manifestations like petechiae and mucosal membrane bleeding (e.g. nose and gums) may be seen (277) (276). Massive vaginal bleeding in women of childbearing age and gastrointestinal bleeding may occur during this phase but is not common (278). The liver is often enlarged and tender after a few days of fever (276). The earliest abnormality in the full blood count is a progressive decrease in total white cell count, which should alert the physician to a high probability of dengue.

**Critical phase**

Around the time of defervescence, usually on days 3 - 7 of illness, the temperature drops to 37.5 - 38°C or less, an increase in capillary permeability in parallel with increasing haematocrit levels may occur (279) (280). This is the beginning of the critical phase. The period of clinically significant plasma leakage usually lasts 24 - 48 hours.

Progressive leukopenia followed by a rapid decrease in platelet count usually precedes plasma leakage (276). At this point patients without an increase in capillary permeability will improve, while those with increased capillary permeability may become worse as a result of lost plasma volume. The degree of plasma leakage varies. Pleural effusion and ascites may be clinically detectable depending on the degree of plasma leakage and the volume of fluid therapy. Hence, chest x-ray and abdominal ultrasound can be useful tools for diagnosis. The degree of increase above the baseline haematocrit often reflects the severity of plasma leakage.

Shock occurs when a critical volume of plasma is lost through leakage. It is often preceded by warning signs. The body temperature may be subnormal when shock occurs.
Recovery phase

In critical phase, if the patient can survives the 24 - 48 hours, a gradual reabsorption of extravascular compartment fluid takes place in the following 48 - 72 hours. General well being improves, appetite returns, gastrointestinal symptoms abate, haemodynamic status stabilizes and diuresis ensues. Some patients may have a rash of “isles of white in the sea of red” (281). May be some patient have experience generalized pruritus, bradycardia and electrocardiographic changes.

Due to the dilutional effect of reabsorbed fluid the haematocrit stabilizes or may be lower. White blood cell count usually starts to rise soon after defervescence but the recovery of platelet count is typically later than that of white blood cell count.

Severe dengue

Severe dengue is defined by one or more of the following this symptom: plasma leakage that may lead to shock (dengue shock) and/or fluid accumulation, with or without respiratory distress, and/or severe bleeding, and/or severe organ impairment.

The patient is considered to have shock if the pulse pressure (i.e. the difference between the systolic and diastolic pressures) is $\leq 20$ mm Hg in children or has signs of poor capillary perfusion (cold extremities, delayed capillary refill, or rapid pulse rate).

Hypotension is usually associated with prolonged shock which is often complicated by major bleeding, severe organ impairment such as severe hepatitis, encephalitis or myocarditis, metabolic acidosis and disseminated intravascular coagulations, this is turn leads to severe haemorrhage causing the haemocrit to decrease in severe shock (3).

3.5.3. Laboratory diagnosis

Efficient and accurate diagnosis of dengue is of primary importance for clinical care. Laboratory diagnosistic method has been develope to support patient management and disease control. The purpose of diagnosis method depends for choice of which the testing is done (i.e. surveillance activities, clinical trials, vaccine development, outbreak control, pathogenesis). Laboratory diagnosis methods for confirming dengue infection may involve detection of the virus, antigens or antibodies, viral nucleic acid, or a combination of these techniques. (Figure 27).
Figure 27: Comparison of diagnostic tests according to their accessibility and confidence (282).

**Direct diagnosis methods**

After the onset of illness, 4 - 5 days during the febrile period, dengue infection maybe diagnosed by virus isolation in cell culture, by detection of viral RNA by nucleic acid amplification tests, by detection of viral antigens by ELISA or rapid tests.

**Virus detection**

Dengue virus can be isolated by the inoculation of a clinical specimen such as serum, plasma or cerebro - spinal fluid, for virus isolation in cell culture, it is important to keep blood samples cooled or frozen to preserve the viability of the virus during transport from the patient to the laboratory. In the cell culture in to mosquitoes are using mosquito cell lines such as C6/36 coloned from *Aedes albopitius* or mammalian cell lines such as Vero and NHEK cells or intracerebral inoculation of suckling mice. For virus identification carried out the immunofluoresen assay using flavivirus group - reactive and serotype specific monoclonal antibodies (mAbs). The isolation and identifiction of dengue in cell cultures usually takes 1 - 2 weeks.

**Viral antigen detection**

Enzyme like linked immunosorbent assay (ELISA) and rapid immunochromographic assays that taget NS1 protein have show that antigen can be detected in patients with dengue infection up to 9 days after the onset of illness. Many
studies investigated utility of NS1 detection as a diagnostic tool during acute phase of a dengue infection and showed a good sensitivity (63-94%), and excellent specificity (98.4-100%) (283)(284)(285). The rapid dengue antigen detection test can be used in field settings (i.e point of care diagnostic test) and provide results in less than one hour (286)(287)(288).

**Viral RNA detection**

Nucleic acid detection assays with excellent performance characteristics identify dengue RNA. Since the 1990s, several reverse transcriptase polymerase chain reaction (RT-PCR) assays have been developed. They offer better sensitivity compared to virus isolation with a much more rapid turnaround time. In situ RT-PCR offers the ability to detect dengue RNA in paraffin - embedded tissues. The utilize a nested RT-PCR assay, using universal dengue primers targeting the C/prM region of the genome for an initial reverse transcription and amplification step, followed by a nested PCR amplification that is serotype -specific.

Up to date, the real time RT - PCR assay is a one step assay system used to quantitative viral RNA and using prime pairs (289), and probes that are specific to each dengue serotype, use of a fluorescent probe enables the detection of the reaction products in real time.

These methods demonstrate a high specificity and sensitivity, it reduces the possibility of cross - contamination, allow the determination of viral load and gives result within 24h.

**Indirect diagnosis methods**

After 3 - 5 days onset of illness, Dengue and antigens disappear from the blood coincidently immune host produces a primary response of antibody. Dengue infection in a non-previously immune host produces a primary response of antibodies characterized by a slow and low titer antibody response.

**IgM ELISA**

The IgM antibody - capture enzyme linked immunosorbent assay (MAC-ELISA) based on detecting IgM in serum using anti - human IgM that is bound to the solid phase. IgM detection is not useful for dengue serotype determination due to the cross - reactivity of the antibody observed even during primary infection, and is not specific in countries
with circulation of other flaviviruses as JEV or YFV in most case due to the presence of cross-reactive antigen shared by flaviviruses.

The detection of dengue-specific IgM is useful diagnostic and surveillance tool. The sensitivity and specificity of IgM-based assay are strongly influenced by the quantity of the antigen used is virus-infected cell culture supernatants or suckling mouse brain preparations (282) (290).

**IgG ELISA**

The IgG ELISA is used for the detection of recent or past dengue infections (if paired sera are collected within the correct time frame). This assay uses the same antigen E/M-specific capture (GAC) as the MAC-ELISA allows detection of IgG antibodies over a period of 10 months after the infection. IgG antibodies are lifelong as measured by E/M antigen coated in direct IgG ELISA. In general, IgG ELISA lacks of specific within the flavivirus serocomplex groups. Following viral infections, newly produced antibodies are less avid than antibodies produced months or years after infection.

**IgM/ IgG ratio**

A dengue virus E/M protein-specific IgM/IgG ratio used to distinguish primary from secondary dengue virus infections. IgM capture and IgG capture ELISAs are the most common assays for this purpose. In some laboratories, dengue infection is defined as primary if the IgM/IgG OD ratio is greater than 1.2 (using patient’s sera at 1/100 dilution) or 1.4 (using patient’s sera at 1/20 dilutions). The infection is secondary if the ratio is less than 1.2 or 1.4. This algorithm also been adopted by some commercial vendors. However, ratios may vary between laboratories, thus indicating the need for better standardization of test performance (291)(292).

**Western-Blot**

Western blot is the most widely used technique for detecting specific proteins in complex samples like cell lysates, cell culture supernatants or body fluids. By offering a unique combination of specific immunodetection and size-based separation, western blotting gives reliable, convenient, high-quality data, with a specific primary antibody. The relative amounts of the protein present in different samples, including: 1) Samples are prepared from tissues or cells that are homogenized in a buffer that protects the protein of interest from degradation; 2) The sample is separated using SDS-PAGE and then transferred to a nitrocellulose membrane for detection; 3) The membrane is incubated with
a generic protein (such as milk proteins) to bind to any remaining sticky places on the membrane. A primary antibody is then added to the solution which is able to bind to its specific protein; 4) A secondary antibody - enzyme conjugate, which recognizes the primary antibody is added to find locations where the primary antibody bound. Detect by enhanced chemiluminescent, the light is then detected by photographic film, and more recently by charge couple devide (CCD) cameras which captures a digital image of the western blot.

3.5.4. Treatment and prevention

Treatment
At present, there is no specific treatment for dengue fever. For DHF, medical care by physicians and nurses experienced with the effects and progression of the complicating haemorrhagic fever can frequently save lives - decreasing mortality rates from more than 20% to less than 1%. Maintenance of the patient's circulating fluid volume is the central feature of DHF care. At present, the only method of controlling or preventing dengue virus transmission is to combat the vector mosquitoes (293).

Prevention
Preventing or reducing dengue virus transmission depends entirely on control of the mosquito vectors or interruption of human - vector contact. Activities to prevent transmission should target the main vector is Ae. aegypti and Ae. albopictus mosquito. Integrate vector management (IVM) is the strategic approach to vector control promoted by WHO, 1991. Defined as” a rational decision - making process for the optimal use of resources for vector control” five keys of IVM considers in the management process are: 1) The promotion development policies, establishment legislative controls for public health; and the empowerment of communities; 2) The collaboration within the health sector and with other sectors in the programme managers the control of vector-borne diseases; 3) An integrarated approach to disease control of non - chemical and chemical vector control methods; and integration with other disease control measures; 4) Routine monitoring and evaluation based on adaptation of strategies and interventions to local vector ecology, epidemiology and resources, research; 5) IVM capacity building include infrastructure, financial and human.
Historically, efforts to control dengue vectors in the WHO Region of the Americas resulted in the elimination of *Aedes* populations from much of the neotropics by the 1970s. However, reintroduction followed, leading to the re-establishment of vector populations. Today, the main target of the most programmes is to reduce the densities of vector populations as much as possible and maintain them at low levels. Where feasible, efforts may also be made to reduce the longevity of adult mosquito by the use of insecticidal methods in order to lessen the risk of virus transmission.

![Diagram](image)

**Figure 28:** Dengue research and training supported and encouraged by the UNICEF-UNDP-World Bank-WHO. Special Programme for Research and Training in Tropical Diseases or the Initiative for Vaccine Research.

**Vaccines**

Because dengue virus is caused by five serologically related but distinct viruses, an effective dengue vaccine needs to induce a protective immune response against all four viruses simultaneously. Unlike other flaviviruses such as JEV, YFV and tick-born encephalitis virus, vaccine for dengue is no licensed exists. To the development of a
successul DENV vaccine is difficulties cause by reasons: 1) The need to develop a separate vaccine for each DENV serotype; 2) The risk of inducing enhanced disease upon subsequent natural infection if antibody to one or more serotype (294); 3) the lack of suitable animal model that reproduce human disease and can be used to evaluate candidate vaccines; and 4) is not fully understood about the lack of validated correlate of protection since the mechanism of protective immunity against DENV infection (3). Therefore, in the development of a dengue vaccine, an effective vaccine must induce long lasting and protective immunity against all four DENV serotypes (295). Despite these many above mentioned challenges, DENV vaccine development have made great strides in recent decades.

Nowadays, the clinical evaluation of candidate vaccines for dengue has several unique aspects, some of which related to the obstacles. The candidate vaccines that have been most extensively evaluated and are most advanced in development are live attenuated DENV vaccines from Sanofi Pasteur. The tetravalent dengue vaccine (TV) candidate utilizes the YFV (17) backbone with DENV prM and E genes from each DENV type replacing those of YFV. Pre - clinical studies demonstrated genetic and phenotypic stability, no hepatotropism, less neurovirulence than YF 17D, and failure to infect orally fed mosquitoes (296)(297)(298).
Table 2: Summarize of current dengue vaccines (299) (300).

<table>
<thead>
<tr>
<th>Institution/commercial partner</th>
<th>Vaccine Approach</th>
<th>Development stage</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carolina Vaccine Institute</td>
<td>Viral replication: Venezuelan equine encephalitis virus replicon expressing DENV E prot.</td>
<td>Pre-clinical: successful monovalent DENV3E-VRP. Tetravalent planned.</td>
<td>(White et al., 2007)</td>
</tr>
<tr>
<td>GenPhar Inc.</td>
<td>Viral replication: non-replicating adenovirus-5 construct with prM and E DENV proteins</td>
<td>Pre-clinical: bivalent candidate (CAdVax-Den1,2 + CAdVax-Den3,4)</td>
<td>(Holman et al., 2007; Raja et al., 2007)</td>
</tr>
<tr>
<td>Pedro Kouri Tropical Medicine Institute, Havana, Cuba</td>
<td>Recombinant: Fusion EDIII of DENV-1 and DENV-2 into P64K protein of N. meningitidis</td>
<td>Pre-clinical: monovalent DENV-1 or DENV-2 + Freund's adjuvant.</td>
<td>(Bernardo et al., 2008)</td>
</tr>
<tr>
<td>WRAIR/GSK</td>
<td>Inactivated: Purified inactivated virus (PIV) produced in VERO cells inactivated by formalin</td>
<td>Pre-clinical: Phase 1: planning.</td>
<td>(Eckels and Putnak, 2003)</td>
</tr>
<tr>
<td>Inviragen Inc.</td>
<td>Replicating: DENV-DENV chimeric (DENV-2 PDK-53 backbone; DENVax)</td>
<td>Pre-clinical: Phase 1: Tetravalent phase 1 Studies planned (U.S. and Columbia).</td>
<td>(Huang et al., 2003; Osorio et al., 2011)</td>
</tr>
<tr>
<td>Hawaii Biotech /Merck &amp; Co.</td>
<td>Recombinant: Truncated recombinant E protein (DENV-80E) expressed in Drosophila S2</td>
<td>Phase 1: DENV-1 monovalent trial completed; Tetravalent phase 1 planned.</td>
<td>(Clements et al., 2010)</td>
</tr>
<tr>
<td>U.S. National Institutes of Health</td>
<td>Replicating: Recombinant live attenuated; Directed mutagenesis and DENV-DENV chimeras (DENV-4 backbone; TetraVax-DV)</td>
<td>Phase 1: 15 phase 1 studies of monovalent Vaccines completed; one tetravalent phase 1 study completed.</td>
<td>(Durbin et al., 2001; Durbin et al., 2006)</td>
</tr>
<tr>
<td>Naval Medical Research Center</td>
<td>DNA: prM and E DENV 1, CMV promoter (DIME-VRP)</td>
<td>Phase 1: DENV-1 phase 1 completed; future testing unsure.</td>
<td>(Reckitt et al., 2011)</td>
</tr>
<tr>
<td>WRAIR/GSK</td>
<td>Replicating: Live attenuated virus (LAV) (PDK passage)</td>
<td>Phase 2: Completed in U.S., Puerto Rico, Thailand; further Development in question (manufacturing complexities)</td>
<td>(Simasathien et al., 2008)</td>
</tr>
<tr>
<td>Sanofi Pasteur</td>
<td>Replicating: Chinnars Yellow fever 17D-DENV (CYD)</td>
<td>Completing phase 2b. Phase 3: in Australia 2010, program expansion expected.</td>
<td>(Guy, 2009; Guy et al., 2011)</td>
</tr>
</tbody>
</table>

Note: WRAI is Walter Reed Army Institute of Research

GSK is GlaxoSmith-Kline

3.5.5. DHF immunopathogenesis

3.5.5.1. Dengue pathogenesis

The understood about mechanisms leading to the severe manifestation of DENV infections are still not completely clear, however they are likely to be multifactorial (5), because no other animals develop symptoms of disease, and research, therefore, has been
limited to studies involving patients (301). The genetic background of the human host or other underlying diseases have been hypothesized to increase disease pathogenesis (302)(303)(304). Upon inoculation of DENV in the dermis, Langerhans cells and keratinocytes will primarily be infected. DENV subsequently spreads via the blood (primary viraemia) and infects tissue macrophages in few organs, especially the macrophages in the spleen. The replication efficiency of DENV in dendritic cells, monocytes, and macrophages (305)(306), as well as its tropism for and replication efficiency in endothelial cell, bone marrow stromal cells and live cells, collectively determine the viral load measured in blood. This viral load represents an important risk factor for development of severe disease. Infected cells die predominantly through apoptosis and to lesser extent through necrosis. Necrosis results in release of toxic products, which activate the coagulation and fibrinolytic systems. Depending on the extent of infection of bone marrow stromal cells and the levels of IL-6, IL-10, and IL-18, haematopoiesis is suppressed, resulting in thrombocytopenia. Platelets interact closely with endothelial cells, and a normal number of functioning platelets is necessary to maintain vascular stability. A high viral load in blood and possibly viral tropism for endothelial cells, severe thrombocytopenia, and platelet dysfunction may result increased capillary fragility, clinically manifested as bleeding symptoms which is characteristic of DHF (307). The infection stimulates development of specific antibody and cellular immune response to DENV at the same time. When IgM antibodies that cross-react with endothelial cells, platelets, and plasmin are produced, resulting in increased vascular permeability and coagulopathy is amplified. Beside, enhancing IgG antibodies bind heterologous virus during secondary infection and enhance infection of antigen presenting cells (APCs) and thereby contribute to the increased viral load that is seen during secondary viraemia in some patients. Furthermore, a high viral load over stimulates both low and high activity cross - reactive T cells. In the context of certain HLA haplotypes, cross - reactive T cells produce high levels of proinflammatory cytokines and other mediators. Ultimately, these high levels of soluble factors, many of which still remain to be identified, induce changes in endothelial cells leading to the coagulopathy and plasma leakage characteristic of Dengue shock syndrome.
3.5.5.2 Dengue risk factor

DENV tropism

Animal models of DENV disease have been very difficult to develop because of the virus’s specificity for infection and replication in certain human cells. Cell and tissue tropism of DENV may have a major impact on the outcome of DENV infections. In vitro data and autopsy studies suggest that three organ systems play an important role in the pathogenesis of DHF/ DSS: 1) the cell of immune system such as immature Langerhans cells, keratinocytes in epidermis and dermis (308), and in Lymph nodes such as monocytes and macrophages; 2) the liver (hepatocytes and Kupffer cells) resulting in viral induced apoptosis and necrosis (5) and 3) endothelial cell specifically the microvessel in dermal papillae (309). The tropism of DENV for cells of these systems and the corresponding pathological effects of DENV infection of these systems contribute to the pathogenesis of DHF.

Virulence

According to the virus virulence hypothesis, certain DENV strains are responsible for more severe disease. DENV serotypes can be further classified into different genotypes on the basis of nucleotide variations. Viral genetic differences have been associated with differences in virulence (310) (311)(312) (313).

The most importance evidence of DENV virulence was observed in the Americas during the first outbreak of DHF occurred in 1981 after the introduction of the possibly more virulent DENV-2 Southeast Asian genotype, as the original American genotype already present was only associated with DF (314) (315). Although DHF occurs more frequently in secondary infection than in primary infection, however DHF also occurs in primary. This suggests that virulence of virus strains may contribute to the development of DHF (316)(311) (317). A study of Tuiskunen et al., 2011a showed that DENV isolation from patient with different degrees of severity could be characterized phenotypically and genetically in cell culture and in BALB/c mice (318) (107) (317). The result revealed that a virus isolated from a DSS patient showed unique features characterized by a lower level of replication in mammalian cells and extensive apoptosis in mosquito cells compared to those isolated from DHF patients (318) (319), while in mice, a virus isolate derived from a DSS patient persisted longer in vivo with extensive neuroinvasion in contrast to other
DENV-1 isolates that originated from milder human cases (317), genomic characterization of the three clinical isolates identified six amino acid substitutions unique for the DSS isolates that were located both in structural genes (M and E) and non structural genes (NS1, NS3 and NS5).

It has also been proposed that intra epidemic evolution of the circulating DENV might be responsible for increased severity of disease and more severe of disease manifestation and case fatality rates were observed toward the end of epidemic (320)(321). This phenomenon suggested that circulating DENV might have become more virulent through passage in hosts during the epidemic. In addition, epidemic with high incidence of DHF have been link to primary infection with DENV-1 followed by infection with DENV-2 or DENV-3 (322) (323). Therefore, in studying DENV virulence, both host and viral factors should be considered.

**Activation of complement system**

The complement system is one of the main humoral components of the innate immunity and interacts closely with the hemostatic system to provide the first line of defense against pathogens (5). Activation of complement is another important in the clinical manifestation in DHF, it was reported that the level of capsid protein (C3a and C5a), complement activation products, are correlated with the severity of DHF. When plasma leakage becomes most apparent and decreased in patients with DSS due to an accelerated consumption the level of C3a and C5a reached the peak at the time of defervescence (324) (325). The pre-existing cross reactive antibody, high levels of secreted NS, immune complexes were implied in mediating complement activation through classical and alternative pathways (324) (326).

**Transient autoimmunity**

The presence of serum antibodies specific to NS1 also has been to correlate with disease severity (327)(328). Antibodies produced during a DENV infection have been shown to cross-react with some self-antigens, so it is not clear if production of these antibodies is associated with secondary DENV infection (329). Cross-reaction of anti NS1 with cell of the liver, EC, and platelets have been observed (330) (331) (332). Anti-NS1 antibodies specific to cross-react with human and mouse platelets leading to transient thrombocytopenia and hemorrhage in mice (333) and with EC causing cells apoptosis (330). It is not clear yet why the autoimmune phenomenon observed in some DENV
infected patients does not persist, thought it is likely that the cross reactive antibodies to self - antigens are of the short - lived IgM isotype (334) (335).

**Host Genetic factors**

Differences in DENV disease severity can be seen at both the individual and population levels. Several human HLA class I and II alleles are associated with development of DHF (336) (337) (338) (339). Some epidemiological studies indicated that genetic factors constitute important components in disease susceptibility. Polymorphism in the tumor necrosis factor alpha (TNF - α), Fcγ receptor, vitaminD receptor, CTLA - 4, and transforming growth factor β (TGF - β) genes has been associated with development of DHF/DSS (336) (340). However, certain host factors, such as glucose 6 - phosphate dehydrogenase (G6PD) deficiency may also contribute to increased replication of DENV in monocytes. Polymorphism in transporters associated with antigen presentation and human platelet antigen, additionally, polymorphysm in the mannose - binding lectin 2 (MBL2) gene were jshown to be associated with thrombocytopenia and an increased risk for developing DHF (341).

The risk to develop DHF and DSS following infection with DENV is likely to be determined by a combination of multiple common genetic traits, each with mild to moderate effects, predisposing to moderate effects, predisposing to a more severe form of disease.

**Anti-Denpendent Enhancement**

Studies in epidemiological have shown an increased risk of developing DHF/DSS after a secondary DENV infection (342) (343) (344) (345). Halsted and colleagues observed the incidence of DHF and DSS peaked divided in two groups of young children, the first group in infants from 6 to 9 months infected with different DENV serotype that infected from their mother, cross- reactive antibodies that lack neutralizing activity are induced in the primary infection. In the second group was observed in children older than 1 year and in secondary infection. DENV and non-neutralizing antibodies from virus - antibody complexes (See figure 29).
Figure 29: Model of antibodies-dependent enhancement (346)

This non-neutralizing cross-reactive antibodies form virus-antibodies complexes bind to Fcγ receptors on target cell and result in enhancement of DENV infection leading to high viral load and to DHF (347). In the most acute virus infection models, the presence of antibodies, both neutralizing and non-neutralizing, correlates with control, elimination and eventually protection. However, a possible detrimental role of virus-specific antibodies has been described for several viruses as measured by in vitro enhancement of infection of cells (348) (349) (350) (351) (352) (353) (354). Although, some studies have shown a correlation between enhancing activity of serum, high levels of viraemia, and an increased risk for DHF/DSS, not all cases of severe disease are associated with antibody-dependent enhancement or preceded infection with a heterologous serotype or by high viral loads (355) (356). In some cases, when DHF/DSS is seen, the presence of viral RNA became undetectable (328).

**Cros reactive T-cell response**

Although memory T cell cross-reactive with a heterologous virus can provide partial protective immunity, they can also cause substantial immunopathology (357). Human infected with DENV result in the development of dengue-specific CD4+ and
CD8+ T cell responses with epitopes in multiple DENV antigens, primarily nonstructural proteins, being recognized by these T cells (358). However, this T cell responses cross-reactivity with heterologous virus can provide partial protective immunity as well as play a role in dengue pathogenesis.

T cell responses pattern is similar to the antibody response, T cells responses are characterized by higher homotypic than heterotypic responses (359). During the acute phase of a secondary of human infection with heterologous DENV, highly cross-reactive CD8+T cells with high avidity for the infecting virus are preferentially activated (360) (361). The majority of these cross-active T cells produce high concentrations of pro - and anti - inflammatory cytokines such as IFN-γ, TNF-α and IL-13, IL-6 but somewhat lower levels of IL-10. The phenomenon where cross-reactive memory T cells for primary infecting virus are more efficiently activated, due to the increased frequency and higher activation state of memory cells, this phenomenon referred to as “original antigenic sin”. However, in accordance to what has been described for several other systems, it is possible that during a heterologous DENV infection, only small subset of cross - reactive memory cells will be stimulated to expand because of a narrowing TCR repertoire with unique specificity within individual has a unique T cell receptor specific (362) (363).

**Soluble factors**

Several studies analyzed sample from infants, children and adult infected with different DENV serotypes have shown it is highly believed dengue pathogenesis to a “storm” of inflammatory cytokines and other mediators that lead to the increased plasma leakage in DHF/DSS. Higher plasma level of IL-1β, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, IL-13, IL-18, TGF-1β, TNF-α and IFN- β have been found in patients with severe DENV infection, in particular in Patient with DSS (355) (364) (365)(366). It is reasonable to assume that synergistic interation between these cytokines will occur. It is more likely that multiple cytokines contribute simultaneously in a complex way to the development of DHF/DSS. Actually, DSS patients recover extremely rapidity after appropriate fluid therapy suggests that cytokines do not cause tissue destruction like in many immunopathology models but rather cause a reversible EC dysfunction. Other mediators and soluble factors found to be increased in severe disease include: vascular endothelial growth factor, granulocyte-macrophage conoly - stimulating factor, monocyte chemoattractant protein 1, macrophage migration inhibitory factor, thrombopoietin, soluble
vascular cell adhesion molecule 1 (VCAM-1), soluble ICAM-1, von Willebrand factor antigen, thrombomodulin, E-selectin, tissue factor, plasminogen activator inhibitor 1, and tissue plasminogen activator (364)(367) (368)(369)(370)(371)(372). Apart from any other considerations, it is reasonable to assume that cytokines and other soluble mediators of the functional, and to a lesser degree the morphological, pathology characteristic of DHF/DSS are also essential for efficient viral clearance.

4. Alphaviruses and Chikungunya virus

4.1. Classification

Chikungunya virus (CHIKV) is a member of the *Alphavirus* genus in the family Togaviridae. *Alphavirus* can be divided into New World and Old World viruses. These two groups have evolved distinct ways of interacting with their respective hosts, and differ in for instance their pathogenicity, and tropism. Chikungunya virus is part of Semliki Forest (SF) group of Old World *Alphaviruses*. Predominantly New World viruses are associated with encephalitis, whereas poly-arthritis and rash is predominatly associated with Old World *Alphaviruses*. There are 29 different types of alphaviruses that cause diseases in human and other mammals.

Genome structure

CHIKV is a small, about 60-70 nm diameter, enveloped, a positistive single - strand RNA virus (Figue 30). In early 2006, according to NCBI/ GenBank accession no.DQ443544.1, the complete sequence of a chikungunya isolate from Reunion Island was made, the virion consists of an envelope and a nucleocapsid. The chikungunya virus genomes is 11,805 nucleotides long encodes for two polyproteins: 1) the nonstructural polyprotein consisting of four proteins from nsP1-4; 2) and the structural polyprotein consisting of five proteins as capsid, E1-3, 6K. The 5’ end of RNA molecule is capped with a 7-methylguanosine while the 3’ end is poly-adenylated (373)
4.2. Genetic evolution

Chikungunya fever swept across many South and South East Asia countries, following extensive outbreak in the India Ocean Island in 2005. However, molecular epidemiology data explain the recent spread and evolution of CHIKV in the Asian region are limited.

Many studies conducted so far to understand the origin and evolution of CHIKV have focused on full genome and E1 gene sequences of the virus (374) (195) (375) (376). Phylogenetic analyses of the CHIKV genome have shown three genetic lineages: Asian, West African, and East, Central and South African (ECSA) (374). It is now clear that the emergence of CHIKV in the Indian Ocean Islands in early 2005 was due to a newer strain of the ECSA lineage (195). Current epidemiological evidence suggests that this strain...
could have moved to the Indian Ocean Islands following CHIKV outbreaks in Kenya in 2004 (377). Although the molecular epidemiology of CHIKV in India has been thoroughly described (378) (375), similar data to explain the evolutionary relationships of CHIKV that spread in the rest of the Asian region after 2005 are still limited. In the study of H.C. Hapuarachchi et al., 2010 (379), they sought to analyses the evolutionary relationships of CHIKV in South and South-east Asian regions after 2005, in order to understand the possible routes of spread of the virus to Sri Lanka, Singapore, Malaysia and the Maldives. Moreover, a hypothetical evolutionary pathway for CHIKV strains that emerged in the Indian Ocean Islands and Asian region after 2005. (See figure 31). The later is circulating in the Caribbean and South America.

![Figure 31: Chikungunya virus and dispersal and evolution.](image)

To date, the difference genotype of ECSA CHIKV have been identified. The acquisition of A226 mutation in the envelope protein E1 of the ECSA genotype, as observed in La Reunion in 2005, has increased the transmissibility of the CHIKV through
the widely distributed *Ae. albopictus* mosquitoes (380). This mutated virus spread from the Indian Ocean to East Africa and Asia such as India, Sri Lanka, Singapore, Malaysia and China, and caused the chikungunya outbreak in Italy. In 2010, CHIKV strain responsible for autochthonous cases in France belong to the ECSA genotype but without the mutation at position 226 (381) (382).

4.3. Replication cycle

Following transmission, CHIKV replicates in the skin and then disseminates to the liver and joints, presumably through the blood. Unlike typical encephalogenic alphaviruses, which infect neurons, CHIKV seems to infect the stromal cell of central nervous system and in particular, the lining of the choroid plexus (383). CHIKV replication has been extensively studied in mammalian and insect cell culture system (384). The replication and propagation of viruses is dependent on entry into permissive cells. Biological samples from acutely and chronically infected humans have been analysed and, together with the development of animal models, have provided invaluable tools for studying the physiopathology of infection. CHIKV share many characteristics with other Old world alphavirus but also displays unique and previous unexpected properties (385) (386) (383).

4.4. Vector

*Aedes* mosquitoes

Historical data report the first detection of chikungunya in 1952 in the Makonde Plateau in Africa (387)(388) where the virus is known to be maintained in the sylvatic cycle of wild primates and mosquitoes such as *Ae. taylori* (389) (390). Later in 1958 it was detected in urban Asia such as Thailand mainly transmitted by *Ae. aegypti* (391). In India, CHIKV was first detected in 1963 in West Begal, where *Ae. aegyti* and *Ae. albopictus* were known to exist and are widely prevalent during the post monsoon season (391). From 1972 to 1986, CHIKV was observation in Kedougou, Senegal from forest mosquitoes, with most of them isolated from *Ae. furcife - taylori, Ae. luteocepphalus* and *Ae. dalzieli* (390), so the most recent one occurred in 1996 in Kaffrine where CHIKV
isolated from *Ae. aegypti* (390). In Europe, *Ae. albopictus* (Asian Tiger mosquito) has also recently emerged as an important vector to transmission CHIKV in temperate country (392) (393).

![Map showing origin, spread, and distribution of chikungunya virus and its vector](image)

**Note:** ECSA denotes eastern, central, and southern Africa.

Figure 32: Origin, spread, and distribution of chikungunya virus and its vector.

The map shows the African origine of enzootic chikungunya virus strains and the patterns of emergence and spread of the Asian lineage and Indian Ocean lineage (IOL) of the virus during epidemics since 1950s, based phylogenetic studies (394) (374). The distribution of the peridomestic vectors, *Ae. aegypti* and *Ae. albopictus*, are also shown (373).

**Transmission cycle**

**Sylvatic Chikungunya cycle**

In Africa, CHIK virus appears to be maintained in a sylvatic cycle involving wild primates and forest-dwelling *Aedes spp.* mosquitoes. Serological studies have repeatedly demonstrated the presence of antibodies in humans and wild primates throughout the moist forests and semi-arid savannas of Africa (395) (396) (397)(398). To date, a vertebrate reservoir or sylvan transmission cycle has not been identified outside Africa, supporting
the historical evidence (399) that CHIK virus originated in Africa and was subsequently introduced into Asia, where it is now typically associated with *Ae. aegypti* mosquitoes. The strains from Africa and Asia are reported to differ biologically, indicating that distinct lineages may exist (400).

**Urban chikungunya cycle**

In Europe where sylvatic cycles are absent, vertical transmission may participate in the maintenance and/or cyclic re-emergences of CHIKV. This critical issue remains to be investigated in diapausing temperate populations of *Ae. albopictus* that may have more efficient vertical transmission than mosquito populations in eastern Italy and tropical regions (401) (402).

### 4.5. Chikungunya Epidemiology

#### 4.5.1. History and origin of chikungunya

The Alphavirus genus, that include the group of viruses to which chikungunya virus belongs, originated around 2000 to 3000 years ago (403). The name “Chikungunya” was derived from a word in the Mokonde language (spoken by a population lives in the Mozamgique region) that mean “that which bends up” (404). These instances of emergence and spread beyond Africa may have begun as early as the 18th century, when sailing ships carried chikungunya virus along with human and *Ae. aegypti* (399). In 1824, epidemics of fever, rash, and arthritis were cited in India and elsewhere. But until 1952, the clinical features of chikungunya virus were first described during an outbreak in villages on the Makonde Plateau in the southern province of Tanganyika, Africa (405) (387) (406). The virus was isolated one year later during an epidemic in Tanzania using human sera and mosquitoes (406) (401). In 1955, the disease was reported be similar to a “Dengue-like fever” (387) (388). Since 1955, most case of CHIKV infection have been describe in Africa and India, during the last 60 years, the epidemic outbreak of CHIKV infection have been reported in India, and in several countries in Africa, in the India Ocean region, and Southeast Asia. The first emergence of the virus in to the urban cycle during the modern scientific occurred between 1897 and 1956, when a member of Eastern, Central, and Southern Africa (ECSA) (373). Another ECSA lineage progenitor began in coastal Kenya
outbreak in 2004 (407) explosive epidemics of millions people before spreading to Indian Ocean islands and India (408) and South East Asia, reaching Myanmar in 2010. The Indian Ocean lineage (IOL) CHIKV strains transmission in the Americas during the peak of 2006 - 2009 outbreaks (409). However, an Asian lineage CHIKV strain was introduced into the island of St. Martin in October 2013 (410) and subsequently spread throughout the Caribbean (11) and Central America as into northern South America and Florida. It seems likely that there will be further spread thoughtout the Americans where CHIKV vectors are widespread, as well as epidemics in Polynesia (410)(11) (373).

![Map of Chikungunya virus dispersal](image)

Figure 33: Predicted dispersal pattern of Chikungunya virus from Africa to the Indian Ocean and Europe during the past 20 to 50 years (411).

4.5.2. Global burden

In the last 60 years, out breaks of CHIKV infection reported for the first time in East Africa in 1952 - 1953, incidence has increasing geographic expansion to new countries and, in the present decade, from urban to rural settings in tropical and subtropical countries in Africa, India, the India Ocean region, and Southeast Asia (392). More
recently, the CHKV diffusion area moved to European as Italy, French or North America countries as Canada, USA. (392) (412) (413)

Figure 34: Chikungunya active transmission regions established from published data illustrate geographic and temporal knowledge of previous outbreaks.

In 2001, CHIKV was first documented in Indonesia, and by 2007, more than 15,000 cases had occurred there. The year 2004 witnessed an outbreak of CHIKV in Kenya followed by another massive outbreak on the French island of La Réunion in 2005 (401). By this point in time, an estimated 266,000 people had developed chikungunya virus (attack rate, 35%) (414). In 2006, a CHIKV epidemic reached Sri Lanka, and through 2007, WHO reported more than 37,000 Sri Lankans were affected by the disease. In 2006, more than 1.3 million cases of CHIKV were reported in India with attack rates as high as 45% in some areas. In 2007, more than 17,000 were infected in Gabon, Africa. Around the same time in 2007, CHIKV first introduced to Europe during the aforementioned outbreak in Italy. However, the attack rate measured only 5.4% in Castiglionedi Cervia and 2.5% in Castiglione di Ravenna, a much smaller figure than in other countries (401) and more recently has spread to the Caribbean region (11).
4.5.3. Epidemiology trend in several regions of the world

4.5.3.1. Epidemiology trend in Africa

Since the first report in 1952, most cases of CHIKV infection have been described in Africa and India. However, during the last 60 years, isolated cases or epidemic outbreaks of CHIKV infection have reported in several countries in Africa, more specifically West Africa from Senegal to Cameroon, Central and East Africa including Central African Republic, Angola, Democratic Republic of Congo, Zambia, Zimbabwe, Tanzania, Malawi, Mozambique, eastern Botswana, and north eastern parts of South Africa, there is also evidence of viral presence in parts of Ethiopia and Sudan (Health Protection Agency reported, 2011). Human infections in Africa have been at relatively low levels for a number of years, but in 1999 - 2000, there was a large outbreak in the Democratic Republic of the Congo, and in 2007 there was an outbreak in Gabon. (415) (416).
Figure 36: Map showing the distribution of chikungunya virus enzootic strains in Africa and the emergence and spread of the Asian lineage (red arrows and dots) and the Indian Ocean lineage (yellow arrows and dots) from Africa (404).

4.5.3.2 Epidemiology trend in Southeast Asia

In recent years, large scale epidemics of CHIKV with considerable morbidity and suffering in their wake have occurred in a number of Member countries of WHO South East Asia Region. In Asia, CHIKV strains were isolated in Bangkok in the 1960s, Sri Lanka in 1969, Vietnam in 1975, Myanmar in 1975 and Indonesia in 1982. Outbreaks were reported from Indonesia (1979, 1985, 2001 and 2003-2007), Myanmar (1975 and 1984), Maldives (2006-2007), Sri Lanka (1965 and 2006) and Thailand (1960, 1978, 1988 and 1995-1996). The outbreaks in Region prior to 2000 were due to Asian strain. In Indonesia, CHIKV occurred sporadically until 1985 after which there were no reports of the disease till a series of outbreaks between 2001 and 2007. The reported 15207 cases from seven provinces with the peak observed in 2003, over 1200 suspected cases of CHIK were reported from 23 sub-districts in 2007, and most of the reported cases were from the province of Java (219).
4.5.3.3. Epidemiology trend in India and India Ocean region

Since CHIKV identification, the first outbreaks of CHIKV in India was documented of the Calcutta in 1963 (417). Afterwards shortly time, several outbreaks of Chikungunya occurred throughout the country until 1973 (418). A gap of several years ensued, during which viral activity in human was thought to have disappeared or to lost its pathogenic potential (419). However, the virus re-emerging in India in 2005 and the country has so far seen more than 1.3 million suspected case of CHIK infection (418) (419). In Southern of India in 2006, an outbreak of CHIK began in Kerala, has so far affected nearly 70,000 people from 14 districts (420) and continues today, in the years of 2009, more than 11,000 suspected cases of CHIK have been reported from Kerala state. The abundance of *Ae. Albopictus* mosquito in the region and molecular evolution by mutation in the glycoprotein envelope gene of CHIK virus may be contributing to the renewed outbreaks.

Starting from the emergence of CHIKV in Kenya in 2004 (421) (422), after that the outbreaks spread to Comoros and Seychelles in early 2005, followed by Mauritius (423) (424) (425). Later the outbreak were reported to have spread to other islands in the Indian Ocean, including La Reunion Islands which is apart of France in 2005, 2006 (195) (426) (427). An causing major outbreaks in there regions (428).

4.5.3.4. Epidemiology trend in European and Americans

Between 2005- 2007, epidemic CHIKV occurred in many European countries (429), CHIKV infection was diagnosed in travelers coming from epidemic areas ( a person traveling from India ). During the summer 2007, and for the first time in a temperate country, an epidemic of this tropical disease occurred in Italy (430), in Castiglione di Cervia and Castiglione di Ravenna (Emilia Romagna, Northern Italy), which together form a single urban area, the mosquito was detected in local is *Ae. albopictus*. Erosurvaillance report *Ae. albopictus* is found in several other European countries, including Albania, France, Belgium, Montenegro, Switzerland, Greece, Spain, Croatia, German, the Netherlands, Slovenia, Bosnia, Herzegovina, and possibly more, suggesting a potential for further spread of the disease (431).
In German describes the first isolation and molecular characterization of CHIKV in 2009. The virus contained the E1 A226V mutation, shown to be responsible for an adaptation to the Asian tiger mosquito *Ae. albopictus*. The E1 coding sequence was identical to chikungunya virus isolates from Sri Lanka and showed three nt-mismatches to the only available E1nt sequence from the Maldives (425). One year later, in 2010, autochthonous transmission of chikungunya virus was recorded in Southeastern France (335), and in Montpellier, southern of France, 2014 (382).
During the past four weeks in 2014, numerous imported cases reported from the Americas and Europe among travellers return from the Caribbean regions, in particular from Haiti or Dominican Republic. Such as USA in the North America; Panama, Suriname, Cuba, Barbados, and Bonaire island in Central America and Caribbean; Venezuela, Brazil, Peru, Chile in South America; France, Italy, Netherlands, and Spain in Europe (432).
Figure 39: Introduction of chikungunya to the Caribbean by epidemiological week first reported in December 2013 to August 2014. Data from PAHO/WHO statistics (433)

4.5.4. Diagnosis

Classification in clinical

In the clinical, serological and molecular diagnosis of CHIKV fever patients and its comparison with dengue viral fever. Classical clinical features of CHIKV infected patients were recorded to differentiate chikungunya from dengue, which were fever, arthralgia, myalgia and rash (434).

Approximately, 3% - 8% of patient infected with CHIKV will remain asymptomatic. For people who develop symptomatic illness, the incubation period is typically 3-7 days (range 2-12 days) with the fever is usually of short duration (435). In some patients, a biphasic pattern of fever has been described with a febrile episode of 4 to 6 days, followed by fever-free period of a few days followed by recurrence of fever (usually 101-102°F) that may last a few days.
Note: The chronology of viral replication in relation to the clinical and biologic signs of disease, including the biomarkers used diagnostic assays to detect chikungunya virus infection (Suhrbier et al, 2012)(436)

Figure 40: Timeline of Infection, Symptom, and Biomarkers

Soon after the onset of fever, severe myalgias and arthralgias occure, 80% of patients. The joint pain is usually symmetric and localized in both arms and legs, estimated in 90% of patients, the large joints are almost invariably symptomatic, as are to a lesser extent, the small joints and the vertebra column (437). Rash occurs in 20-80% of cases, less common, nonspecific signs and symptom include lymphadenopathy, pruritus, and digestive abnormalities, more common after viremia has resolved. In acute phase, feelings of faintness, fainting, confusion and attention - deficit disorders (373). Rare complications can occur including conjunctivitis, uveitis, iridocyclitis and retinitis, with typically resolve (438). Manifest in severe chikungunya fever as encephalopathy and encephalitis, myocarditis, hepatitis, and multiorgan failure. These rare forms can be fatal and typically arise in patients with underlying medical conditons. Hemorraghic complications are rare and consideration of alternative if coninfection with dengue virus or coexisting conditions such as chronic hepatopathy. In infant group, neonates at risk for severe infecton
associated with neurologic signs, the rare extremely, 50% of neonates born of infection to viremic mother, and exposed to the virus during birth, leading to severe disease and encephalopathy in half and resuming in long term neurology sequelae (439).

**Disease course**

After the incubation period, the illness begins abruptly and its followed by three phases: Acute phase, onset phase and chronic phase.

**Acute phase**

CHIK fever affects all age groups, and both genders are equally affected. The incubation period ranges from 2 to 12 days (usually 3-7 days) (440) (441) (405) (442) (422) (443). In susceptible populations, the attack rates can be as high as 40-85 %.

**Onset phase**

Prodromal symptoms are very rare. In the acute stage, the onset is usually abrupt and sudden with high - grade fever, severe arthralgias, myalgias, and skin rash (440) (441) (405) (442) (422) (443). Headache, throat discomfort, abdominal pain, and constipation may also be evident. Conjunctival suffusion, persistent conjunctivitis, cervical, or sometime generalized lymphadenopathy may be present.

**Chronic phase**

In a majority of the patients, the joint pains resolve in 1 to 3 weeks. In a majority of the patients, the joint pains resolve in 1 to 3 weeks. However, the arthritis can persist in about 33% of patients for 4 months, 15% for 20 months, and in 12% for 3-5 years (422) (444)(444) (445). The chronic stage is characterized by unpredictable relapses that include sensation of fever, asthenia, and exacerbation of arthralgias and stiffness. Affected patients may manifest inflammatory polyarthritis, severe subacute tenosynovitis/bursitis (consequently nerve tunnel syndromes) in hands, wrists, and exacerbation of pain on movement in previously injured joints (441)(446). Older individuals and those with underlying rheumatic and traumatic joint disorders seem to be more vulnerable to develop the chronic stage (441) (405) (442) (422) (443). Rarely, rheumatic manifestations resulting in joint destruction before resolution after 15 years have been reported (447). Some studies have documented occurrence of rheumatoid arthritis following chikungunya fever, suggesting that the viral infection may have a role in the initiation or unmasking of rheumatoid arthritis (448)(449).
Laboratory diagnosis

Laboratory diagnosis depends on antibody-capture IgM ELISA and plaque-reduction neutralization tests of serum. Comparative serologic tests for closely related alphaviruses (e.g., o'nyong-nyong and Sindbis viruses) should be conducted as geographically appropriate, and tests for dengue usually are indicated. Virus isolation attempts and PCR assays are performed selectively. Serologic tests should be performed on both acute and convalescent phase serum specimens collected at least 2 weeks apart, but clinicians should not delay submission of acute phase samples pending collection of convalescent phase samples (CDC). There is no specific assay for assessing chronic signs and symptoms associated with chikungunya fever, although elevated levels of C-reactive protein and proinflammatory cytokines correlate with disease activity as do IgG and IgM (450) (436).

4.5.5. Treatment and prevention

Treatment

There is currently no effective antiviral treatment for chikungunya. Treatment is therefore purely symptomatic and based on non-salicylate analgesics and non-steroidal anti-inflammatory drugs. Synergistic efficacy was reported between interferon-α and ribavirin on chikungunya virus in vitro (451)(452) and other antiviral compounds are under investigation (453). Analgesic drugs often combined with nonsteroid antiinflammatory drug (454). Although morphine effective during the initial phase but seldom used (387). In the incapacitating form, corticosteroids was sometime prescribed to treat (454). Chloroquine used treating in certain forms of chronic arthralgia (455), and there was no justification for treat acute infection (456).

Vaccines

Chikungunya fever represents a simple vaccine target than DF. There is currently no commercial vaccine for chikungunya virus, although some candidate vaccines have been tested in human beings (457) (458). Since the 1970, CHIK vaccine approaches have been pursued using mainly formalin killed and live approaches (VADIP). In the trials conducted by the US Army Medical Research Institute, very satisfactory seroconversion rates (98% on day 28) and neutralising antibody titres were obtained, persisting in 85% of
cases at 1 year, but these American vaccine trials were interrupted in 2003. On 6 September, 2006, the US Army Medical Research and Materiel Command signed a Material Transfer Agreement with the French National Institute of Health and Medical Research focusing on the records of previous clinical studies. Have tested a live vaccine (TSI-GSD-218) in Phase I and II where the vaccine was shown to be safe and immunogenic in 88 volunteers, although some vaccines experienced transient arthralgia (457). A phase III trial of the US Army candidate vaccine is in preparation (US Embassy in France; press release, Sept 14, 2006). The candidate vaccine is a live vaccine (TSI-GSD-218) based on chikungunya virus strain 15561 and 1962 isolated from a patient in Thailand and attenuated by serial passage in MRC-5 cells (458) (459). The status of TSI-GSD-218 is currently unclear although the US government allowed French authorities to collaborate based on the situation in La Reunion. In 2008 new vaccine candidates were proposed (460) (461). In 2009, a formalin inactivated vaccine candidate prepared used Indian strain implicated in epidemic in 2006 (462). This vaccine candidate has very good immunogenic potential to neutralize the virus infectivity.

**Prevention and control**

The immediate prospects for the control of chikungunya fever are poor. There are no specific therapeutic agent to treat patients and no licensed vaccine to prevent CHIKV. Pending vaccine development, the only effective preventive measures consist of individual protection against mosquito bites and vector control. Control of both adult and larval mosquito populations uses is the same model as for dengue and has been relatively effective in many countries and settings. Mosquito control is the best available method for preventing chikungunya, as reduce the vector and limit the contact between human and *Ae. aegypti* and *Ae. albopictus* mosquito (463), including wearing protective clothing, bednet or curtains with insecticides impregnated. The focus on reduce or treat water containers or wet discard products where eggs are laid and larve develop. Mosquito population is reduce through traditional larvicide and adulticide applications penetrate the house and premises where mosquito rest and feed. Another reduce transmission is use of wolbachia bacteria (464)(465) and a novel strategies for vector control include the release of transgenic *Ae. aegypti* engineered to carry a late-acting lethal genetic system (466).
4.5.6. Chikungunya immunopathogenesis

4.5.6.1. CHIK pathogenesis

The pathogenesis of chikungunya in human and the mechanism by which it causes arthritic disease is poorly understood (467). Apart from the clinical manifestation of CHIK infection, the information about the pathogenesis of the virus in human is little document. Some study in clinical of CHIK patients reported the occurrence of rhabdomyolysis with elevated creatine phosphokinase levels. To determine whether pathogenesis of CHIK is based on studied of the arthritogenic alphaviruses in vitro, and a mouse model of virus - induced arthritic/arthralgia has been used to study the pathology and immunology (468), infection results in severe inflammation and necrosis of skeletal muscle. The histopathological and immunohistochemical (IHC) finding in human are similar in the CHIKV - infected mice (467).

4.5.6.2 Risk factors

The many experts in the field of infectious diseases, epidemiology, entomology, and risk assessment were to assess the short - term risk of Chikungunya virus in Europe. An artificial distinction was made between the risks of establishment of CHIKV transmission in Europe related to the three key determinants: 1) Risk related to the introduction of the virus, considering the highest likelihood for virus introduction comes from viraemic persons. That is the high frequency of travel between high incidence areas in the Indian Ocean and Europe, limited likelihood for introduction through blood transfusion from a viraemic donor; 2) Risk related to the presence and characteristics of the vector were the spread of *Ae. albopictus* in Europe has been documented, but the map would need to be update, such as taking in to account ecological and climatic information, and considering a more detailed administrative level, the vectorial capacity (host preference, longevity density) and competence (Susceptibility of local strain) for transmitting CHIKV in Europe, needs to further investigation particular in highly infested areas; 3) Risk related to interaction with the host was factors influencing the host and
related risk include the likelihood of being bitten, immunological susceptibility, duration and level of viraemia, proportion of asymptomatic case and capability to detect a case.

5. Combinated arboviral infections

5.1. Combinated Flavivirus infections

**Dengue and encephalitis**

Although both dengue and Japanese encephalitis virus (JEV- is one of the most important cause of viral encephalitis worldwide) belong to the genus Flaviviridae, however, the biological characteristics of these two viruses are somewhat different. JEV is mainly transmitted by mosquitoes of the genus Culex (469), isolated of this virus are also reported from Anophelinae mosquitoes (470).

The investigation on the activity of two DENV and JFV were conducted in and around Malina, Philippines, and Luzon islands, they could not demonstrate the DENV and JFV combination (470). But encephalopathy has been well reported and has classically been thought to result from the multisystem derangement that occurs in severe dengue infection with liver failure, shock, and coagulopathy causing cerebral insult, there is increasing evidence for DENV neurotropism, these may be an element of direct viral encephalitis (471). DENV infections represent a significant burden of disease in the tropics, and neurologic manifestations are increasingly recognized, but remain relatively poorly understood.

**Dengue and Yellow fever**

Dengue and Yellow fever viruses are single - stranded RNA viruses in the Flaviridae, they are endemic to and epidemic in tropical and subtropical regions (472). In their original habitat, both are Zoonotic infection transmitted by forest-dwelling mosquitoes, *Aedes*. There is little doubt that the yellow fever virus (YFV) originated in Africa, and that viruses circulating in the New World are of African origin (473). Curiously, YFV never been recorded in Asia, although *Ae. aegypti* is widespread there (473) (See figure 41).
Figure 41: Distribution of Dengue, Yellow Fever, and their principal vector, the Aedes aegypti mosquito.

Although YFV is now largely controlled by vaccination and successful mosquitoes eradication campaign, many regions are susceptible to a reemergence if the movement of infected person (472), and both of viruses continually rising (474) (475). The large urban outbreaks of yellow fever were common until the early 20th century remain a real and constant danger in enzootic countries that do not enforce routine vaccination. However, it is reasonable to assume areas were prone to dengue transmission was equally prone to YFV, so areas without history of the latter, including those in South East Asia, may well be at risk (473).

5.2. Combined Dengue and Chikungunya viruses in the world

Dengue and Chikungunya co-infection

Co - infection by DENV and CHIKV in patient has been known for along time. The first described in patients, and reports of co - infections with DENV and CHIKV in 1964 in South India (476), a co - infection in human can occur following the bite of two main mosquitoes infected with one virus or to the bite of a mosquito infected with two viruses. In the some outbreaks, CHIKV affected areas overlap with dengue fever - endemic areas and provide opportunities for mosquitoes to become infected with both the viruses, and co
- infection are increasing, particularly after the emergence of CHIK in the India Ocean in 2005 - 2006 due to a new variant highly transmitted by Ae. albopictus, a dengue outbreak in the same geographic area transmitted by Ae. albopictus was shortly before the emergence of chikungunya, and co - infections (476). In Asia, the first case report of CHIKV and DENV co-infection confirm by molecular methods was from Sri Lanka (477) and the CHIKV affected areas overlap with DENV in endemic areas (478). In 1967, co - infections with DENV and CHIKV reported in Calcutta, India. Subsequent serologic investigation in Southern India indicated that the two viruses can co-exist in the same host (418).

In clinical, the common symptom of both disease included fever, joint and bone pain, nausea, vomiting, headache, and fatigue. Therefore, while screening considering both dengue and chikungunya infection is necessary because though the clinical features are similar, the outcomes maybe different, chikungunya is nonfatal while dengue may lead to severe health complication and including death (479). A study from Department of Microbiology, Sri Venkateswara Institute of Medical Sciences, Tirupati, India showed that the co - infection with dengue and chikungunya fever was found in 2.7% of the cases in India (479).

**Dynamic Dengue and Chikungunya co-infection**

In the past years, DENV and CHIKV have caused large and geographically wide ranging epidemics (6)(480) (481). The actual situation of co - infection is much more complex. Fist, Ae. albopictus was repeatedly show to be highly competent vector of CHIKV during the recent outbreak in the Indian Ocean and Italy (482). Second, the overall distribution of Aedes mosquitoes is rapidly changing. Specifically, Ae. albopictus has dispersed globally in to new territories previously occupied by Ae. aegypti. As a consequence, the characteristics of DENV and CHIKV circulation and their outbreak dynamics are likely to be modified (483). The CHIKV affected areas overlap with DENV endemic areas and provide opportunities for mosquitoes to become infected with both viruses (484). Co - infection with DENV- 1 and DENV- 2 was reported in Puerto Rico in 1982 (485). Since then, many cases of concurrent infections with multiple DENV serotypes have been reported in many countries, such as co - infections with more than two DENV serotypes in India in 1967 and 2006. The co - infection with DENV and CHIKV in Calcutta, India show that subsequent serologic investigation the two viruses can coexist in the same host (486) (418).
Seasonal trend observed with both the fevers with rise of the cases during the post monsoon period. *Ae. aegypti* is sensitive to changes in temperature and available moisture, they decrease in number in dry and cool seasons, and increase when temperatures increase and when the wet season begins (487) (488).

Beside, in the some countries setting, overcrowding, low socioeconomic conditions, and poor sanitary conditions, mixed population of mosquitoes thriving together cannot be excluded is reason to make dynamic of CHIKV and DENV co-infection.

**Mechanisms of Dengue and Chikungunya co-infection**

The exact mechanisms of the DENV and CHIKV co-infection still remain a mystery. Despite the threat of this virus to public health and its importance to research on viral hemorrhagic fevers our understanding of the virulence, pathogenesis, and mechanisms of re-emergence of the dengue virus is limited. Unlike dengue, chikungunya typically consists of a self-limiting and nonfatal acute illness characterised by fever, rash and incapacitating arthralgia. Several mechanisms including a complex interaction between various factors such as the susceptibility of humans and the mosquito vectors to the virus, conditions facilitating mosquito breeding resulting in a high vector density, ability of the vector to efficiently transmit the both of virus are all thought to play a role.
PART II
DENGUE AND CHIKUNGUNYA IN VIETNAM
CHAPTER 1
ROLE OF AEDES SPECIES IN THE TRANSLISSION OF DENGUE IN URBAN AREAS IN NORTH VIETNAM

1.1. Context of study

Hanoi, capital of Vietnam, is an urban center located in the northern part of the country. It is a large city with a population estimated at 2.6 million for the urban districts and 6.5 million for the metropolitan jurisdiction (489) (490).

Figure 43: Location of the eight selected study districts in Hanoi, Vietnam
Hanoi is known as a low-transmission area for DF (491), but recently DF appeared to be emerging (492). Public health authorities in Vietnam are now considering dengue as an emerging health problem in Hanoi. The climate is contrasted with hot and humid summers and a rainy season from May to September with temperatures from 38 - 40°C. Winters are relatively dry and cool from November to March with temperatures as low as 6°C. Spring is marked by light rains. The period from June to September is suitable for the development of mosquito vectors (493). Besides, Hanoi experiences annual seasonal dengue outbreaks with the peaks of epidemics usually falling in September/October and ending in November/December. There are only few studies published on the epidemiology of dengue in Hanoi all based on public surveillance data routinely collected by the Ministry of Health (494). DF was first described in northern Vietnam in 1958, where DHF was first reported (495) (496), and later expanded to the southern area where it was described in 1960 (497). During the first 1958 DHF outbreak in Hanoi, 68 patients with identical clinical symptoms were hospitalized with a mortality rate of 7% (19). Dengue infections have been regularly reported since then, but during the 1998-2009 decade, two large outbreaks occurred in the central urban area of Hanoi, which resulted in a total 25983 cases mostly among young adults (494) (498). Incidence rates of DF have increased significantly during the last few years in many province and cities, especially Hanoi.

The invasion of Aedes mosquito is assumed to be high in tropical, dengue endemic, countries like Vietnam. A. aegypti is considered the most important vector of DENV while A. albopictus is generally believed to be a less competent vector resulting in milder epidemics (18). However, dengue outbreaks have been attributed to both A. aegypti and A. albopictus in different regions of the world including Asia (499) (495) (18) (500). Each species displays a specific ecology, behavior and geographical distribution. A. aegypti prefers urban habitats, whereas A. albopictus is primarily a forest species that has become adapted to rural, suburban and urban human environments (18) (501) (502). Owing to this co-circulation of both mosquito species in Vietnam (503) (504), and although Hanoi has a cool winters (505), both species are found in Hanoi (506).

1.2. Objective

To assess the spread of dengue virus and the risk factors for this virus, we conducted a surveillance of mosquitoes and blood samples from hospitalized patients
collected during outbreaks from August 2011 to December 2011 in eight districts of Hanoi as Ba Dinh, Hai Ba Trung, Dong Da, Ha Dong, Thanh Xuan, Thanh Oai, Thanh Tri, and Tu Liem. This study was conceived to investigate the respective role of A. aegypti and A. albopictus in DENV transmission and correlation between mosquito abundance and size and duration of outbreaks in Ha Noi, Vietnam.

1.3. Discussion and conclusions

This study conducted in Hanoi, Vietnam, reported 140 confirmed cases of DF in 24 outbreaks over eight districts. The patients were mainly males older than 15 with the highest number of dengue cases found in the 15-34 years age class. Only 10% of patients were under 15 years old. The age distribution reported in this study differs from other works which reported dengue mainly in children (507) (508) (509) (510) (511) (512) (513) (514). However, our result are supported by reports from both Latin America and Southeast Asia where increasing dengue incidence has been found among older age groups (515) (516) (517) (518). During the study period, we also found proportionately more males affected than females. Others have reported similar findings in Vietnam, China and Nepal (519) (520) (507). There is no clear explanation for this bias which might be associated to an occupational factor.

The presence of only DENV 1 and DENV 2 along with the predominance of DENV 2 reported in this work are in agreement with previous reports on from Hanoi in recent years (494) (519). This suggests that DENV 1 and DENV 2 were already co-circulating during previous outbreaks in the same area and most likely maintained over time through transmission in mosquito populations. This importance of mosquito populations in the maintenance and development of outbreaks is clearly highlighted in this work with the widespread distribution of A. aegypti together with high local densities during the outbreak period in Dong Da, Hai Ba Trung, Ba Dinh, Ha Dong and to a lesser extent in other districts. Ae. aegypti was also the single vector in simultaneous outbreaks of dengue fever in Hanoi. Furthermore, high population densities of A. aegypti was corelated with the number of human cases reported in outbreaks. The number of A. aegypti individuals collected in the early period of outbreaks was higher than the number collected towards the end of the outbreaks. However, due to the small size of mosquito samples
collected in Thanh Tri, Thanh Oai and Tu Liem districts, we cannot exclude that this result was biased as mosquitoes may have been collected under different meteorological conditions or time periods. Nevertheless, altogether these results provide evidence that *A. aegypti* populations from eight districts were involved in dengue virus transmission, and probably played a pivotal role during the 2011 dengue outbreaks and before as a maintenance host.

Despite the fact that is considered to be a less efficient vector, *Ae. albopictus* is adapted to urban domestic environments and was described as vector in DENV outbreaks in different regions including China, Gabon or Madagascar (521) (18) (522). However, in this work, DENV were not detected in *Ae. albopictus* and no correlation was found between *Ae. albopictus* populations and increase in number of human cases. These data corroborate other reports suggesting that *Ae. albopictus* is not an important vector in urban environment when compared to *Ae. aegypti* (523) (502) (524) (525) (526).

The importance of mosquito population densities in the dynamic of dengue fever highlighted by this work might however be underestimated. Indeed, a limitation to this study is that it only covered the latter part of the rainy season, considered an ideal time for dengue transmission. Additionally, no information was available for artificial containers that might have acted as breeding habitats for *Aedes* mosquitoes. There may also have been case ascertainment biases as we relied on patients presenting themselves to health services, thus milder and asymptomatic cases may not have been identified. Nevertheless, this work strongly supports the need of further investigation in other geographic areas and environment, i.e. suburban and rural, to determine the distribution and relative role of *Ae. aegypti* and *Ae. albopictus* in the transmission of DF and DHF in Vietnam. This work also underline the need of a better understanding of the dynamics of mosquito populations to implement efficient and adapted mosquito population monitoring and mosquito control strategies, which is at the moment the best way of controlling dengue and other mosquito-borne diseases.

The results of this work are summarized in the article entitled “Role of *Aedes aegypti* and *Aedes albopictus* during the 2011 dengue fever epidemics in Hanoi, Vietnam”. This article published in “Asian Pacific Journal of Tropical Medicine” is presented thereafter.
Role of Aedes aegypti and Aedes albopictus during the 2011 dengue fever epidemics in Hanoi, Vietnam

Pham Thi Kim Lien1,2, Vu Trong Duc3, Laurent Gavotte1, Emmanuel Corbillot1, Phan Thi Nga1, Laurence Briant1, Roger Prud'homme4, Tran Nhu Dong1
1National Institute of Hygiene and Epidemiology, 1 Yersin Street, 10000 Hanoi, Vietnam
2CPBP, UMR 5206, CNRS-UM1-UM2, 1919, route de Mende 34293 Montpellier Cedex 5, France
3ISEM, UMR CNRS 5534, IRD-UM2-IRD, Université Montpellier 2, CC063, Place E. Bataillon, 34095 Montpellier Cedex 5, France
4Interpsy, UMR 17, CNRS-IRD. Campus International de Baillarguet, 34958 Montpellier Cedex 5, France

ARTICLE INFO
Article history:
Received 15 Apr 2015
Received in revised form 20 May 2015
Accepted 15 Jun 2015
Available online xxx

Keywords:
Aedes aegypti
Aedes albopictus
Dengue
Vector density

ABSTRACT

Objective: To record the human cases of dengue fever (DF) and investigate the Aedes mosquito species circulating during the Hanoi 2011 DF epidemics.

Methods: 24 different outbreak points were recorded in 8 districts between August and December 2011. Results: 140 patients were hospitalized following dengue diagnostic with a predominance of males (59.3%) and the 15–34 age class. Only DENV-1 (11.27%) and DENV-2 (88.73%) serotypes were detected in human samples. Mosquito sampling performed in and around patients households revealed the predominance of Aedes aegypti (A. aegypti) (95.19%) versus Aedes albopictus (4.85%). Conclusions: There is a positive correlation between the population density of A. aegypti and the number of human cases and duration of outbreaks. This was not observed for Aedes albopictus. Three pools of A. aegypti were positive with dengue virus, two with DENV-1 and one with DENV-2.

1. Introduction

Four distinct DENV serotypes are currently described which cause dengue fever in humans resulting in a range of clinical symptoms including fever, headache, muscle, joint pains, and a characteristic skin rash similar to measles [1–3]. Dengue fever (DF) can also evolve into severe forms such as dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS), which could result in death [4]. An estimated 390 million dengue infections occur every year, of which 96 million are asymptomatic [5], which could make the burden of dengue three times higher than considered [6]. More than 100 countries are affected by outbreaks of dengue and more than 60 have reported the occurrence of DHF [5]. Southeast Asia is among the regions most affected by dengue and Vietnam is one of the five countries in this region with the highest burden [7]. DF was first described in northern Vietnam in 1958 and expanded to the southern area in the 1960s [14–16]. DHF was first described in Hanoi during the rainy season of 1958 [17–18] with a mortality rate of 7% [19]. During the 1998–2009 decade, two large outbreaks occurred in the central urban area of Hanoi, which resulted in a total of 259,831 cases mostly among young adults [20–21].

Dengue virus (DENV) is transmitted to humans by two mosquito species, Aedes aegypti (A. aegypti) and Aedes albopictus (A. albopictus). A. aegypti is considered the most important vector of DENV while A. albopictus is generally believed to be a less competent vector resulting in milder epidemics [18]. However, dengue outbreaks have been attributed to both A. aegypti and A. albopictus in different regions of the world including Asia [11,13,19]. Each species displays a specific ecology, behaviour and geographical distribution. A. aegypti prefers urban habitats, whereas A. albopictus is primarily a forest species that has become adapted to rural, suburban and urban human environments [14,22–23]. Owing to the increasing presence of A. albopictus and the co-circulation of both mosquito species in...
Vietnam [22,23], this study was undertaken to investigate their respective potential role in DENV transmission in the recent epidemics and correlation between mosquito abundance and size and duration of outbreaks.

2. Materials and methods

2.1. Ethics and enrollment of patients

The study protocol was cleared and approved by the Scientific and Ethical Committee of the National Institute of Hygiene and Epidemiology, Vietnam. The study was conducted as part of the Vietnamese National Dengue Prevention and Control Program. All patients considered in the analysis gave a written informed consent of participation to the study.

2.2. Location of sampling

Mosquitoes and blood samples from hospitalized patients were collected during outbreaks from August 2011 to December 2011 in eight districts of Hanoi, Ba Dinh, Hai Ba Trung, Dong Da, Hoa Dong, Thanh Xuan, Thanh Oai, Thanh Tri, and Tu Liem (Figure 1). The population of the Northern city of Hanoi was estimated in 2009 to be 2.6 million for urban districts, and 6.5 million for the metropolitan jurisdiction [24]. Climate is contrasted with hot and humid summers, a rainy season from May to September with temperatures from 38 °C to 40 °C. Winters are relatively dry and cool from November to March with temperatures as low as 6 °C. Spring is marked by light rain. The period from June to September is suitable for the development of the mosquitoes [25]. The DF outbreak areas were defined according to Ministry of Health guidelines as geographic areas (town/village/hamlet, population groups or equivalent) where patients were tested positive for DENV and simultaneous detection of mosquitoes was confirmed [26]. Small outbreaks were defined as occurrences with less than 20 positive patients, medium outbreaks comprised 21 to 100 positive patients and large outbreaks were considered as involving more than 100 patients. Outbreaks were considered terminated when no case was reported for at least 14 days.

2.3. Case definition and sampling

Patients admitted to the National Hospital for Tropical Diseases in Hanoi between August 1, 2011 and December 21, 2011 were considered in the study when presenting dengue symptoms as defined both by WHO and Vietnamese Ministry of Health guidelines on surveillance, diagnosis, treatment of dengue. These symptoms were a continuous fever for 2–7 days in an individual from an endemic area and displaying two or more of the following clinical manifestations of DF: nausea, vomiting, rash, arthralgia, and pain; positive tourniquet test; leucopenia, and any warning sign [27]. Blood samples were systematically collected from patients corresponding to the above-mentioned criteria. Acute phase serum sample was collected after fever onset from day 1 to 7 and a follow-up stage serum sample was taken, stored at 4 °C until being sent each day to the virology laboratory, NHEI for RNA extraction then stored at −80 °C. Description of cases included the onset date and place, age and gender of patients with notified cases of DF infection. The serum obtained was subjected to serological and molecular testing to determine the presence of dengue virus and identify the serotype. With the patient’s consent, the following data were collected: full name, residence address, gender, time of onset and intensity, and location of symptoms. After data collection, contacts were taken with Preventive Medicine Centers in each district to implement captures of mosquitoes in patient’s house and households.

2.4. Mosquito collection and identification

Adult mosquitoes were collected from patient’s house, and 15 households around the patient’s household located within a radius of approximately 20–50 m using a backpack sprayer (Figure 2). For each outbreak area, 50–100 households were randomly selected for daily collection. For each household, sampling was performed indoor and outdoor for approximately 15 min during the day. Mosquito collection was carried out by 4 groups volunteer with 2 persons per day between 5–10 AM and 4–8 PM. Collected mosquitoes were stored in RNA later solution (Qiagen) and kept refrigerated at 2 °C–8 °C. Identification of A. aegypti and A. albopictus was performed according to morphological criteria following binocular examination. Mosquito samples were sorted according to species, gender, date of collection, geographical coordinates and number of mosquitoes for each location, and then stored at −80 °C in RNA later solution until further use.

2.5. RNA extraction and RT-PCR amplification

Viral RNA was extracted from 140 μL patient blood serum and from 970 mosquitoes (923 A. aegypti and 47 A. albopictus individuals) by pools of up to 10 mosquitoes depending upon sample size. Males and females were pooled separately. Viral RNA was extracted using QIAamp viral RNA Mini kit (Qiagen) according to the supplier and stored at −80 °C until further use. DENV RNA was detected and typed using a single tube multiplex RT-PCR according to an experimental protocol adapted from previously published procedures [28,29]. Both reverse transcription and PCR were conducted using the Access Quick RT-PCR kit (Promega). Reverse transcription was conducted at 45 °C for 30 min using random primers.
(Invitrogen). PCR was then performed in a 50 µl reaction volume using a set of five primers (25 µmol each) comprising a dengue virus consensus reverse primer and four serotype-specific forward primers (Table 1). PCR was conducted for 35 cycles under the following conditions: denaturation at 94 °C for 2 min, annealing at 55 °C annealing for 45 s and extension at 72 °C for 90 s followed by a final extension for 10 min at 72 °C. PCR products were analysed in a 2% agarose gel electrophoresis using 10% SYBR safe DNA dye (Invitrogen) in 1% TAE buffer. The expected size of the amplicons was 492 bp, 119 bp, 290 bp and 392 bp for DENV-1, DENV-2, DENV-3 and DENV-4, respectively.

2.6. Data analysis

Data were analyzed using STATA 10.0. Spearman’s Rank correlation coefficient analysis was used to investigate the association between the density of Aedes mosquitoes, number of confirmed dengue cases and duration of outbreaks.

3. Results

3.1. Outbreaks location, size and duration

During the study period, a total of 24 infectious feet were detected within the eight districts in Hanoi, all of them being small or medium outbreaks (Figure 1). The mean duration of an individual outbreak was 89.3 days, ranging from 17 to 123 days (median duration 76 days). Samples were collected from a total of 140 hospitalized patients confirmed with dengue by serology. The number of confirmed cases in each district varied from 2 to 42 (mean = 16, and median = 23) (Table 2). No shock or haemorrhagic characteristic of severe dengue was reported among cases included in the study. Men (59.3%) were more affected than women (40.7%) (Table 3). The youngest patient was 3 years old and the oldest was 88 (mean age = 33 years, median = 29 years) (Table 3).

3.2. Collection of mosquitoes in and around patients’ households

A total of 1200 households were sampled during the study and 970 mosquitoes were collected (Table 2). All mosquitoes collected belonged to the genus Aedes. 923 (95%) belonged to the A. aegypti species whereas 47 (5%) were A. albopictus. For each district, the total number of Aedes collected ranged from 5 to 322. A. aegypti largely predominated in each district with the exception of Thanh Oai and Thanh Tri where the number of A. albopictus was higher. Hanoi District reported the highest number of captured A. albopictus (17/47 or 56%). The observed density of Aedes mosquitoes was higher during outbreaks. However, due to the small size of mosquito samples collected in Thanh Tri, Thanh Oai and Tu Liem districts, we cannot conclude that this result was biased as mosquitoes may have been collected under different meteorological conditions or time periods.

3.3. Detection and identification of dengue virus

Out of the 140 dengue serology-positive blood samples, 71 were tested by PCR. Only DENV-1 and DENV-2 serotypes were detected. Only 8 patients (11.27%) distributed over four districts, i.e. Ba Dinh, Hai Ba Trung, Dong Da, and Thanh Tri, tested positive for DENV-1 (Table 3). 63 patients (88.73%) tested positive for DENV-2 which was present in all the districts investigated with the exception of Thanh Tri. In three districts, i.e. Dong Da, Hai Ba Trung and Ba Dinh, the presence of both DENV-1 and DENV-2 was recorded.

3.4. Correlation between Aedes population size and outbreak intensity

A positive correlation was observed between the population density of A. aegypti and the number of human cases recorded during an outbreak ($R = 0.57, P = 0.005$). A similarly positive association was observed between the number of A. aegypti mosquitoes collected at outbreak sites and the duration of outbreaks. A. aegypti population density was found higher when outbreak was longer ($R = 0.57, P = 0.005$). The number of A. aegypti individuals collected in the early period of outbreaks was higher than the number collected towards the end of the outbreaks. Conversely, no correlation was found between the number of A. albopictus collected in outbreak areas and the number of confirmed dengue cases in the same areas ($R = 0.42$) or with

<table>
<thead>
<tr>
<th>Table 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primer</td>
</tr>
<tr>
<td>D1</td>
</tr>
<tr>
<td>T1</td>
</tr>
<tr>
<td>T2</td>
</tr>
<tr>
<td>T3</td>
</tr>
<tr>
<td>T4</td>
</tr>
</tbody>
</table>

Note: D1 is reverse primer, and forward primers are T1 (DENV1), T2 (DENV2), T3 (DENV3) and T4 (DENV4).

<table>
<thead>
<tr>
<th>Table 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>District</td>
</tr>
<tr>
<td>Ba Dinh</td>
</tr>
<tr>
<td>Hai Ba Trung</td>
</tr>
<tr>
<td>Dong Da</td>
</tr>
<tr>
<td>Thanh Oai</td>
</tr>
<tr>
<td>Thanh Tri</td>
</tr>
<tr>
<td>Tu Liem</td>
</tr>
<tr>
<td>Hai Dong</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>
The detection of only DENV-1 and DENV-2 in mosquitoes along with the predominance of DENV-2 reported in this work is in agreement with previous reports on from Hanoi in recent years [18,42]. This suggests that DENV-1 and DENV-2 were already co-circulating during previous outbreaks in the same area and probably maintained over time through vertical transmission in mosquito populations. The overwhelming presence of A. aegypti in the captured mosquitoes, its widespread distribution and the positive correlation of higher local density with the number of human cases reported in outbreaks, altogether strongly suggest that A. aegypti is involved in dengue virus transmission in Hanoi, with a pivotal role during the 2011 dengue outbreaks and before as a maintenance host.

Despite the fact that it is considered to be a less efficient vector, A. albopictus is adapted to urban domestic environments and was described as a vector in DENV outbreaks in different regions including China, Gabon or Madagascar [44–46]. However, in this work, DENV were not detected in A. albopictus and no correlation was found between the number of A. albopictus captured and the number of human cases. These data corroborate reports suggesting that A. albopictus is not an important vector in urban environment when compared to A. aegypti [47,48]. Despite its growing importance and presence it remains a secondary dengue vector, indicating that control actions must remain directed towards A. aegypti habitats.

The importance of mosquito population densities in the dynamics of dengue fever highlighted by this work might, however, be underestimated. Indeed, a limitation to this study is that it only covered the latter part of the rainy season, considered an ideal time for dengue transmission. Additionally, no information was available for artificial containers that might have acted as breeding habitats for Aedes mosquitoes. There may also have been case ascertainment biases as we relied on patients presenting themselves to health services, thus milder and asymptomatic cases may not have been identified. Nevertheless, this work strongly supports the need of further investigation in other geographic areas and environment, i.e. suburban and rural, to determine the distribution and relative role of A. aegypti and A. albopictus in the transmission of DENV in Vietnam and a potential evolution linked to the spread of A. albopictus. This work also underlines the need of a better understanding of the dynamics of mosquito populations to implement efficient and adapted mosquito population monitoring and mosquito control strategies, which is at the moment the best way of controlling dengue and other mosquito-borne diseases.

### Conflict of interest statement

We declare that we have no conflicts of interest.

### Acknowledgements

PTKL was supported in part by the Heavam Mundiis project MAIEVA and by the CNRS-UM1-UM2 PEP5 project.
Mo-ByCA. The study was supported by the Entomology Department, National Institute of Hygiene and Epidemiology, Hanoi, Vietnam. The authors are grateful to leaders and medical staff of the National Hospital for Tropical Diseases, the Center for Preventive Medicine in Hanoi, the District Health Centre and commune health centres in Hanoi city for their enthusiastic support, active participation and close collaboration. The authors are very grateful to Dr Babahinde Olusoware, WIOM, for his support and fruitful comments on the manuscript.

References
[37] Trang AK, Suth S. Epidemiology and new initiatives in the prevention and control of dengue in Malaysia. 2001 Dec (Online Available from: http://repository.utsa.edu/handle/123456789/15837 [Accessed on 2nd November, 2013].
ARTICLE IN PRESS


CHAPTER 2
SURVEILLANCE OF DENGUE AND CHIKUNGUNYA VIRUS INFECTION
IN DONG THAP

2.1. Context of the study

Dengue is endemic throughout Vietnam, but transmission is highest in the South where very large epidemics occur regularly (527). Dengue occurs year-round, but a marked seasonal peak occurs during the rainy season from June to December. Since 1960, DF epidemics tend to spread widely with a continuous increase in number of patient and deaths (528)(529)(527). 1,518,808 DHF cases and 14,133 deaths were reported between 1963 and 1995 (530). The dengue surveillance program in Southern Vietnam shows epidemic peaks of increasing magnitude occurring approximately every 5 years between 1975 and 1987, with a longer period of 11 years preceding a large epidemic of 119,429 DHF cases and 342 fatalities in 1998 (531). All four DENV serotypes were found to circulate in Southern Vietnam (532). Over the past 15 years, the number of DENV cases has been increasing (529).

Although chikungunya was first described in Vietnam in the 1960s (533), national serological evidence of its activity in Vietnam remains sparse and mainly historical. In 1966, ten America soldiers were identified (534), and serological surveys among children identified antibodies to CHIKV in 1967 (535). A number of review articles have also shown that Vietnam is one of several Asian countries to have reported chikungunya. (536)(537)(538)(539)(540).

Dong Thap general hospital located in Dong thap province in the Mekong Delta region of southern Vietnam. Dong Thap is 165 km away from Ho Chi Minh city, shares a 48-km border with the Preay Veng province of Cambodia. In recent years, Cambodia, already endemic for dengue, declared chikungunya infection in provinces bordering Vietnam (541). The disease can easily be imported by travellers and spread rapidly resulting social, economic and healthcare system impacts. This is currently threatening Vietnam and may happen in the coming year.
2.2. Objective

Vietnam being at risk of joint DENV and CHIKV infections, characterized by overlapping clinical manifestations and differences in clinical management, clinicians should be aware of the need to include CHIK in the differential diagnosis of DF. This work was conducted to evaluate the real burden of dengue infection in the general population and to identify the presence of CHIKV in Dong Thap. Another objective was to determine whether underdiagnosis of CHIKV was occurring through prospective screening of sera from patients admitted with an acute febrile episode in one hospital in southern Vietnam. In addition, the study also examined DENV serotypes in the same cohort of patients, and whether there was co-infection with CHIKV.

2.3. Discussion and conclusions

The initial objective of this work was to assess within 13 months the occurrence of dengue and chikungunya among patients from Dong Thap general hospital admitted for acute fever and dengue/chikungunya-related symptoms. The most common symptoms on the day of admission were headache, fever, myalgia, arthralgia, and a positive tourniquet test. Although the majority of clinical manifestations were similar between adult and pediatric patients, adults were significantly more affected by arthralgia than pediatric patients. More males were found to be affected than females. The most affected age class was the 5-14 year class which in agreement with other studies which have reported dengue mainly in children.

The co-circulation of four serotypes of DENV is in agreement with the status of region of hyperendemicity of both southern Vietnam and Cambodia with a predominance of DENV2 and DENV4. Reports from Cambodia have stressed the predominance of DENV2 and DENV3. Although, the 13-months surveillance described in this work did not show any presence of CHIKV, the risk is still present and this surveillance should be maintained.

An important outcome from this work is the differential efficiency of detection of dengue through serology. DENV infection was hardly detected in acute phase through serological tests with only 29% of plasma and 14% of sera to be positive. Conversely,
DENV infection was detected at 53% in clinical samples obtained during the convalescence phase and up to 74% when using PCR. Time of seroconversion should be taken into account when implementing detection procedures. Indeed there is no control on the time between onset and admission and this time might varies greatly from one patient to another. Time for seroconversion should be taken into account when implementing detection procedures. However, for practical reasons, admission is the only time when blood samples can be taken since patients can hardly be followed up after leaving the hospital. The best solution would be therefore to implement multiplex PCR detection on blood sample taken at admission. Cost of PCR is nowadays not higher than that of serological tests and the possibility to combine several detection tests, i.e. dengue and chikungunya, at the same time in a one-step single tube procedure as well as the higher efficiency of PCR make it a highly cost-effective option. A recommendation from this work would therefore be to replace current procedures for serological detection of dengue by a standard operating procedure for DENV-CHIKV multiplex single step PCR.

26% of patients hospitalized with acute fever symptoms were negative for both DENV and CHIKV. This unknown etiology may need further work to identify what the causative pathogens involved. Other limitations of this study is the limited number of patients enrolled and therefore of samples available. Owing to the dynamics of both chikungunya and dengue and the potential of emergence for chikungunya in Vietnam it is of importance to implement a larger surveillance system which will provide valuable information on the prevalence and incidence of DENV infection and CHIKV circulation which are essential for planning an appropriate public health strategy.

This work is presented in an article currently in press at Asian-Pacific Journal of Tropical Medicine (Elsevier) and entitled “Surveillance of dengue and chikungunya infection in Dong Thap, Vietnam: A 13-months study ». The corrected proof version of the article is presented there after.
Surveillance of dengue and chikungunya infection in Dong Thap, Vietnam: A 13-month study

Pham Thi Kim Lien1,2, Laurence Brant2, Truong Ba Tang3, Bui Minh Trang1, Laurent Gayotte4, Emmanuel Comillot5, Vu Trong Duc6, Tran Nhu Duong2, Roger Frutos2,4*, Phan Thi Nga1

1National Institute of Hygiene and Epidemiology, 1 Yersin Street, 100000 Ha Noi, Vietnam
2University of Montpellier, CEMIPAL-CFIRS, UMR 5236, 1919, rue de Mende, 34293 Montpellier Cedex 5, France
3Department of Biology, Dong Thap General Hospital, 144, Mai Van Khai, My Xuan, 870000 Can Lanh, Dong Thap, Vietnam
4University of Montpellier, DEM, CC083, Place E. Bataillon, 34095 Montpellier Cedex 5, France
5Grenet, PHU-217/6, Campus International de Baillarguet, 34958 Montpellier Cedex 5, France

1. Introduction

Arthropod-borne viral infections (or arboviral infections) are common causes of fever syndromes worldwide and more than 100 kinds of arboviruses are known to cause disease in humans[4]. Dengue fever (DF) is caused by a flavivirus belonging to the family of Flaviviridae[4] while the chikungunya virus (CHIKV) is an alphavirus from the family Togaviridae[4–7]. Both dengue and chikungunya diseases are transmitted by Aedes aegypti (A. aegypti) and Aedes albopictus (A. albopictus)[1,8] and can cause potentially severe and/or debilitating chronic disease[9]. While dengue has been recorded as the most rapidly spreading mosquito-borne viral disease in the world[10,11], chikungunya has recently re-emerged after an interval of several decades. It represents a risk for millions of people in the Indian Ocean areas, Africa, Southeast Asia and more recently has spread to the Caribbean, Pacific and Europe[12–14]. Coinfection with DENV and CHIKV has been reported on patients from Asian, African and Pacific countries[15–19]. Vietnam is a hyperendemicity country with all four serotypes being present all year long throughout the country[20], but affecting
mostly the southern part with major seasonal outbreaks during the rainy season from June to December [21]. Since 1960, dengue fever (DF) epidemics have become more frequent and widespread with an increasing number of cases and deaths over the past 15 year [21,22]. From 1963 to 1995, 1,518,808 DF cases and 14,133 deaths were reported [21,22]. The dengue surveillance program in the Southern Vietnam has demonstrated the occurrence of epidemic peaks of higher magnitude approximately every 5 years from 1975 to 1987 [24]. Following an 11-year gap a major outbreak of 119,426 DF cases and 342 fatalities occurred in 1998 [24]. 592,938 dengue cases were reported during the 2001-2010 decade in 19 southern Vietnam provinces, which corresponds to a median annual incidence of 232 cases per 100,000 [28].

DENV and CHIKV are both transmitted by the same mosquito species, Ae. aegypti and Ae. albopictus. Although chikungunya was first described in Vietnam in the 1960’s [25], serological evidence of its presence remains scarce and is mainly associated with the Vietnam War era. In 1966, ten American soldiers were identified to be infected with CHIKV [28] and serological surveys among children have detected anti-CHIKV antibodies as early as 1967 [27]. Cambodia which has a long and extensive border with Vietnam, is not only endemic for dengue, but also for chikungunya which has developed recently [26]. Both diseases can easily be imported by travelers, spread rapidly through common vectors and result in social, economic and healthcare system impacts.

Vietnam is at risk to be like Cambodia affected both by dengue and chikungunya and be an overlapping area of distribution for both viruses. Furthermore, owing to the similarity in clinical manifestations and differences in clinical management, clinicians should be aware of the need to include CHIKV in the differential diagnosis of DF. The aim of the study was therefore to assess, through a dual screening of clinical samples of acute febrile episode patients in Dong Thap general hospital in Southern Vietnam, the respective prevalence of dengue and chikungunya.

2. Material and methods

2.1. Cohort design and ethical clearance

The study was approved by the Institutional Review Board of National Institute of Hygiene and Epidemiology (NIHE), Hanoi, Vietnam (No: 14IRB July 23, 2012) in charge of ethical clearance. Patients were eligible for recruitment if they were admitted to the infectious diseases department of Dong Thap general hospital between January 1, 2012 and February 28, 2013. All hospitalized patients with suspected arbovirus infection were eligible for participating in this study provided they displayed acute fever in addition to two of any of the following symptoms: headache, rash, myalgia, joint pain and arthralgia.

2.2. Study setting

Dong Thap general hospital is located in Cao Lãnh city, Đồng Tháp province. The province is located in the Mekong delta region in southern Vietnam, and bordered by Cambodia to the north (Figure 1). Dong Thap is characterised by a tropical climate with two distinctive seasons: the rainy season from May to November and the dry season from December to April. The annual average temperature is around 26 °C. Dong Thap is one of the provinces of southern Vietnam with people movement from Cambodia and display a high rate of dengue infection.

![Figure 1. Location and map of the Dong Thap province](image)

2.3. Patient enrollment, clinical sample and data management

After obtaining informed consent from patients, a total of 131 paired blood samples were collected from January 2012 to February 2013 from acute fever cases suspected to be infected by dengue within 1-14 days from the day onset of illness according to WHO guidelines [29]. The collection of clinical samples was performed twice and 3 mL or 5 mL of blood were collected each phase: (1) In acute phase, blood samples were collected <7 days from onset of illness and then divided into two tubes: One tube for serum analysis and the other one for plasma analysis; (2) Ten to fifteen days later, in convalescent phase, a second blood sample was collected from the same patients. Samples were kept at -20 °C and kept at -80 °C for virological diagnosis by ELISA and PCR. For each patient, the collected information included a unique identification number and demographic data such as full name, age, gender, residential address, day of onset, date of first and second sample collection. Signs and symptoms were recorded on the day of admission. Samples were coded prior to laboratory analysis.

2.4. RNA Extraction and cDNA synthesis

The viral RNA was extracted from 140 µL of sample using the QIAamp viral RNA Mini kit (Qiagen, Hilden, Germany). Elution was performed in 60 µL according to the supplier and RNA stored at -80 °C until further use. RNA was reverse transcribed into cDNA using SuperScript III reverse transcriptase (RT; Invitrogen). cDNA template was mixed with DNase, incubated at 37 °C for 30 minutes and then 75 °C for 15 minutes, reverse transcription mix was then added and incubated at 63 °C for 5 minutes and then transferred in ice immediately. To prepare double-stranded cDNA, annealing was performed at 25 °C for 5 minutes, followed by extension at 42 °C for
60 minutes, and inactivation by holding the mixture at 75 °C for 15 minutes.

2.5. Laboratory confirmation of dengue and chikungunya

Detection of DENV and CHIKV was conducted both by a Dengue IgM capture ELISA (first samples [plasma and serum]) and by a multiplex PCR amplification for both first and second samples. IgM antibody capture Enzyme Linked Immunosorbent Assay (MAC-ELISA) was conducted using the Capture DxSelect™ kit made in CDC Fort Collins, United States according to the supplier. PCR detection of DENV and CHIKV was conducted in a one-step, single tube serotype specific assay using double-stranded cDNA templates as previously described[3,31]. The amplification was carried out in 50 μl reaction volume with DENV a group-specific consensus forward primer and four serotype-specific reverse primers. Nonstructural protein 2 (nsP2) primers were used for the detection of CHIKV. All relevant aspects of the PCR reaction (Master Mix, Primer, Tag polymerase, number of cycles and annealing temperature) were initially optimized using a quantitated purified DENV ds-cDNA to achieve a maximum level of sensitivity. Target RNA was amplified in 50 μl volume containing 5 μl of cDNA was combined with 10 pmol of each specific primer DENV 1–4. PCR was conducted with 35 cycles under the following conditions: denaturation at 94 °C for 2 minutes, annealing at 57 °C for 45 seconds and extension at 72 °C for 1.30 minutes with a final extension at 72 °C for 10 minutes. PCR products were analyzed by Agarose gel electrophoresis in Tris-acetate-EDTA (TAE) buffer.

The expected size of amplicons were 492 bp (DENV1), 119 bp (DENV2), 290 bp (DENV3), 392 bp (DENV4) ad 120 bp (CHIKV).

2.6. Data analysis

All the results were summarized in terms of medians and ranges for continuous data, odds ratio (OR), Chi square and Fisher’s exact tests were used as appropriate. Data for study clinical symptom of patients was compared, which includes age, gender, province and district.

3. Results

3.1. Clinical features

A total of 131 eligible MIP suspected cases were enrolled at Dong Thap general hospital over 13 months starting in January 2012. 118 patients were from 11 districts in the Dong Thap province, 16 patients from neighboring provinces such as An Giang and 1 case from Ho Chi Minh City. The cohort comprised 62 females and 69 males, ranging in age from 5 months to 49 years with a median age of 15 years. The mean body temperature of patients on the day of admission was 39 °C, and fever was observed from 37.5 °C - 40.5 °C of patients. The most common clinical features observed were: headache (88.5%), myalgia (72.0%), arthralgia (40.5%), rash (12.2%) a positive tourniquet test (16.8%), and nausea/vomiting (3.8%). The mean length of time to admission was 4 days after

Table 1

<table>
<thead>
<tr>
<th>Signs and symptoms</th>
<th>Value</th>
<th>Odds ratio (OR)</th>
<th>&lt;18 years(n=98)</th>
<th>&gt;18 years(n=33)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>88.5%</td>
<td>12.10</td>
<td>84.7</td>
<td>97.0%</td>
<td>0.0025</td>
</tr>
<tr>
<td>Myalgia</td>
<td>72.0%</td>
<td>2.54</td>
<td>75.5</td>
<td>60.6%</td>
<td>0.0900</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>40.5%</td>
<td>0.70</td>
<td>32.6</td>
<td>66.5%</td>
<td>0.0039</td>
</tr>
<tr>
<td>Rash</td>
<td>12.2%</td>
<td>0.14</td>
<td>10.0</td>
<td>18.0%</td>
<td>0.2000</td>
</tr>
<tr>
<td>Petechiae</td>
<td>19.9%</td>
<td>0.20</td>
<td>20.4</td>
<td>15.5%</td>
<td>0.5000</td>
</tr>
<tr>
<td>Nausea/Vomiting</td>
<td>3.8%</td>
<td>0.09</td>
<td>8.0</td>
<td>6.0%</td>
<td>0.4300</td>
</tr>
<tr>
<td>Positive Tourniquet test</td>
<td>16.8%</td>
<td>0.23</td>
<td>14.3</td>
<td>24.2%</td>
<td>0.1800</td>
</tr>
</tbody>
</table>

Note: Values are the mean (range) or number (%). Calculated by Chi square test and Fisher test.

Table 2

<table>
<thead>
<tr>
<th>Diagnostic test</th>
<th>Type of sample</th>
<th>No. of samples tested</th>
<th>No. of positive samples</th>
<th>% positive cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgM capture ELISA</td>
<td>Plasma</td>
<td>131</td>
<td>38</td>
<td>29</td>
</tr>
<tr>
<td></td>
<td>Serum</td>
<td>131</td>
<td>18</td>
<td>14</td>
</tr>
<tr>
<td>Concomitant</td>
<td>Serum</td>
<td>131</td>
<td>70</td>
<td>53</td>
</tr>
<tr>
<td>Multiplex PCR</td>
<td>Plasma</td>
<td>131</td>
<td>97</td>
<td>74</td>
</tr>
<tr>
<td></td>
<td>Serum</td>
<td>131</td>
<td>95</td>
<td>73</td>
</tr>
</tbody>
</table>

Table 3

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>No of DENV patients</th>
<th>No. Male</th>
<th>No. Female</th>
<th>DENV1</th>
<th>DENV2</th>
<th>DENV3</th>
<th>DENV4</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-4</td>
<td>8</td>
<td>3</td>
<td>5</td>
<td>0</td>
<td>3</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>5-14</td>
<td>55</td>
<td>25</td>
<td>30</td>
<td>7</td>
<td>20</td>
<td>11</td>
<td>17</td>
</tr>
<tr>
<td>15-24</td>
<td>19</td>
<td>8</td>
<td>11</td>
<td>4</td>
<td>6</td>
<td>2</td>
<td>10</td>
</tr>
<tr>
<td>25-34</td>
<td>14</td>
<td>8</td>
<td>6</td>
<td>2</td>
<td>6</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>35 or more</td>
<td>5</td>
<td>2</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Total</td>
<td>101</td>
<td>46</td>
<td>55</td>
<td>11</td>
<td>36</td>
<td>19</td>
<td>35</td>
</tr>
</tbody>
</table>
reported onset of fever ranging from 1-7 days. The first blood sample occurred in a median time of 4 days (3 to 7 days) after onset (time of admission) while the second blood sample was taken at median time of 7 days (admission to 14 days).

3.2. Prevalence of dengue and chikungunya in Dong Thap hospital

Among the 131 acute fever patients enrolled in the cohort, none of them were found to have been infected with chikungunya. All CHIKV PCR tests proved to be negative. However, results were totally different with respect to dengue and were dependent upon the detection method implemented and on the time of blood sampling when using serology. Out of the 131 paired serum/plasma samples collected on the day of admission (first sample collection) during the acute phase, 38 patients (29%) were dengue-positive when analyzing sera samples whereas 18 (14%) patients only were positive when using the plasma fraction (Table 2). When analyzing sera from convalescent patients, i.e. second collection time, the number of IgM positive samples rose to 70 (53%) (Table 2).

3.3. Distribution of dengue serotypes in Dong Thap positive dengue cases

101 samples (77%) out of 131 collected were positive for dengue. All four dengue serotypes were identified and the respective number of positive was 11 (31%) for DENV1, 36 (36%) for DENV2, 19 (19%) for DENV3, and 35 (35%) for DENV4 (Table 3). Males were more affected than females (Table 3). Age was another discriminative criterion with the 5-14 year class comprising 54.5% of all cases (55 out of 101) (Table 3).

4. Discussion

The initial objective of this work was to assess within 13 months the occurrence of dengue and chikungunya among patients from Dong Thap general hospital admitted for acute fever and dengue/ chikungunya-related symptoms. The most common symptoms on the day of admission were headache, fever, myalgia, arthralgia, and a positive tourniquet test. Although the majority of clinical manifestations were similar between adult and pediatric patients, adults were significantly more affected by arthralgia than pediatric patients. Males were found to be affected than females which corresponds to other reports from Nepal, China, and Vietnam. The most affected age class was the 5-14 year class which in agreement with other studies which have reported dengue mainly in children.

The co-circulation of four serotypes of DENV is in agreement with the status of region of hyperendemia of both southern Vietnam and Cambodia. However, if the overall predominance recorded in this work is for DENV2 and DENV4, reports from Cambodia have stressed the predominance of DENV2 and DENV3 with a rotation and regular replacement of serotypes. Dong Thap is located along the Mekong River at the Cambodian border where cases of chikungunya have been described along the major northwest to southwest routes and in provinces bordering Vietnam. This dynamic of expansion might lead to emergence in neighboring Vietnam provided that the Cambodian-Vietnamese border in Dong Thap is a highly active zone of transboundary movements. Although, the 13-month surveillance described in this work did not show any presence of CHIKV, but the risk is still present and this surveillance should be maintained.

An important outcome from this work is the differential efficiency of detection of dengue through serology. DENV infection was hardly detected in acute phase through serological tests with only 29% of plasma and 14% of sera to be positive. Conversely, DENV infection was detected at 53% in clinical samples obtained during the convalescence phase and up to 74% when using PCR. Time of seroconversion should be taken into account when implementing detection procedures. Indeed there is no control on the time between onset of fever and this time which would vary greatly from one patient to another. Time for seroconversion should be taken into account when implementing detection procedures. However, for practical reasons, admission is the only time when blood samples can be taken since patients can hardly be followed up after leaving the hospital. The best solution would be therefore to implement multiplex PCR detection on blood sample taken at admission. Cost of PCR is nowadays not higher than that of serological tests and the possibility to combine several detection tests, i.e. dengue and chikungunya, at the same time in a one-step single tube procedure as well as the higher efficiency of PCR make it a highly cost-effective option. A recommendation from this work would therefore be to replace current procedures for serological detection of dengue by a standard operating procedure for DENV-CHIKV multiplex single step PCR.

25% of patients hospitalized with acute fever symptoms were negative for both DENV and CHIKV. This unknown etiology may need further work to identify what is the causative pathogens involved. Other limitations of this study is the limited number of patients enrolled and therefore of samples available. DENV was found to be the causative agent for all cases that were positive.

Declare of interest statement

We declare that we have no conflict of interest.

References


CHAPTER 3
DENGUE VIRUS, CHIKUNGUNYA VIRUS AND RISK FACTORS IN SEVERAL PROVINCES OF VIETNAM.

3.1. Context of study

With an estimated 93 Million people, Vietnam undergoes a rapid urban population growth due to the influx of workers and students from rural areas (247). Vietnam is a country with poor health and economic indicators. The S-shaped country shares borders with China, Laos and Cambodia.

Figure 42: Location of the five selected study provinces in the north, center, south of Vietnam.
Vietnam is recognized as one of five countries in Southeast Asia with the highest dengue burden (542). Dengue fever (DF) was first described in northern Vietnam in 1958 and expanded to the southern area in 1960 (543). Despite the existence of a National Dengue Control Program since 1998, Dengue remains a major health problem in Vietnam. Over the past 15 years, the number of DENV cases has been increasing (529), DF and DHF are leading causes of hospitalization, period 1991 - 2004 accounting for 1,000,866 case reported in Vietnam, and increasing year to year in the high urban central areas of Hanoi (544). Dengue is highly endemic in tropical southern Vietnam, while increasing larger seasonal epidemics have occurred in northern Vietnam over the last decade (545). All four dengue virus serotypes have been found circulating in Vietnam with the dominant one varying over time (546). The predominant circulating viruses have DENV 1 and DENV 2, but until the late 1990s, DENV 3 emerged and was responsible for the large outbreak of 1998, whereas DENV 4 was also detected between 1999 and 2003 (547). Dengue transmission occurs throughout the year in Vietnam, with peaks in the number of cases (72% of total cases) reported between June and November. In the Northern and Central Highland regions, dengue notifications are low during the winter time from December to March (548) (549). In the South, dengue transmission is higher in the rainy season from July to September, specially transmission is highest in the South where very large epidemics occur regularly (550), Aedes mosquitoes, which are the vectors of dengue and chikungunya, are widely prevalent in the region (551).

Chikungunya virus (CHIKV) was first isolated in Tanzania in 1953 (552) and was until 2004 known to cause debilitating rheumatologic disease in many parts of Sub-Saharan Africa and Asia (553). The symptoms of CHIKV infection are quite similar to those caused by many other infectious agents in the endemic areas. One particular difficulty in identifying CHIKV infection is its overlapping distribution with dengue viruses. It has been postulated that many cases of dengue virus infection were misdiagnosed. In many endemic areas of Asia, CHIKV overlaps with DENV, providing thus opportunities for Aedes mosquitoes to be coinfected by both viruses. Co-circulation of CHIKV and DENV is not uncommon in South - East Asia (14). Although CHIKV affected areas often overlap with DENV - endemic areas (554), however, simultaneous outbreak are rare. So far, no case of chikungunya has been reported in Vietnam, excepted in 1966 with 10 infected American soldiers (555) and and a study on IgM in children between 2 and 14
years in Tien Giang general hospital (556). There is currently a lack of information on CHIKV in Vietnam.

There is in Vietnam the simultaneous presence of the primary vector of dengue and chikungunya, i.e. A. aegypti in Vietnam and of the considered secondary vector, A. albopictus. Besides, weather conditions and local Vietnamese habit of storing water in containers at their house favor the development of mosquitoes. Identification of vectors and potential vectors of CHIKV and DENV in a given geographical areas has therefore important implications with respect to outbreak control.

There are many reasons to believe that dengue and chikungunya are expanding and cocirculating in Vietnam. Movement of human populations from neighboring countries is considered a cause of expansion. Chikungunya infection was recently identified as a problem in Cambodia. During this reemergence of CHIKV in 2011, 24 patients was detected positive with CHIKV, during tests for Flaviviruses and Alphaviruses (557), with two chikungunya cases in two provinces border with Vietnam. In 2012, chikungunya outbreaks were reported in Laos with 197 cases in the Moonlpmok and Khong Districts of the Chamasak province (29). Vietnam shares borders with Cambodia and Laos and people mobility and trade between the neighboring countries may be a cause of transmission to Vietnam.

3.2. Objective

The objective of this part of the PhD was to understand the potential role of CHIKV and DENV as a cause of febrile illnesses in five provinces border with Laos and Cambodia in three regions of north, center and south of Vietnam during a non-epidemic period. In this section we investigated the incidence and clinical features of dengue and chikungunya infections. We also surveyed the populations of mosquitoes collected in the five provinces in order to identify circulating viruses. In addition, a phylogenetic analysis of the collected adult mosquitoes was conducted to characterize the potential vectors.

3.3. Discussion and conclusions

To monitor the dissemination of the dengue and chikungunya viruses in Vietnam, we conducted active surveillance of acute febrile syndromes suspect DENV and CHIKV
throughout Vietnam from 2012 - 2014. To our knowledge, this study is the first to prospectively investigate the circulation of DENV and CHIKV, and the risk factors i.e. mosquitoes and water containers in three different regions, north, centre and south of Vietnam. Mosquito samples were collected in five provinces sharing borders with Cambodia and Laos. DENV is still a high burden in Vietnam but the presence of chikungunya is still unclear, for part because of lack of proper laboratory diagnosis capacity in patients samples. Although, both CHIKV and DENV have been detected in Cambodia and Laos, no CHIKV was detected among the hospitalized patients in Vietnam. However, CHIKV was detected in adult A. aegypti mosquitoes.

The number of symptoms in patients under 18 was higher than in the older group. The most common symptoms on admission were myalgia, headache, fever, rash, petechia, and arthralgia. The dominant symptoms were myalgia and headache. From the clinical survey presented in this work, the only similar symptom between adult and pediatric patients was rash. Several symptoms, i.e. myalgia, fever, petechia and arthralgia ($p < 0.01$), were shown to be significantly different between adult and pediatric patients. More males were found affected than females, in agreement with other reports in Nepal, China and Vietnam (558) (559) (560). There is no clear explanation for this bias which might be associated to occupational factors. Although all four DENV serotypes were circulating in three regions throughout the study period, the predominant serotype was DENV-1, circulating in both human and mosquito samples. The presence of the co-circulating four serotypes of DENV along with predominance of DENV-1 reported in this work was similar to the result of previous research on DENV in Vietnam (561) and Cambodia (562).

Entomological investigations conducted in this work provided an interesting insight on the potential dynamic of infection over the two years of the study. With the exception of Hue, where A. albopictus were as numerous as A. aegypti, the latter was overwhelming present in households in all other provinces. The most important ratio in favor of A. aegypti was found in Long An. These results match those from a previous survey conducted in 2010 where A. aegypti dominated in the south and A. albopictus was more present in the cool mountainous areas. This work provides however an insight on dengue dynamic different from what was expected. First, although A. aegypti is the most represented species most of the dengue-infected mosquitoes captured were A. albopictus. This species thus appears to be the main vector in Vietnam. This situation is particularly
sticking in the Southern province of Long An, neighbour of both Cambodia and Ho Chi Minh City and where the main tranboundary road system is located. In addition, Long An is the province where the highest number of mosquitoes have been captured with *A. albopictus* making less than 1% of the mosquitoes. Nevertheless, although *A. albopictus* represents 0.9% of the sampled population, it represents 50% of the infected mosquitoes in Long An. Another important conclusion from this work is that if there is indeed a regular introduction of dengue virus to Vietnam, the suspected introductions from Cambodia or Laos might represent only a small part of the process. As shown by phylogenetic data, there is no single local endemic population of mosquitoes but rather the cocirculation of several distinct populations countrywide. With the exception of QT_LB_albo_55M1 which belonged to the haplotype alb9 described in Thailand, all the other dengue-infected *A. albopictus* individuals belonged to the same population, with no haplotype name, characterized in Romania and described as an invasive population in Europe. The alb9 dengue-infected-mosquito was a male indicating thus the presence of vertical transmission, a trait already known in dengue. The last dengue-infected mosquito was found not to be *A. albopictus* but instead *Culex vishnui*. This is to our knowledge the first time, *C. vishnui*, known for transmitting Japanese encephalitis, is found infected with dengue.

Further indication of involvement of exogenous mosquitoes is also provided by the *A. aegypti* individuals. The dengue-infected *A. aegypti* mosquitoes were found to be associated to haplotypes described in Tamil Nadu, India (i.e. BUZOO-M-Aa), in the Martinique Island in the French West Indies (i.e. Martinique1) and in Thailand (i.e. aeg7). Interestingly, other individuals from the same haplotypes described in India and Martinique Island, i.e. BUZOO_M_Aa and Martinique 1, were found to be infected by CHIKV. Tamil Nadu and Martinique Island have been heavily infected by chikungunya (563) (564) (565) and the similarity of haplotypes also suggests that the chikungunya dynamic, like that of dengue, might be significantly supported by long distance-travelling mosquitoes rather than local populations.

It seems important to decipher the movement of mosquitoes but not only at the Lao PDR and Cambodian borders as previously considered but rather through routes of international trade. This work is stressing the need to establish a genotype-based survey of circulating mosquitoes in Vietnam, not based as currently done on the species but instead on the population at the infra-species level. An integrative analysis encompassing the
genetic study of viral lineages on human patents and in mosquitoes along with the genotyping of mosquito population should be undertaken to provide clear information on the dynamic of dengue and chikungunya. Although no clinical chikungunya case was declared and no CHIKV was found on human samples in this work, the detection of CHIKV in mosquito haplotypes bound to worldwide movements and to areas with major chikungunya outbreaks indicate that the threat should be taken seriously and a dedicated surveillance programme should be implemented. From this work, dengue and chikungunya, appear as global threats that should not be addressed at a national or even regional scale but rather at a global, worldwide dimension of permanent exchanges and movements.

This part of the PhD is presented in Manuscript under final stage of preparation for submission to Emerging Infectious Diseases. The manuscript, entitled “Aedes mosquitoes mobility, diversity and risk factors for the diffusion of dengue and chikungunya in Vietnam” is presented thereafter.
For *Emerging Infectious Diseases*

Corresponding author

**Tran Nhu Duong**
National Institute of Hygiene and Epidemiology
1 Yersin Street
10000 Hanoi
Vietnam

**Roger Frutos**
UMR 17, Intertryp
TAA 17/G
Campus International de Baillarguet
CIRAD
34398 Montpellier Cedex 5
France

*Aedes* mosquitoes mobility, diversity and risk factors for the diffusion of dengue and chikungunya in Vietnam

Pham Thi Kim Lien¹,²,³, Laurence Briant², Laurent Gavotte⁴, Pierrick Labbe⁴, Marco Perriat-Sanguinet⁴, Laurent Gavotte⁴, Emmanuel Cornillot², Vu Trong Duoc¹, Nguyen Thi Yen¹, Tran Vu Phong¹, Nguyen Van Soai¹, Tran Duc Dong¹, Tran Chi Cuong¹, Phan Thi Nga¹, Tran Nhu Duong¹*, Roger Frutos²,³*

1) National Institute of Hygiene and Epidemiology, 1 Yersin Street, 10000 Hanoi, Vietnam
2) CPBS, UMR 5236, 1919, route de Mende, 34293 Montpellier Cedex 5, France
3) Cirad, TA-A17/G, Campus International de Baillarguet, 34398 Montpellier Cedex 5, France
4) University of Montpellier, ISEM, CC063, Place E. Bataillon, 34095 Montpellier Cedex 5, France

+: Current address: Institut de Recherche en Cancérologie de Montpellier (U1194), Campus Val d'Aurelle, 34298 Montpellier Cedex 5, France

*: Corresponding authors
Running title: Aedes, dengue and chikungunya in Vietnam

Keywords: Dengue, Chikungunya, Vietnam, Aedes aegypti, Aedes albopictus

Abstract

An active surveillance was conducted in Vietnam to assess the presence of dengue and chikungunya virus in patients hospitalized with acute fever in five Vietnam provinces neighbouring Lao PDR and Cambodia. This work conducted from 2012 to 2014 was completed by a survey of the mosquitoes found in the same areas. A total 558 human serums were collected along with 1104 adult mosquitoes (991 A. aegypti and 113 A. albopictus) and 10995 larvae (8542 A. aegypti and 2453 A. albopictus) from 2250 households. Dengue virus was found in 17 (3%) human serum samples. No chikungunya virus was detected in human. Differing densities of mosquito populations were found with the highest one being in the Long An province border with Cambodia. Dengue viruses were detected mostly in A. albopictus. But CHIKV was also detected in A. aegypti. The phylogenetic analysis of the collected mosquitoes showed a large diversity of genotypes, all of them having been described in other parts of the world. New haplotypes were found, a Culex vishnui mosquito was found positive for dengue, making this species a potential vector.
In the current absence of vaccines and efficient therapeutic drugs, both dengue and chikungunya are expanding. There is an estimated number of 390 million dengue infections per year, out of which 96 million are asymptomatic (1). Over the past 50 years dengue has spread inexorably from 9 countries reporting dengue transmission prior to 1970 to over 124 today (2). Incidence has also increased 30 fold (2). Vietnam is one of five countries in the Southeast Asia with the highest dengue burden (3). Dengue fever was first described in northern Vietnam in 1958 and expanded to the southern area in 1960 (4). Despite the existence of a National Dengue Control Program since 1998, Dengue remains a major health problem in Vietnam and the number of cases has increased over the last past 15 years (5). Dengue Fever (DF) and Dengue Haemorrhagic Fever (DHF) were leading causes of hospitalization from 1991 to 2004, accounting for 1,000,866 case over the whole country (6). It also increased every year in the urban central areas of Hanoi (7), while seasonal outbreaks have occurred in northern Vietnam over the last decade (8). Vietnam is a hyperendemicity country with all four dengue virus serotypes circulating, the dominant one varying over time (9). DENV 1 and DENV 2 are the most predominant serotypes, however DENV 3 emerged in the late 1990s and was responsible for the large outbreak of 1998 whereas DENV 4 was also detected between 1999 and 2003 (10). Dengue transmission occurs throughout the year in Vietnam, with peaks (72% of total cases) reported between June and November, in especially in the southern part of the country during the rainy season from July to September (11). In the Northern and Central highland regions, dengue notifications are low during the winter time from December to March (12, 13).

Chikungunya, a disease caused by an alphavirus, was isolated in Tanzania in 1953 (13), but has been present in Asia where a specific genotype circulates since the 1960s and was described in Vietnam in 1967 with 10 cases of American soldiers (14). In 2004, a new variant of CHIKV emerged in East Africa which quickly spread and generated major outbreaks over the Indian Ocean, India and Thailand (15, 16, 17, 18). This East-African reemerging CHIKV has been described in Cambodia in 2011 and in 2012, chikungunya outbreaks were reported in Laos with 197 cases in the Moonlpamok and Khong districts of the Chamasak province. However until now no clinical case of chikungunya has been described in Vietnam. Vietnam shares a border with Cambodia and Laos and there is thus
the possibility that CHIKV might circulate already in Vietnam but without being detected. Dengue and chikungunya symptoms are very similar, in particular in the early stage (19) making thus easy to confuse both diseases and underestimate the burden of chikungunya. Surveillance studies in Vietnam focus on dengue and detection of chikungunya is not considered. There are many reasons to suspect that chikungunya might have already expanded to Vietnam and might cocirculate with dengue. Long distance migration of DENV and CHIKV in Asia as well as transboundary movements of human populations can contribute to it. Furthermore, the same Aedes mosquito species are vectoring both viruses and are widely prevalent in the region (20). Co-circulation of CHIKV and DENV have already been reported, however, simultaneous outbreaks are rare.

This work was therefore undertaken in connection with the National Vietnamese programs dengue surveillance to investigate a potential co-circulation of DENV and CHIKV and assess their respective role in febrile illnesses in several provinces in three regions of North, Central and South Vietnam having borders with Laos and Cambodia. This survey was conducted over two years to assess the prevalence of both viruses in patients hospitalized with acute fever and in mosquito populations present around the patient’s households.
Material and Methods

Ethics. The study was approved by the Scientific and Ethical Committee of the National Institute of Hygiene and Epidemiology (NIHE), Hanoi, Vietnam, under supervision by the Ministry of Health. The study was conducted jointly with the Provincial Preventive Medicine Offices and the study received clearance and approval from the regional health directors.

Location of sampling. Active surveillance of acute febrile syndromes was and collection of human blood samples were conducted from September 2012 to September 2014 in five preventive medicine centres in Ha Tinh, Thua Thien Hue, Quang Tri, Dac Nong and Long An (Figure 1). Mosquitoes were collected from districts of Huong Khe, Ha Tinh, A Luoi, Huong Hoa, Dac min, Moc Hoa belonging to the Ha Tinh, Hue, Quang Tri, Dac Nong and Long An provinces, respectively. All collection points were recorded by GPS. All selected provinces have borders with either Laos or Cambodia.

Case definition and sampling. Acute phase blood samples were collected from patients admitted with high fever ($\geq 38.5^\circ$C) and at least two of the following symptom: rash, myalgia, joint pain, swelling of joints, nausea/vomiting, and headache. Sera of acute febrile cases were obtained within 7 days after the onset of disease. Informed consent was obtained from the patient or from the parent or legal guardians of minors before the collection of sample. The information collected for each patient included a unique identification number and demographic data such as full name, age, gender, residential address, date of symptom onset or diagnosis, date of the first and second sample collection. Samples were coded and sent to the virology laboratory, National Institute of Hygiene and Epidemiology (NIHE), Hanoi, Vietnam. Acute phase serum samples was collected follow up serum sample taken from 3 to 5 ml, stored at $4^\circ$C or in ice dry during the time for transferring in the day to preventive medicine centers of provinces in - $20^\circ$C until being transfer to NIHE for RNA extraction and stored at - $80^\circ$C.

Mosquito collection. Collection of larvae, pupae and adult mosquitoes were conducted four times, i.e. in rainy and dry seasons, over two years from September 2012 to
September 2014. For each province, collections were conducted in four communes of a district border with either Laos or Cambodia. Each selected commune was geo-referenced using a portable global positioning system (GPS). Door to door entomological survey was also conducted. However, procedures were slightly different for adult collection and for larvae and pupae collections. Adult mosquitoes were collected in and around households. A household was defined as single residential building, including any storage building, kitchen, latrine huts and garden as well as the outside areas up to the fenced partition separating a house from its neighbour. Household selection was performed in a systematic random manner. If it was not possible to include a house chosen in the study due to the absence of the owner, the closest neighbouring household was chosen instead. Mosquitoes were captured outdoor and indoor during day time day from 5 to 10 AM and 4 to 8 PM using a backpack aspirator. A total of 30 households were investigated in each commune. Collected mosquitoes were stored in RNAlater (Qiagen) and kept refrigerated at 4°C prior to identification. Only *A. aegypti* and *A. albopictus* were retained and identification was performed according to morphological criteria following binocular examination. Mosquito samples were sorted according to species, sex, date of collection, geographical coordinates and number of mosquitoes for each location, and then stored at -80°C in RNA later solution until further use. For the collection of larvae and pupae, all accessible artificial larval developmental sites such as discarded tires, water containers, fish water pot, flower pot, water jar/ pot, water tank, vase, wet container, etc., were searched for potential larval habitats in indoor and outdoor. Developmental sites were inspected using dippers, as previously described (21, 22). The equipment used for collection consisted of a standard mosquito dipper with extendable handle, pipette, spoon and torchlight. All of the potential developmental sites were examined using a flashlight. All collected mosquitoes were placed into plastic vials and labelled according to the date, location and container type. Identification was performed using morphological taxonomic keys. Only *A. aegypti* and *A. albopictus* were retained.

**DNA, RNA extraction and cDNA synthesis.** Viral RNA was extracted from the human serum samples, and mosquito’s abdomens, DNA was extracted from the heads of mosquito samples using the QIAamp viral RNA Mini kit and QIAamp® DNA Micro Kit procedure (QIAGen, Hilddden, Germany). Elution was performed in 60 µl according to the supplier
and DNA, RNA stored at - 80°C until further use. Purified RNA templates were transcribed into cDNA using Super transcript III reverse transcriptase (RT- Invitrogen). RNA templates were mixed with RNase-free DNase and incubated at 37°C for 30 minutes and then 75°C for 15 minutes. Annealing was performed at 25°C for 5 minutes, followed by extension at 42°C for 60 minutes and reaction was terminated by holding the mixture at 70°C for 15 minutes.

**PCR detection of DENV, CHIKV and COI gene.** Multiplex PCR amplification was performed for dengue virus detection whereas Real Time PCR was implemented for chikungunya virus. For DENV, a one-step single tube serotype specific multiplex PCR was adapted from previously reports of Lanciotti et al. Amplification was carried out in 50µl with a dengue-virus group specific consensus forward primer and four serotype-specific reverse primers. Nonstructural protein 2 (nsP2) primers were used for CHIKV and COI primers for genome of mosquitoes (Table 1). PCR products were analyzed in a 2% (W/V) agarose gel containing 10% SYBR safe DNA gestain (Invitogen, S33102) in Tris- acetate-EDTA (TAE) buffer 1%. A 100-bp ladder was used as a molecular weight marker. The expected size of amplicons was 492 bp, 119 bp, 290 bp and 392 bp for DENV1, DENV2, DENV3 and DENV4, respectively. Chikungunya virus was detected by using quantitative Real-Time PCR. The non-structural protein 2 of CHIKV was used as template and amplified using light cycler 480 Syber Green I master enzyme (Roche). RT-PCR was run in a final volume of 50 µl. The standard cycling conditions were incubation at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 15 sec, annealing at 56°C for 30 sec, extension at 72°C for 30 sec, and to monitor potential non-specific amplification, one cycle of 95°C for 15 sec, 60°C for 1 min, and 95°C for 15 sec. Data collection occurred during the 72°C extension step. Amplification was done using a Rotor-gene RG3000 (Corbett Research).

**Entomological data analysis.** All statistical analysis were done using R. All results were summarized in terms of medians and ranges for continuous data, odds ratio (OR), Chi square and Fisher exact tests were used as appropriate. Abundance was defined as the number of individuals of a species per container and used rainy and dry season relative as variables. The presence or absence of larvae of *A. aegypti* and/or *A. albopictus* or both
species co-occurrence were treated as binary dependent variables. Predictor variables were season collection, physiographic, container type and their possible two-way interactions. Entomological indices were defined as follows: House Index (HI), which is the percentage of houses infested with larvae and/or pupae. Container Index (CI), which is the percentage of positive containers (i.e. infested with larvae and/or pupae). Breteau Index (BI), which is the number of positive containers per 100 households. The 95% confidence interval was calculated for using an exact binomial test.

**Phylogeny analysis.** Multiple sequence alignment was conducted using the MUSCLE program (23) available in the Seaview 4.5.1 package (24, 25). To determine the best fit model of nucleotide substitution, we used the MODELTEST program (26). Phylogenetic analysis was performed using maximum likelihood (ML) approach available within the PHYML package (27) and incorporating the GTR+Γ₄ model of nucleotide substitution. A bootstrap resampling process (1,000 replications) was performed to assess the robustness of individual nodes on each phylogeny utilizing the ML substitution model.
Results

**General description of the study patient population.** A total of 558 serum samples were collected from patients admitted in the 2012-2014 period in the five preventive medicine centres with acute fever and symptoms compatible to DENV- CHIKV infection. The patient cohort consisted of 253 females and 305 males, ranging from 4 months to 74 years with a median age of 24 years, and a mean age of 26 years (Table 2). No significant difference was recorded with respect to age with 269 patients below 18 (from 0.4 to 18) and 289 patients above 18 (from 19 to 74). The sex ratio was slightly biased towards males with 305 males patients out of 558 (54.6%) for 259 females patients out of 558 (45.4%). The most frequent symptom was myalgia (59%), followed by headaches (41%) and arthralgia (21%) (Table 2). All symptoms were significantly more represented in the population over 18 with the exception of rash which was similarly represented in both populations and nausea/vomiting which was more frequent for patients under 18 (Table 2).

**Frequency of DENV and CHIKV in the human cohort.** 100, 91, 97, 142 and 128 serum samples were collected from Ha Tinh, Hue, Quang Tri, Long An and Dac Nong, respectively (Table 3). Out of these 558 acute-phase serum samples collected, 17 (3.05 %) were positive for dengue (Table 3). Dengue-positive samples were detected in all five provinces. The percentage of positive samples ranged from 2.06% to 5.47%. The highest rate was found in the southern province of Dac Nong. Rates of positive DENV samples were 2.06%, 2.11%, 3.00%, 3.30% and 5.47% for Quang Tri, Long An, Ha Tinh, Hue and Dac Nong, respectively (Table 3). The four serotypes were simultaneously found only in Dac Nong. The combination of DENV1 and DENV2 was found only in Hue and Long An whereas the combination of DENV1 and DENV3 was found in Ha Tinh and Quang Tri (Table 3). Altogether, the most frequent serotype was DENV1 (1.25 %), followed by DENV2 (0.90 %); DENV3 (0.72 %) and DENV4 (0.18 %). No positive CHIKV sample was identified.

**Frequency of DENV and CHIKV in adult mosquitoes.** A total of 1104 adult *Aedes* mosquitoes have been captured from an overall 2268 households. *A. aegypti* made up 89.8 % (991 individuals) of the captures while *A. albopictus* represented only 10.2 % (113
individuals) (Table 4). When considering the breakdown per province, the two southernmost provinces displayed a far higher density of adult mosquitoes in the vicinity of households with 285 and 580 individuals captured in Dac Nong and Long An, respectively whereas in Ha Tinh, Hue and Quang Tri, the number of adults captured was 74, 92 and 70, respectively (Table 4). This Southern / Central-North Central difference was also observed in the A. aegypti / A. albopictus ratio (Table 4). Out of 580 individuals captured in Long An, no A. albopictus was identified and in Dac Nong only 3 A. albopictus were present for 285 A. aegypti. In Ha Tinh the rate of A. albopictus was 25.7 % (19 out of 74) and in Quang Tri 9.35 % were A. albopictus (6 out of 64). In Hue the ratio was reversed with a strong predominance of A. albopictus (92.4 % or 85 out 92 individuals) (Table 4). Out of the 1104 adults Aedes mosquitoes collected, 9 (0.8%) were infected with dengue. 4 positive samples were found in Long An, 3 bearing a DENV2 virus and 1 bearing a DENV4 strain. 2 dengue-positive mosquitoes were found in Dac Nong, each one bearing a different DENV serotype (DENV1 and DENV4). Two infected mosquitoes were also found in Quang Tri, both with a DENV1 virus and only one DENV1-infected mosquito in Ha Tinh. No infected mosquito was found in Hue. With respect to species distribution, only A. aegypti were infected in the two southern provinces whereas only A. albopictus individuals were found infected in the central/north central provinces (Table 4). Two mosquitoes were found to be infected by CHIKV, both in the southern province of Long An, and both in A. aegypti which was the only species captured in this province (Table 4).

**Distribution of mosquito populations.** A total 8269 water containers coming from 2698 households were sampled from September 2012 to September 2014. A total of 12041 larvae were collected from the five provinces. 9588 larvae (80%) were identified as A. aegypti whereas 2453 (20 %) were A. albopictus individuals (20%) (Table 5). When considering the provincial breakdown, the ratio between A. aegypti and A. albopictus was 1046/551, 1147/423, 1147/1022, 760/411 and 5126/46 for Ha Tinh, Quang Tri, Hue, Dac Nong and Long An, respectively (Table 5). Entomological indexes indicated some disparities between the provinces and no correlation between the number of infected houses, number of containers and mosquito density (Table 5). In Long An, while about five more times open water containers were present, only 19.2% of the containers were
positive for mosquito larvae and only 3% of the houses were infected. The Breteau Index (205) was highest of all the provinces analysed while the House Index (3.02) was the lowest. Conversely, in Dac Nong the Breteau Index (35.71) was 6 times lower than in Long An and the number of larvae 10 times lower (1693 vs. 16480) while the House Index (9.21) was three time higher (Table 5).

**Vectoring capacity and genetic structure of mosquito populations.** DENV-positive adult mosquitoes were found in four out of the five provinces studied (Table 4). In Dac Nong, two adult females were found positive, an *A. albopictus* individual infected with DENV4 and an *A. aegypti* mosquito infected with DENV1. In Long An four infected mosquitoes were identified, an *A. albopictus* female harbouring DENV4 and three other individuals, one *A. albopictus* and two *A. aegypti*, all infected with DENV2. In Ha Tinh, one infected mosquito was captured, an *A. albopictus* female carrying DENV2. In Quang Tri, two *A. albopictus* individuals infected with DENV2 were found, one of those being a male which indicates the occurrence of vertical transmission. No infected mosquito was found in Hue. With respect to CHIKV, two infected *A. aegypti* mosquitoes were found, one in the province of Long An and the second one in the province of Dac Nong (Table 4).

The COI phylogenetic analysis of the captured mosquitoes revealed the simultaneous presence in all sites of genetically diverse populations (Figure 2). Two main groups were found which corresponded to the main vectoring species, i.e. *A. aegypti* and *A. albopictus*. Each group was divided into several clusters of identical or nearly identical sequences (Figure 2). No geographic discrimination was found. Several mosquito individuals did not fall within any of the clusters and when analysing their sequence on BLAST, they were found to correspond either to unknown haplotypes, to known haplotypes described in other countries (i.e. Colombia, or to different mosquito species mistakenly identified as *A. albopictus* when sampling, i.e. *Aedes w-albus, Aedes mcintoshi, Aedes cogilli, Culex vishnui* and *Ochlerotatus flavescens*. One of these misidentified mosquito, i.e. *Culex vishnui*, was found to harbor the dengue virus DENV4 (Table 6). Interestingly, the COI mosquito haplotypes found in the five provinces covered by the study and distributed over the 10 clusters identified (Figure 2; Table 6) have been described in other parts of the world (Table 6).
Discussion

To our knowledge, this study is the first to investigate vectors distribution, DENV and CHIKV circulation and occurrence in patients hospitalized with acute febrile symptoms, in a comparative way over several provinces throughout Vietnam. Results coming from this active surveillance conducted over two years in five provinces neighbours with Lao PDR where dengue is present and Cambodia where both dengue and chinkungunya are present bring a new perspective on the dynamic of these diseases.

The average rate of dengue among acute fever patients was about 3% and ranged from 2.06 % to 5.7% depending on the province. This is 10- to 5-times less than previously reported incidence rates among acute fever inpatients (28, 29). This lower incidence could be related to an improved primary dengue diagnostic, the current study being more recent. It could also be a consequence of the focus of this study on regional health centres while suspected dengue cases might be directed to major hospitals. The presence of all four serotypes of dengue is in accordance with the hyper-endemic status of Vietnam (30, 8).

The main result of this work is the lack of correlation observed between the incidence rates, the mosquito population density and the data on their genetic diversity which could shed a new light on the complex dynamic of dengue in Vietnam. Dengue virus was shown to undergo a complex dynamic involving both serotype and lineage replacements (31, 32, 33, 34, 35). Although many parameters could be involved in this mechanism, replacement was thought to be more stochastic than selective (32, 36). Raghwani et al. (36) reported the occurrence of differential dynamics depending upon rural or urban areas in South Vietnam. They demonstrated that infections were moving from urban to rural populations, which in turn could explain, at least in part, the lower incidence rate observed in this work, with Ho Chi Minh City playing a major role as an infection foci. The transmission gradient was linked to the human population density and the low rate of virus dispersal, i.e. 20km/year, associated to mosquito-mediate dispersal (36). Although in full agreement with these conclusions, the data reported here lead to a slightly different insight on the dynamic of dengue in Vietnam.
Dengue is considered being regularly introduced to Vietnam from Cambodia, mostly through people mobility (36). South-Vietnam and the Mekong River delta represent therefore regions at risk for high incidence. The data reported here provide a slightly different picture. The province of Long An, neighbour to Cambodia on one side and to Ho Chi Minh City on the other did not display the higher rate of incidence as expected but instead one of the lowest despite a very high Breteau Index indicative of a bad mosquito management system, proximity to high human population density and presence of the main cross border road system. The province with the highest incidence rate was the southern province Dac Nong. However, the province was also the one with the lowest population density of mosquitoes, i.e. Long An 10-times less than the other provinces. The Breteau and Container Indexes were the second lowest ones whereas the House Index was the highest one, in agreement with the observed incidence rate. This suggest that it is not the overall *Aedes* density that should be considered but rather some specific populations, perhaps less numerous but more actively involved in the effective transmission of the virus.

Another set of data from this work could bring together these conclusions and those from Raghwani et al., 2011 (36). The phylogeny and genetic diversity of the adult mosquitoes captured near the health centres investigated shed a new light on the mechanisms involved in the dynamic of dengue. The captured mosquitoes corresponded to COI haplotypes described in other parts of the world. Furthermore, unknown haplotypes were sequences along with other species mistakenly identified as *A. albopictus*. The high genetic diversity observed combined with clearly delineated cluster gathering mosquitoes from the different provinces indicated the absence of geographic discrimination. The sampled mosquito haplotypes are present all over the country but also in other countries and continents. It is not possible to say whether these mosquito populations originated in Vietnam and were moved to other places or conversely were moved to Vietnam from other parts of the world. Nevertheless, this worldwide description of the same haplotypes indicates a very large mobility of mosquitoes, most likely due to international trade, and therefore of viruses. This could participate to the explanation for regular virus replacement (31, 32,33, 34, 35), for the stochastic determinism of these replacements (32, 35), and for the higher presence in urban areas more prone to international trade exposure (36).
seems that if there is indeed a regular introduction of dengue virus to Vietnam, the suspected introductions from Cambodia might represent only part of the process. As shown by phylogenetic data, there is no single local endemic population of mosquitoes but rather the cocirculation of several distinct populations countrywide. This conclusion is reinforced by the presence of unknown haplotypes among the samples. Two interesting facts also emerged from the study. The first one is that although *A. aegypti* outnumbered *A. albopictus*, the latter appeared to be more present among the infected individuals. This is particularly true for the southern province of Long An where *A. albopictus* made 50% of the infected mosquitoes while they only represented 0.9% of the sampled mosquitoes. In the Northern/Central provinces of Ha Tinh and Quang Tri, where *A. albopictus* made up to 27-28% of the sampled mosquitoes, this species was the only one to harbour dengue viruses. Interestingly, in Hue where *A. albopictus* represented 47% of the captured mosquitoes, no infected individual was found. The other interesting fact relates to the haplotype of the dengue-infected *A. albopictus* mosquitoes. With the exception of QT_LB_albo_55M1 which belonged to the haplotype alb9 described in Thailand, all the other dengue-infected *A. albopictus* individuals belonged to the same population, with no haplotype name, characterized in Romania and described as an invasive population in Europe (37). The alb9 dengue-infected-mosquito was a male indicating thus the presence of vertical transmission, a trait already known in dengue (38, 39, 40). The last dengue-infected mosquito was found not to be *A. albopictus* but instead *Culex vishnui*. This is to our knowledge the first time, *C. vishnui*, known for transmitting Japanese encephalitis, is found infected with dengue. There is no evidence from the data reported here that *C. vishnui* can efficiently transmit dengue to human through a blood meal. However, there is at least the demonstration that *C. vishnui* can take the dengue virus and therefore be considered a potential vector. Further research should be considered to investigate the occurrence of efficient transmission of dengue in this already medically-important mosquito group.

Further indication of involvement of exogenous mosquitoes is also provided by the *A. aegypti* individuals. The dengue-infected *A. aegypti* mosquitoes were found to be associated to haplotypes described in Tamil Nadu, India (i.e. BUZOO-M-Aa), in the Martinique Island in the French West Indies (i.e. Martinique1) and in Thailand (i.e. aeg7).
Interestingly, other individuals from the same haplotypes described in India and Martinique Island, i.e. BUZOO_M_Aa and Martinique 1, were found to be infected by CHIKV. Tamil Nadu and Martinique Island have been heavily infected by chikungunya (18, 41, 42) and the similarity of haplotypes also suggest that the chikungunya dynamic, like dengue, might be significantly supported by long distance-travelling mosquitoes rather than local populations.

It seems important to decipher the movement of mosquitoes but not only at the Lao PDR and Cambodian borders as previously considered but rather through routes of international trade. High human population density foci are thus important to target as proposed by Raghwani et al. 2011 (35), but perhaps more because of their exposure to international exchanges than purely because of population density.

This work is stressing the need to establish a genotype-based survey of circulating mosquitoes in Vietnam, not based as currently done on the species but instead on the population at the infra-species level. An integrative analysis encompassing the genetic study of viral lineages on human patents and in mosquitoes along with the genotyping of mosquito population should be undertaken to provide clear information on the dynamic of dengue and chikungunya. Although no clinical chikungunya case was declared and no CHIKV was found on human samples in this work, the detection of CHIKV in mosquito haplotypes bound to worldwide movements and to areas with major chikungunya outbreaks indicate that the threat should be taken seriously and a dedicated surveillance programme should be implemented. From this work, dengue and chikungunya, appear as global threats that should not be addressed at a national or even regional scale but rather at a global, worldwide dimension of permanent exchanges and movements.
References


Acknowledgements

Pham This Kim Lien was supported in part by the ADB funded, Erasmus Mundus project MAHEVA and by the CNRS - Virus host cell interactions Laboratory; and Montpellier University, France. The study was supported by the Entomology department, Arbo Virus laboratory in National Institute of Hygiene and Epidemiology, Hanoi, Vietnam. To the Parasitology, Evolutionary Biology, Ecology Department; and Evolution,Vector, Adaptation in Symbioses Department in Montpellier University, France for their help and supported. The authors are grateful to leaders and medical staff of the Center for Preventive Medicine in Ha Tinh, Thua Thien Hue, Quang Tri, Dac Nong, Long An, the District Health Centre and commune health centre/wards in their provinces for their enthusiastic support, active participation and close collaboration. The authors are very grateful to Dr Babatunde Olowokure, Disease Prevention and Control, Caribbean Public Health Agency, for his support and fruitful comments on the manuscript.
Table 1: Oligonucleotide primers used to amplify and type dengue, chikungunya viruses and COI gene

<table>
<thead>
<tr>
<th>Primer</th>
<th>Sequence</th>
<th>Position</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DENV</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D1</td>
<td>5'-TCAATATGCTGAAACGCGAGAA ACCG-3'</td>
<td>616-644</td>
<td>511</td>
</tr>
<tr>
<td>TS1</td>
<td>5'-CGTCTCAGTGATCCGGGGG-3'</td>
<td>568-586</td>
<td>482 (D1 and TS 1)</td>
</tr>
<tr>
<td>TS2</td>
<td>5'-CGCAC AAG GGC CAT GAA CAG-3'</td>
<td>232-252</td>
<td>119 (D1 and TS 2)</td>
</tr>
<tr>
<td>TS3</td>
<td>5'-TAA CAT CAT CAT GAG ACA GAGC-3'</td>
<td>400-421</td>
<td>290 (D1 and TS 3)</td>
</tr>
<tr>
<td>TS4</td>
<td>5'-TGTTGTCTTTAAAAACAAGAGGTC-3'</td>
<td>506-527</td>
<td>392 (D1 and TS 4)</td>
</tr>
<tr>
<td><strong>CHIKV</strong></td>
<td>NSP2-F</td>
<td>5'-GGCACPCTGTCCCAGATAATTCAG-3'</td>
<td>3181-3241</td>
</tr>
<tr>
<td></td>
<td>NSP2-R</td>
<td>5'-GCTGCTAGTACACCCCCCACATG-3'</td>
<td></td>
</tr>
<tr>
<td><strong>COI gene</strong></td>
<td>COI F</td>
<td>5'-TATCGCCTAAACTTCAGCC-3'</td>
<td>1651</td>
</tr>
<tr>
<td></td>
<td>COI R</td>
<td>5'-CCTAAATTTGCTCATGGCCA-3'</td>
<td></td>
</tr>
</tbody>
</table>
Table 2: Frequency of symptoms upon admission

<table>
<thead>
<tr>
<th>Patient (n = 558)</th>
<th>Value</th>
<th>Odds ratio (OR)</th>
<th>&lt;18 years n = 269</th>
<th>&gt;18 years n = 289</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years); (mean, range)</td>
<td>26 (0.4-74)</td>
<td></td>
<td>(0.4-18)</td>
<td>(19-74)</td>
<td></td>
</tr>
<tr>
<td>Sex (M/F) (%)</td>
<td>305/253 (54.6%/45.4%)</td>
<td>1.2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration of febrile (mean, range)</td>
<td>3.6 (1-7 days)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Signs and symptoms</td>
<td>Temperature on admission (°C) (range)</td>
<td>38.8 (38-40 °C)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>248 (44%)</td>
<td>0.8</td>
<td>36.4%</td>
<td>51.9%</td>
<td>0.0003</td>
</tr>
<tr>
<td>Myalgia</td>
<td>328 (59%)</td>
<td>1.4</td>
<td>30.8%</td>
<td>64.8%</td>
<td>0.0001</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>117 (21%)</td>
<td>0.3</td>
<td>10.0%</td>
<td>31.1%</td>
<td>0.0001</td>
</tr>
<tr>
<td>Rash</td>
<td>189 (16%)</td>
<td>0.5</td>
<td>35.3%</td>
<td>32.5%</td>
<td>0.5311</td>
</tr>
<tr>
<td>Petechia</td>
<td>156 (10%)</td>
<td>0.4</td>
<td>15.6%</td>
<td>38.8%</td>
<td>0.0001</td>
</tr>
<tr>
<td>Nausea/Vomiting</td>
<td>68 (3.2%)</td>
<td>0.13</td>
<td>13.7%</td>
<td>1.04%</td>
<td>0.0001</td>
</tr>
<tr>
<td>Positive Tourniquet test</td>
<td>53 (9.5%)</td>
<td>0.1</td>
<td>4.5%</td>
<td>14.2%</td>
<td>0.0001</td>
</tr>
<tr>
<td>Warning sign</td>
<td>Back pain</td>
<td>56 (10%)</td>
<td>0.11</td>
<td>1.85%</td>
<td>17.7%</td>
</tr>
<tr>
<td>Bleeding gums</td>
<td>18 (3.2%)</td>
<td>0.03</td>
<td>0.74%</td>
<td>5.54%</td>
<td>0.0001</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>38 (6.8%)</td>
<td>0.07</td>
<td>3.34%</td>
<td>10.03%</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Note: Value are the mean (range) or number (%)
Table 3: Frequency of DENV and CHIKV in the human serum.

<table>
<thead>
<tr>
<th>Province</th>
<th>Nb patients</th>
<th>Dengue serotype</th>
<th>Chikungunya</th>
</tr>
</thead>
<tbody>
<tr>
<td>D1</td>
<td>D2</td>
<td>D3</td>
<td>D4</td>
</tr>
<tr>
<td>Ha Tinh</td>
<td>100</td>
<td>1 0 1 0 0</td>
<td>0</td>
</tr>
<tr>
<td>Hue</td>
<td>91</td>
<td>1 2 0 0 0</td>
<td>0</td>
</tr>
<tr>
<td>Quang Tri</td>
<td>97</td>
<td>1 0 1 0 0</td>
<td>0</td>
</tr>
<tr>
<td>Dac Nong</td>
<td>128</td>
<td>2 2 2 1 0</td>
<td>0</td>
</tr>
<tr>
<td>Long An</td>
<td>142</td>
<td>2 1 0 0 0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>558</td>
<td>7 5 4 1 0</td>
<td></td>
</tr>
</tbody>
</table>

Table 4: Incidence of dengue and chikungunya virus in collected adult mosquitoes

<table>
<thead>
<tr>
<th>Province</th>
<th>Number of mosquito</th>
<th>Dengue-positive</th>
<th>Chikungunya-positive</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A. aegeyti</td>
<td>A. albopictus</td>
<td>A. aegeyti</td>
</tr>
<tr>
<td>Ha Tinh</td>
<td>55 (5.55%)</td>
<td>19 (16.81%)</td>
<td>1 x DENV 1</td>
</tr>
<tr>
<td>Hue</td>
<td>7 (0.7%)</td>
<td>85 (75.2%)</td>
<td>0</td>
</tr>
<tr>
<td>Quang Tri</td>
<td>64 (6.46%)</td>
<td>6 (5.3%)</td>
<td>2 x DENV 1</td>
</tr>
<tr>
<td>Dac Nong</td>
<td>285</td>
<td>3 (2.65%)</td>
<td>1 x DENV 1</td>
</tr>
<tr>
<td></td>
<td>(28.8%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long An</td>
<td>580</td>
<td>0 (0%)</td>
<td>2 x DENV 2</td>
</tr>
<tr>
<td></td>
<td>(58.5%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>991 (100%)</td>
<td>113 (100%)</td>
<td>3</td>
</tr>
</tbody>
</table>
Table 5. Distribution of *Aedes* larvae and entomological indexes

<table>
<thead>
<tr>
<th>Province</th>
<th>Nº Houses</th>
<th>Nº Positive</th>
<th>Nº Containers</th>
<th>Nº Positive</th>
<th>A. <em>aegypti</em></th>
<th>A. <em>albopictus</em></th>
<th>BI</th>
<th>CI</th>
<th>HI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Explored</td>
<td>Houses</td>
<td>Explored</td>
<td>Containers</td>
<td>Larvae</td>
<td>Larvae</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ha Tinh</td>
<td>450</td>
<td>41 (8.1%)</td>
<td>936</td>
<td>79 (8.4%)</td>
<td>1046</td>
<td>551</td>
<td>17.56</td>
<td>8.44</td>
<td>8.12</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>17.56</td>
<td>8.44</td>
<td></td>
<td>8.12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quang Tri</td>
<td>420</td>
<td>24 (4.9%)</td>
<td>778</td>
<td>170 (21.9%)</td>
<td>1147</td>
<td>423</td>
<td>40.48</td>
<td>21.85</td>
<td>4.82</td>
</tr>
<tr>
<td>Hue</td>
<td>480</td>
<td>40 (6.8%)</td>
<td>730</td>
<td>202 (27.7%)</td>
<td>1147</td>
<td>1022</td>
<td>42.08</td>
<td>27.67</td>
<td>6.77</td>
</tr>
<tr>
<td>Dac Nong</td>
<td>420</td>
<td>47 (9.2%)</td>
<td>807</td>
<td>150 (18.6%)</td>
<td>760</td>
<td>411</td>
<td>35.71</td>
<td>18.59</td>
<td>9.21</td>
</tr>
<tr>
<td>Long An</td>
<td>480</td>
<td>18 (3.0%)</td>
<td>5128</td>
<td>984 (19.2%)</td>
<td>5126</td>
<td>46</td>
<td>205</td>
<td>19.19</td>
<td>3.02</td>
</tr>
<tr>
<td>Total</td>
<td>2250</td>
<td>170 (7.5%)</td>
<td>8549</td>
<td>1585 (18.5%)</td>
<td>8542</td>
<td>2453</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

BI: Breteau Index = Nb Positive Containers / Nb Houses Explored x 100
CI: Container Index = Nb Positive Containers / Nb Containers Explored x 100
HI: House Index = Nb Positive Houses / Number Houses Explored x 100
Table 6. Distribution of haplotypes among captured adult mosquitoes

<table>
<thead>
<tr>
<th>Strain</th>
<th>Cluster</th>
<th>Species</th>
<th>Haplotype</th>
<th>Country</th>
<th>Accession number</th>
</tr>
</thead>
<tbody>
<tr>
<td>19M22</td>
<td>Individual</td>
<td>Aedes aegypti</td>
<td>Unknown</td>
<td>Unknown</td>
<td>NA</td>
</tr>
<tr>
<td>19M32</td>
<td>Individual</td>
<td>Aedes aegypti</td>
<td>Unknown</td>
<td>Unknown</td>
<td>NA</td>
</tr>
<tr>
<td>22F4</td>
<td>Individual</td>
<td>Aedes aegypti</td>
<td>Unknown</td>
<td>Unknown</td>
<td>NA</td>
</tr>
<tr>
<td>19M34</td>
<td>Individual</td>
<td>Aedes aegypti</td>
<td>Haplotype 68</td>
<td>Colombia</td>
<td>KM203207</td>
</tr>
<tr>
<td>19M25</td>
<td>Individual</td>
<td>Aedes aegypti</td>
<td>Haplotype 80</td>
<td>Colombia</td>
<td>KM203219</td>
</tr>
<tr>
<td>22F7</td>
<td>Individual</td>
<td>Aedes aegypti</td>
<td>Haplotype 14</td>
<td>Colombia</td>
<td>KM203153</td>
</tr>
<tr>
<td>39F2</td>
<td>Individual</td>
<td>Aedes aegypti</td>
<td>Unknown</td>
<td>Unknown</td>
<td>NA</td>
</tr>
<tr>
<td>49F7</td>
<td>Individual</td>
<td>Aedes aegypti</td>
<td>Unknown</td>
<td>Unknown</td>
<td>NA</td>
</tr>
<tr>
<td>20M3</td>
<td>Individual</td>
<td>Aedes aegypti</td>
<td>Unknown</td>
<td>Unknown</td>
<td>NA</td>
</tr>
<tr>
<td>19M24</td>
<td>Individual</td>
<td>Aedes aegypti</td>
<td>Haplotype 68</td>
<td>Colombia</td>
<td>KM452747</td>
</tr>
<tr>
<td>19M20</td>
<td>root individual</td>
<td>Aedes aegypti</td>
<td>CDC11</td>
<td>Colombia</td>
<td>KM452747</td>
</tr>
<tr>
<td>19M29</td>
<td>Individual/C1</td>
<td>Aedes aegypti</td>
<td>Guinea 1</td>
<td>Guinea</td>
<td>JQ926700</td>
</tr>
<tr>
<td>19M33</td>
<td>Individual/C1</td>
<td>Aedes aegypti</td>
<td>BUZOO-M-Aa</td>
<td>India</td>
<td>KR817731</td>
</tr>
<tr>
<td>34M14</td>
<td>Cluster 1</td>
<td>Aedes aegypti</td>
<td>Haplotype 70</td>
<td>Colombia</td>
<td>KM203209</td>
</tr>
<tr>
<td>24F1</td>
<td>Cluster 1</td>
<td>Aedes aegypti</td>
<td>BUZOO-M-Aa</td>
<td>India</td>
<td>KR817731</td>
</tr>
<tr>
<td>26F3</td>
<td>Cluster 1</td>
<td>Aedes aegypti</td>
<td>BUZOO-M-Aa</td>
<td>India</td>
<td>KR817731</td>
</tr>
<tr>
<td>19M23</td>
<td>Root Cluster 2</td>
<td>Aedes aegypti</td>
<td>Haplotype 37</td>
<td>Colombia</td>
<td>KM203176</td>
</tr>
<tr>
<td>34M7</td>
<td>Root Cluster 2</td>
<td>Aedes aegypti</td>
<td>BUZOO-M-Aa</td>
<td>India</td>
<td>KR817731</td>
</tr>
<tr>
<td>9M5</td>
<td>Root Cluster 2</td>
<td>Aedes aegypti</td>
<td>None</td>
<td>India</td>
<td>KJ680548</td>
</tr>
<tr>
<td>19M10</td>
<td>Cluster 2</td>
<td>Aedes aegypti</td>
<td>aeg7</td>
<td>Thailand</td>
<td>KP843388</td>
</tr>
<tr>
<td>30F5</td>
<td>Cluster 2</td>
<td>Aedes aegypti</td>
<td>aeg7</td>
<td>Thailand</td>
<td>KP843388</td>
</tr>
<tr>
<td>19M21</td>
<td>Cluster 2</td>
<td>Aedes aegypti</td>
<td>aeg7</td>
<td>Thailand</td>
<td>KP843388</td>
</tr>
<tr>
<td>28F5</td>
<td>Cluster 2</td>
<td>Aedes aegypti</td>
<td>aeg7</td>
<td>Thailand</td>
<td>KP843388</td>
</tr>
<tr>
<td>06F3</td>
<td>Root Cluster 3</td>
<td>Aedes aegypti</td>
<td>Isolate 4</td>
<td>Brazil</td>
<td>JX456414</td>
</tr>
<tr>
<td>19M5</td>
<td>Cluster 3</td>
<td>Aedes aegypti</td>
<td>Martinique 1</td>
<td>Martinique (French Caribbean)</td>
<td>JQ926606</td>
</tr>
<tr>
<td>06F2</td>
<td>Cluster 3</td>
<td>Aedes aegypti</td>
<td>Martinique 1</td>
<td>Martinique (French Caribbean)</td>
<td>JQ926606</td>
</tr>
<tr>
<td>01F14</td>
<td>Cluster 3</td>
<td>Aedes aegypti</td>
<td>Martinique 1</td>
<td>Martinique (French Caribbean)</td>
<td>JQ926606</td>
</tr>
<tr>
<td>47F2</td>
<td>Cluster 3</td>
<td>Aedes aegypti</td>
<td>Isolate 2</td>
<td>Brazil</td>
<td>JX456412</td>
</tr>
<tr>
<td>29F3</td>
<td>Cluster 4</td>
<td>Aedes aegypti</td>
<td>BUZOO-M-Aa</td>
<td>India</td>
<td>KR817731</td>
</tr>
<tr>
<td>01F10</td>
<td>Cluster 4</td>
<td>Aedes aegypti</td>
<td>Isolate 1</td>
<td>Vietnam</td>
<td>JQ926687</td>
</tr>
<tr>
<td>59F3</td>
<td>Cluster 5</td>
<td>Aedes aegypti</td>
<td>BUZOO-M-Aa</td>
<td>India</td>
<td>KR817731</td>
</tr>
<tr>
<td>20M1</td>
<td>Cluster 5</td>
<td>Aedes aegypti</td>
<td>Haplotype 94</td>
<td>Colombia</td>
<td>KM203233</td>
</tr>
<tr>
<td>72F1</td>
<td>Cluster 6</td>
<td>Aedes albopictus</td>
<td>AB7</td>
<td>Thailand</td>
<td>KM613099</td>
</tr>
<tr>
<td>7M6</td>
<td>Cluster 6</td>
<td>Aedes albopictus</td>
<td>ab1b</td>
<td>Thailand</td>
<td>KP843400</td>
</tr>
<tr>
<td>49F13</td>
<td>Cluster 6</td>
<td>Aedes albopictus</td>
<td>ab1b</td>
<td>Thailand</td>
<td>KP843400</td>
</tr>
<tr>
<td>49F11</td>
<td>Cluster 6</td>
<td>Aedes albopictus</td>
<td>AB7</td>
<td>Thailand</td>
<td>KM613099</td>
</tr>
<tr>
<td>49F3</td>
<td>Cluster 6</td>
<td>Aedes albopictus</td>
<td>None</td>
<td>Romania</td>
<td>HF536717</td>
</tr>
<tr>
<td>22F5</td>
<td>Cluster 6</td>
<td>Aedes albopictus</td>
<td>None</td>
<td>Romania</td>
<td>HF536717</td>
</tr>
<tr>
<td>45F4</td>
<td>Cluster 6</td>
<td>Aedes albopictus</td>
<td>None</td>
<td>Romania</td>
<td>HF536717</td>
</tr>
<tr>
<td>45M4</td>
<td>Cluster 6</td>
<td>Aedes albopictus</td>
<td>None</td>
<td>Thailand</td>
<td>KP843400</td>
</tr>
<tr>
<td>Code</td>
<td>Cluster</td>
<td>Species</td>
<td>Gene</td>
<td>Country</td>
<td>Genbank ID</td>
</tr>
<tr>
<td>-------</td>
<td>----------</td>
<td>-----------------</td>
<td>------</td>
<td>-------------</td>
<td>------------</td>
</tr>
<tr>
<td>46F4</td>
<td>Cluster 7</td>
<td><em>Aedes albopictus</em></td>
<td>None</td>
<td>Romania</td>
<td>HF536717</td>
</tr>
<tr>
<td>50m4</td>
<td>Cluster 7</td>
<td><em>Aedes albopictus</em></td>
<td>None</td>
<td>Romania</td>
<td>HF536717</td>
</tr>
<tr>
<td>19m13</td>
<td>Cluster 7</td>
<td><em>Aedes albopictus</em></td>
<td>None</td>
<td>Romania</td>
<td>HF536717</td>
</tr>
<tr>
<td>55M1</td>
<td>Cluster 7</td>
<td><em>Aedes albopictus</em></td>
<td>alb9</td>
<td>Thailand</td>
<td>KP843400</td>
</tr>
<tr>
<td>50M1</td>
<td>Cluster 8</td>
<td><em>Aedes albopictus</em></td>
<td>alb9</td>
<td>Thailand</td>
<td>KP843400</td>
</tr>
<tr>
<td>50M14</td>
<td>Cluster 8</td>
<td><em>Aedes albopictus</em></td>
<td>alb9</td>
<td>Thailand</td>
<td>KP843400</td>
</tr>
<tr>
<td>49F10</td>
<td>Cluster 9</td>
<td><em>Aedes albopictus</em></td>
<td>alb9</td>
<td>Thailand</td>
<td>KP843400</td>
</tr>
<tr>
<td>56F1</td>
<td>Root C10</td>
<td><em>Aedes albopictus</em></td>
<td>None</td>
<td>Romania</td>
<td>HF536717</td>
</tr>
<tr>
<td>44f6</td>
<td>Individual</td>
<td><em>Aedes aegypti</em></td>
<td>BUZOO-M-Aa</td>
<td>India</td>
<td>KR817731</td>
</tr>
<tr>
<td>44f6</td>
<td>Individual</td>
<td><em>Aedes w-albus</em></td>
<td>NIBGE MOS-00132</td>
<td>Pakistan</td>
<td>KF406649</td>
</tr>
<tr>
<td>63f1</td>
<td>Individual</td>
<td><em>Aedes mcintoshi</em></td>
<td>SEN5</td>
<td>Senegal</td>
<td>KJ940759</td>
</tr>
<tr>
<td>80m1</td>
<td>Individual</td>
<td><em>Aedes albopictus</em></td>
<td>H_5</td>
<td>Vietnam</td>
<td>LM999976</td>
</tr>
<tr>
<td>01F8</td>
<td>Individual</td>
<td><em>Ochlerotatus flavescens</em></td>
<td>NHM014_5</td>
<td>UK</td>
<td>KC602635</td>
</tr>
<tr>
<td>39F1</td>
<td>Individual</td>
<td><em>Aedes cogilli</em></td>
<td>NIBGE MOS-01588</td>
<td>Pakistan</td>
<td>KF406621</td>
</tr>
<tr>
<td>39F3</td>
<td>Individual</td>
<td><em>Aedes cogilli</em></td>
<td>NIBGE MOS-01588</td>
<td>Pakistan</td>
<td>KF406621</td>
</tr>
<tr>
<td>38M2</td>
<td>Individual</td>
<td><em>Aedes cogilli</em></td>
<td>NIBGE MOS-01588</td>
<td>Pakistan</td>
<td>KF406621</td>
</tr>
<tr>
<td>38M3</td>
<td>Individual</td>
<td><em>Aedes cogilli</em></td>
<td>NIBGE MOS-01588</td>
<td>Pakistan</td>
<td>KF406621</td>
</tr>
</tbody>
</table>
Figure 1: Viet Nam map and sampling sites
Figure 2: The genetically diverse populations of mosquitoes
GENERATION CONCLUSION AND PERSPECTIVES

This work on the surveillance and dynamic of dengue and chikungunya in Vietnam has brought a new insight and raised questions upon situations, which happened to be preconceived ideas. First of all this work is to our knowledge the first one to have been conducted in a comparative way at such a scale over the whole country. All previous reports have described local events and outbreaks and although rightful conclusions have been drawn, they reflected the local dynamic. A broader view was needed to understand the dynamic of these diseases.

The first conclusion is that it very difficult to draw general conclusions on the main vector of dengue. In this work, two opposite conclusions were reached depending on location and perhaps time. In the dengue outbreak in Hanoi in 2011, *A. aegypti* was clearly shown to be the vector responsible for the diffusion dengue. A clear correlation was observed between the density of local populations of *A. aegypti* and clinical cases of dengue. *A. albopictus* did not play any role. When the global analysis was conducted in several provinces from North, Central and South Vietnam, the main vector was clearly *A. albopictus* and even more importantly haplotypes described in other parts of the world, including the haplotype recently described as invasive in Europe. Several hypotheses could be drawn to explain this apparent discrepancy. This difference could be explained by a specific situation in Hanoi, which is a highly densely populated urban area where *A. aegypti* might be more prevalent owing to its adaptation to the urban environment when compared to *A. albopictus*. *A. aegypti* is indeed far more anthropophilic than *A. albopictus* and then might be logically more important in high urban areas like the capital city. The survey conducted within this PhD work on the several provinces where *A. albopictus* was found to be the most important vector was conducted on rural areas where *A. albopictus* might be more competitive than *A. aegypti*. Another explanation might be found in the fact that the Hanoi analysis was conducted in 2011 whereas the several provinces analysis was conducted in 2012-2014. It is not possible to exclude a replacement of mosquito populations in the meantime. This hypothesis is however not very strong since in the several provinces study, *A. aegypti* was clearly the dominant species. A last explanation
might be found in the way the analysis was designed, which could be also a self-criticism of this work. The conclusions from the Hanoi study were based essentially on the correlation between the density and time of occurrence of mosquito populations and the number of clinical cases. However the ample size was limited. In the several provinces analysis, \textit{A. albopictus} was shown to be the main vector for dengue although population density of \textit{A. aegypti} was higher. This is particularly true for the Long An province were \textit{A. albopictus} made 0.9\% of the mosquitoes captured and 50\% of the dengue-infected individuals. However, if the number of clinical cases in Long An had been correlated to the population density of mosquitoes using a smaller sample, the study might have instead concluded in the overwhelming role of \textit{A. aegypti}.

This PhD work demonstrates the need of a comprehensive and coordinated approach when analyzing the dynamic of dengue, and chikungunya. Such studies should not be conducted on isolated outbreaks as the sum of individual studies does not necessarily give a true vision of the whole context. Instead, surveillance studies should be designed at the national level and based on the same master plan including both clinical and entomological studies with virus detection in all samples. Genotyping of mosquito populations should be mandatorily performed but also virus genotyping, from both human and insect samples, in order to be able to conduct the analysis of the dynamic of the disease at the level of the viral lineage. The viral lineage is the true level at which virus circulation should be considered, just like populations, i.e. infra specific, for the mosquitoes. The species and serotype levels are not accurate enough to allow for a precise analysis of circulation and association mapping. A first recommendation and perspective from this work would be therefore to develop such an integrated analysis framework and propose it to NIHE and at the national level. This should also include an homogeneous and integrated database and database management system compatible with spatio-temporal analysis.

This is particularly relevant when considering, another major conclusion from this PhD work, that mosquito populations involved are not local populations but instead populations circulating worldwide. The analysis should therefore not concentrate on local populations of mosquito, although they can play a role, but instead on the regular monitoring of mosquito populations, and in particular at the points of entry like seaports.
Such procedures should also be developed, and this could be another perspective from this work. Genotyping, suitable databases and comparative analysis of worldwide mosquito and virus sequences must be developed but also geographic analysis and international trade movements.

A last aspect unveiled by this work is the limited adaptation of the current surveillance and monitoring procedures implemented at hospitals and public health centers. As shown in the Dong Thap surveillance work, serological tests done upon admission are underestimating the number of dengue-positive patients. In addition, it does not allow for lineage identification. Chikungunya is not tested at all. It would be too expensive and practically difficult to implement a multi-step serological test and still the results would not be fully satisfactory. We therefore propose as a final recommendation and perspective from this PhD work to implement a multiplex-PCR test detecting at once the four types of dengue virus and the old an reemerging chikungunya viruses associated with the sequencing of the positive samples. The cost of PCR and sequencing is now very low and the public health benefits largely compensate the cost of the surveillance. This should be linked to the same integrated system of dynamic databases as for mosquito surveillance. A proposal should be made at NIHE and at the national level for such a procedure.

As a final word, this PhD work as underlined some key issues to be addressed in a coordinated way in order help developing an efficient surveillance and monitoring system for both dengue and chikungunya in Vietnam. Developing these systems and tools will thus be both a challenge and an exciting outcome of this work.
REFERENCES


29. Inc GI, Berger DS. Infectious Diseases of Laos. GIDEON Informatics Inc; 2014. 405 p.


96. Maguire JH, Strickland GT, Ryan ET, Solomon T, Hill DR. Hunter’s Tropical Medicine and Emerging Infectious Disease,Expert Consult - Online and Print,9:
Hunter’s Tropical Medicine and Emerging Infectious Disease. Elsevier Health Sciences; 2012. 1215 p.


173. Vasilakis N, Weaver SC. Chapter 1 The History and Evolution of Human Dengue Emergence. In: Karl Maramorosch AJS and FAM, editor. Advances in Virus Research


248. WHO. Dengue and severe dengue. 2015.
249. Inc GI, Berger DS. Chikungunya and Zika: Global Status. GIDEON Informatics Inc; 2015. 80 p.


283. Chuansumrit A, Chaiyaratana W, Pongthanapisith V, Tangnararatchakit K, Lertwonggrath S, Yoksan S. The use of dengue nonstructural protein 1 antigen for the


328. Libraty DH, Young PR, Pickering D, Endy TP, Kalayanarooj S, Green S, et al. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue


515. Teng AK, Singh S. Epidemiology and New Initiatives in the Prevention and Control of Dengue in Malaysia. 2001 Dec [cited 2013 Nov 2]; Available from: http://repository.searo.who.int/handle/123456789/15837

154


553. Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus [Internet]. [cited 2015 Mar 4]. Available from: http://vir.sgmjournals.org/content/88/9/2363.full?ijkey=3deea1c17d6f4bb7821b6d33a06bc2d6859008&keytype2=tf_ipsecsha


Summary

Dengue and chikungunya are both transmitted by *Aedes aegypti* and *Aedes albopictus* and can cause potentially severe and or debilitating chronic disease. They are the fastest spreading diseases, in part because of the climate change. Vietnam is a hyperendemicity country for dengue and is at risk to be like neighboring Cambodia affected both by dengue and chikungunya and be an overlapping area of distribution for both viruses. The aim of this PhD work was therefore to assess the status of single and dual infections all over the country, investigate the presence of chikungunya, assess the efficiency of the surveillance procedures routinely established and assess the diversity of mosquito populations and their potential respective role. A first part of the PhD dissertation is devoted to a bibliographic review. The second part comprises three chapters associated to three different publications. The first chapter is devoted to a surveillance study in the general hospital if the Southern Province of Dong Thap. A cohort of 131 patients with acute fever symptoms was investigated for the presence of dengue and chikungunya. 101 patients out of 131 were confirmed with dengue. All four dengue serotypes were detected with a predominance of DENV2 and DENV4. No chikungunya infection was detected although reported in neighboring Cambodia. A differential efficiency of serological dengue detection was observed. Efficiency was 29% upon admission and 53% after seven days on the same patients. There is thus a clear risk of dengue being underestimated while chikungunya is not systematically detected. Changes in detection and surveillance procedures are therefore proposed to increase the efficiency of dengue detection and continue the monitoring the emergence of CHIKV. The second Chapter is dedicated to the respective role of *A. aegypti* and *A. albopictus* in the 2011 outbreak in the Northern capital city of Hanoi. Only DENV-1 and DENV-2 serotypes were detected from the 140 patients hospitalized. A positive correlation was found between the population density of *A. aegypti* and the number of human cases and duration of outbreaks. This was not observed for *A. albopictus*. Three pools of *A. aegypti* were positive with dengue virus, two with DENV-1 and one with DENV-2. This work indicate clearly the role of *A. aegypti* in the 2011 Hanoi epidemics. The last chapter of the PhD is devoted to a crosscutting country wide survey in five provinces border with Lao PDR and Cambodia. In this work, a total of 558 serum samples were collected from patients admitted in the 2012-2014 period in five provincial preventive
medicine centers with acute fever and symptoms compatible to DENV-CHIKV infection. All four dengue serotypes were found altogether but not in the same province. Only two serotypes were found at the maximum in a single province. No CHIKV was detected. A total of 1104 adult mosquitoes were collected inside and outside houses at the same place. Mosquito population density and vector indexes were assessed following capture of larvae. Differing densities of mosquito populations were found with the highest one being in the Long An province border with Cambodia. Dengue viruses were detected mostly in *A. albopictus*. CHIKV was also detected in *A. albopictus* mosquitoes. The phylogenetic analysis of the collected mosquitoes showed a large diversity of genotypes, all of them having been described in other parts of the world. This part of the PhD work underlines the dual role of *A. aegypti* and *A. albopictus*, the increasing role of the latter and the high level of man-related very long distance mobility of mosquitoes. This work underlines the need of novel approaches for surveillance both at the clinical and at the entomological level to efficiently tackle the risk of dengue and chikungunya outbreaks.
Résumé

La dengue et le chikungunya sont des maladies transmises par *Aedes aegypti* et *Aedes albopictus* pouvant causer des pathologies sévères et des atteintes incapacitantes chroniques. Ce sont aussi les maladies qui se diffusent le plus rapidement, en partie à cause du changement climatique. Le Vietnam est une zone d’hyperendémicité pour la dengue et à risque pour le chikungunya comme le Cambodge voisin qui est atteint par les deux maladies et représente une source de diffusion. L’objectif de cette thèse est d’évaluer le statut de ces deux maladies et la présence du chikungunya, d’évaluer l’efficacité du système de surveillance et d’évaluer la diversité des populations de moustiques vecteurs et leurs rôles respectifs dans la transmission. Une première partie de la thèse est dévolue à une revue bibliographique. La seconde partie comprend trois chapitres associés à trois publications. Le premier chapitre est consacré à une étude de la surveillance à l’hôpital général de la province sud de Dong Thap. Une cohorte de 131 patients avec une fièvre aigue a été étudiée pour tester la présence de dengue et de chikungunya. 101 patients sur 131 ont été positifs pour la dengue et les quatre sérotypes ont été détectés avec une prédominance de DENV1 et DENV4. Aucun cas de chikungunya n’a été détecté. Une variation d’efficacité dans la détection sérologique de la dengue a été observée avec un passage de 29% lors de l’admission à 53% sept jours après admission. Il y a donc clairement un risque de sous-estimation de la dengue alors que le chikungunya, n’est pas du tout testé. Des changements dans la procédure de détection et de surveillance sont proposés pour améliorer l’efficacité de la surveillance et surveiller l’émergence du chikungunya. Le deuxième chapitre est consacré à l’étude du rôle respectif d’*A. aegypti* et *A. albopictus* dans l’épidémie de Dengue de 2011 à Hanoi. Seuls DENV1 et DENV2 ont été détectés chez les 140 patients étudiés. Une corrélation positive a été observée entre la densité de population d’*A. aegypti* et le nombre de cas humains et la durée des épidémies. Ceci n’a pas été observé chez *A. albopictus*. Trois lots d’*A. aegypti* se sont révélés positifs pour la dengue, deux pour DENV1 et un pour DENV2. Cette étude montre clairement le rôle d’*A. aegypti* dans l’épidémie de 2011 à Hanoi. Le dernier chapitre est consacré à une analyse transversale sur 5 provinces frontalières du Laos et du Cambodge. 558 sérums collectés chez des patients admis pour fièvre aigue et de symptômes compatibles avec la dengue et chikungunya entre 2012 et 2014 dans des centres de médecine préventive. Les
quatre sérotypes ont été détectés mais pas tous dans la même province. Seulement deux sérotypes ont été détectés au maximum dans une même province. Le chikungunya n’a pas été détecté. Un total de 1104 moustiques adultes a été prélevé dans les mêmes zones à l’intérieur et à l’extérieur des habitations. La densité de population de moustiques et les indices entomologiques ont été évalués suite à la capture de larves. Des densités très différentes ont été observées et la densité la plus importante a été obtenue dans la province de Long An, voisine du Cambodge. Le virus de la dengue a été détecté principalement chez *A. albopictus*. Le virus du chikungunya a également été détecté chez *A. albopictus*. L’analyse phylogénétique des moustiques collectés a montré une grande diversité génétique avec des génotypes décrits sur d’autres continents. Cette partie de la thèse met en évidence le rôle différentiel d’*A. aegypti* et *A. albopictus*, le rôle croissant de ce dernier et le transport anthropique des moustiques sur de grandes distances. Ce travail souligne le besoin de nouvelles approches de surveillance, au niveau clinique et au niveau entomologique, pour s’attaquer de façon efficace au risque épidémique de dengue et de chikungunya.